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ABSTRACT 
 
Obesity is an increasing worldwide problem and yet current pharmaceutical treatments 
only produce modest weight loss which is rarely sustained. Glucagon and glucagon-like 
peptide-1 (GLP-1) are members of the secretin family of peptide hormones. Both 
hormones are products of the preproglucagon gene, and are produced in the pancreas 
and gut respectively. GLP-1 is an incretin hormone that enhances glucose-mediated 
insulin release and inhibits glucagon secretion. In contrast, glucagon counter-regulates 
insulin and stimulates gluconeogenesis in response to low circulating levels of glucose. 
Despite their opposing roles in glucose homeostasis, both hormones reduce food intake 
in rodents and humans. In addition, glucagon increases energy expenditure. 
In this thesis, I have investigated for the first time the effects of co-administration of 
glucagon and GLP-1 in energy balance. Co-administration of glucagon and GLP-1 in mice 
significantly reduced food intake compared to controls and appeared to do so in an 
additive manner. Glucagon and GLP-1 alone and in combination activated similar areas 
within the brainstem and amygdala. Prolonged co-administration of novel, protease-
resistant analogues of glucagon and GLP-1 reduced body weight in diet-induced obese 
(DIO) mice, despite similar food intake compared to saline controls. Furthermore, 
glucagon and GLP-1 analogue co-administration improved glucose homeostasis 
compared to saline controls in DIO mice. 
Intravenous infusion of glucagon alone and in combination with GLP-1 increased energy 
expenditure in overweight humans whilst GLP-1 alone had no effect. This represents a 
first in man study of the effects of co-administration of glucagon and GLP-1 on energy 
homeostasis. Sub-anorectic doses of glucagon and GLP-1 in combination reduced food 
intake whilst alone they had no effect. Co-administration of both hormones ameliorated 
the rise in plasma glucose seen following glucagon infusion alone, demonstrating an 
additional benefit of GLP-1 and glucagon in combination.  
These findings suggest that the combination of GLP-1 and glucagon represents an 
exciting therapeutic target for development of a novel anti-obesity agent.  
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1.1 Introduction 
The World Health Organisation estimates that worldwide over one billion adults and 
over forty two million children under the age of five are overweight 1,2. In the UK,  a 
quarter of all adults are obese3 and 30% of children are classified as overweight or 
obese4. Obesity reduces life expectancy by approximately nine years and accounts for 
almost 600 deaths a week in England alone5. When homeostatic mechanisms controlling 
food intake are poorly adapted to the unique modern environment of plenty, both 
excess energy intake and decreased exercise results in weight gain. Obesity is an 
increasing health and socioeconomic burden that is associated with type 2 diabetes 
mellitus, hyperlipidaemia, hypertension, cardiovascular disease and certain forms of 
cancer6. 
1.2 Regulation of appetite and body weight  
The control of food intake is complex and consists of neural and hormonal signals 
between the gut and central nervous system (CNS). In addition, hormones such as leptin 
indicate ‘energy reserves’ within adipose tissue and are strongly implicated in feeding 
behaviour and energy expenditure (EE). The brain is responsible for the interpretation 
of signals from the periphery and for modifying feeding behaviour depending on energy 
requirements and the ‘wanting’ of food. Even prior to eating, gut hormones are released 
which begin the process of meal termination and feelings of satiation. Gut hormones act 
within key brain areas such as the hypothalamus and brainstem which contain intricate 
neuronal networks and connections related to energy homeostasis, regulation of food 
intake and glucose homeostasis. 
 
1.2.1 Central regulation of energy balance 
 
1.2.1.1 Hypothalamus 
 
Early lesioning studies led to a dual-centre hypothesis, in which the ventromedial nuclei 
(VMN) were responsible for the inhibition of food intake and the lateral hypothalamic 
areas (LHA) stimulated appetite7. However, it is now clear that nuclei within the 
hypothalamus are closely integrated within complex networks that signal to areas 
within the brain involved in the regulation of appetite. Interconnecting hypothalamic 
nuclei such as the arcuate nucleus (ARC), paraventricular nucleus (PVN), dorsomedial 
nucleus (DMN), VMN and LHA are implicated in the regulation of food intake, EE and 
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glucose homeostasis (Figure 1.1). These nuclei also project to other important areas 
within the brain including the brainstem, reward centres such as the amygdala and 
nucleus accumbens, and the prefrontal cortex which is involved in conditioned taste 
aversion (CTA). 
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Figure 1.1. Schematic diagram outlining hypothalamic circuits involved in the regulation 
of food intake. Circulating hormones act on the ARC where orexigenic NPY/AgRP and 
anorexigenic POMC/CART neurones are present. Abbreviations: arcuate nucleus (ARC), 
paraventricular nucleus (PVN), ventromedial nucleus (VMN), dorsomedial nucleus (DMN), lateral 
hypothalamic area (LHA), brain-derived neurotrophic factor (BDNF), melanin concentrating 
hormone (MCH), cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), 
peptide YY (PYY), agouti related protein (AgRP), neuropeptide Y (NPY), pro-opiomelanocortin 
(POMC), cocaine- and amphetamine-related transcript (CART), adenosine mono-phosphate 
protein kinase (AMPK), thyrotrophin-releasing hormone (TRH), corticotrophin-releasing 
hormone (CRH), tri-iodothyronine (T3).  Reproduced from Simpson et al (2009)8. 
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Arcuate Nucleus (ARC) 
The ARC is a key hypothalamic nucleus in the regulation of appetite. In mice, 
subcutaneous injection of monosodium glutamate induces necrosis in the ARC with 
subsequent development of obesity 9. Anatomically related to the median eminence, the 
ARC is not fully insulated from the circulation by the blood brain barrier (BBB) and 
hence, is strategically positioned to integrate a number of peripheral signals controlling 
food intake10,11. Two major neuronal populations in the ARC are prominently implicated 
in the regulation of feeding. One population is localised more medially in the ARC, 
increases food intake and co-expresses neuropeptide Y (NPY) and agouti-related protein 
(AgRP)12. The second population of neurones co-expressing cocaine- and amphetamine-
related transcript (CART) and pro-opiomelanocortin (POMC), inhibits food intake and 
tends to cluster more laterally in the ARC13. Neuronal projections from these two 
populations then communicate with other hypothalamic areas involved with appetite 
regulation such as the PVN, DMN and LHA14-17.  
Melanocortin peptides, including -MSH, released from ARC POMC neurones bind to 
downstream MC4-Rs to inhibit food intake18,19. The MC4-R is highly expressed in the 
hypothalamus, most notably the PVN20.  AgRP is the endogenous antagonist at the MC3-
R and MC4-R21. Whereas intracerebroventricular (ICV) administration of -MSH to rats 
reduces food intake, this effect is inhibited by the simultaneous ICV administration of 
AgRP22. The majority of CART neurones in the ARC also contain POMC mRNA23. Animal 
studies have shown that ICV administration of CART inhibits food intake24, whereas ICV 
injection of CART antiserum increases food intake24,25. This suggests that CART peptide 
is an endogenous inhibitor of feeding.   
Within the hypothalamus, NPY has been implicated as an important physiological 
regulator of body weight through its effects on food intake and EE26. NPY/AgRP 
neurones have extensive projections within the hypothalamus including the PVN, DMN 
and LHA which appear to be the main targets for the orexigenic effects of NPY27-32. 
Approximately 20% of ARC NPY neurones innervate the PVN and DMN29,30. Stimulation 
of this pathway leads to increased food intake through direct stimulation of Y1 and Y5 
receptors in addition to AgRP antagonism of MC3 and MC4-Rs in the PVN33.  
Furthermore, local release of NPY within the ARC inhibits POMC neurones34. ICV 
injection of NPY potently stimulates food intake in rats35. Repeated daily injections of 
NPY results in chronic hyperphagia and increased weight gain in rats36. In support of the 
critical role of the NPY/AgRP system in energy balance, ablation of ARC NPY/AgRP 
neurones in adult mice reduces food intake and body weight37-40.  
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Paraventricular Nucleus (PVN) 
Microinjection of almost all known orexigenic peptides into the PVN, including NPY and 
AgRP stimulate feeding41-43. NPY/AgRP and POMC neurones from the ARC communicate 
with PVN neurones containing corticotrophin releasing hormone (CRH) and 
thyrotrophin releasing hormone (TRH)44,45. Both CRH and TRH have been implicated in 
the control of energy balance, by contributions to both food intake and EE46,47. 
Therefore, in energy balance, a key role for the PVN is to convey information from the 
ARC to other brain areas involved in appetite regulation.  
Lateral Hypothalamic Area (LHA) 
The LHA is another key downstream target of neuronal projections from the ARC and 
contains the orexigenic neuropeptides melanin concentrating hormone (MCH) and 
orexins. Lesioning of the LHA reduces body weight7,48. NPY, AgRP and α-MSH 
immunoreactive terminals are extensive in the LHA and are in contact with MCH and 
orexin-expressing cells49,50. MCH immunoreactive fibres project to the cortex and spinal 
cord, consistent with a potential role in appetite control and EE51,52. Interestingly, work 
by another group found that a subpopulation of MCH neurones in the LHA co-express 
CART53 and mainly project to the brainstem54. In contrast, MCH fibres lacking CART have 
been found to project to the forebrain, suggesting MCH may modulate food intake and 
EE through two separate neuronal projections depending on the presence of CART54.   
Dorsomedial Nucleus (DMN) 
Destruction of the DMN results in hyperphagia and obesity, although less dramatically 
than VMN lesioning55. The DMN contains a large number of NPY terminals29,56,57  and α-
MSH terminals originating in the ARC58. α-MSH fibres also project from the DMN to the 
PVN, terminating on TRH-containing neurones59.  In the DMN, α-MSH fibres are in close 
apposition to NPY neurones60. It has been postulated that α-MSH suppresses NPY gene 
expression in the DMN indirectly via separate inhibitory inter-neurones, possibly 
through GABA-ergic pathways60. In diet-induced obese (DIO) mice 61, obese agouti 
mice62 and MC4-R knockout mice62, NPY mRNA expression is increased in the DMN, 
whereas it is reduced in the ARC. This difference in NPY response is again highlighted by 
the finding that NPY levels in the DMN, in contrast to the ARC and PVN, are not elevated 
during fasting63. It is thought that lack of leptin signalling on NPY neurones in the DMN 
may partly account for this since leptin deficient ob/ob mice show increased NPY mRNA 
in the ARC but not in the DMN62.  
 24 
Cholecystokinin (CCK) has also been implicated in the DMN modulation of NPY 
signalling and hence food intake64. CCK-1 receptors and NPY co-localise in DMN 
neurones and administration of CCK into the DMN downregulates NPY gene expression 
and inhibits food intake in rats65. Furthermore, Otsuka Long Evans Tokushima Fatty 
rats, a CCK-1 receptor knockout model, exhibit hyperphagia and increased NPY mRNA 
expression in the DMN 66.  
Ventromedial nucleus (VMN) 
Lesions of the VMN result in rapid onset hyperphagia and obesity48. The VMN has a large 
population of glucoresponsive neurones that respond to blood glucose levels and 
numerous histamine, dopamine, serotonin, and GABA neurones that respond to feeding-
related stimuli67. The VMN receives NPY, AgRP and POMC neuronal projections from the 
ARC. Brain-derived neurotrophic factor (BDNF) is highly expressed in the VMN and is 
important during development for neuronal survival68. Lateral ventricle administration 
of BDNF reduces food intake and body weight69. Previous studies have implicated ARC 
POMC neurones in activating VMN BDNF neurones to decrease food intake70. The VMN 
has also recently been described as the site of a novel hypothalamic appetite regulatory 
circuit involving tri-iodothyronine (T3).  Administration of T3 peripherally increases 
food intake in rats and activates neurones in the VMN71.  
 
1.2.1.2 Brainstem 
 
In comparison to hypothalamic circuits controlling food intake, much less is known 
about those in the brainstem. Extensive reciprocal neuronal projections exist between 
brainstem and hypothalamic feeding circuits to provide an alternative pathway through 
which circulating satiety factors can communicate with the hypothalamus72,73. The vagus 
nerve is the major neuroanatomical link between the gastrointestinal (GI) tract and the 
brain.  Cell bodies of afferent fibres of the abdominal vagus nerve are located in the 
nodose ganglia, which project onto the brainstem. Here, the dorsal vagal complex (DVC), 
consisting of the dorsal motor nucleus of the vagus nerve (DMV), the area postrema 
(AP), and the sensory nucleus of the tractus solitarius (NTS), interfaces with 
hypothalamic and higher centres73,74. In addition, the parabrachial nucleus (PBN) 
receives information related to feeding including taste, gastric distension and hepatic 
vagal afferents75-78.  
Transection of all gut sensory vagal fibres results in increased meal size and meal 
duration79,80. Increased gastric volume, nutrient content of the small intestine and gut 
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hormones such as CCK all dose dependently decrease meal size and increase c-fos 
expression in the NTS81-84. The anorectic response to CCK85,86, glucagon-like peptide-1 
(GLP-1)87 and peptide tyrosine tyrosine (PYY)87,88 are attenuated following vagotomy. 
Within the brainstem, vagal afferent neurones have been shown to express a variety of 
receptors including CCK-1R and CCK-2R (at which both CCK and gastrin act)89, the leptin 
receptor Ob-R which is involved in the regulation of energy intake90, the PYY receptor 
subtype Y2R, at which PYY acts to reduce food intake88, GLP-191 and GLP-2R92, growth 
hormone secretagogue receptor (GHS)-R1 at which ghrelin acts93 and the orexin 
receptor, OX-R194. In addition, the AP and a significant portion of the caudal medial NTS 
contains fenestrated capillaries which are thought to allow direct contact with 
circulating factors in the bloodstream95,96. Therefore, the vagotomy studies show that 
these hormones regulate food intake indirectly via the vagus nerve. Alternatively they 
may act directly at the AP by binding to their respective receptors via an incomplete 
BBB 96.  
Extensive projections of NTS neurones have been localised to parasympathetic and 
sympathetic preganglionic neurones in the spinal cord, and important cardiovascular, 
respiratory and gut motility control centres in the medullary reticular formation97,98. 
NTS projections are also found in hypothalamic nuclei such as the PVN, DMN and 
LHA73,99-102 and amygdala103. The majority of NTS neurones to the hypothalamus are 
noradrenergic101,102 and terminate in the PVN and supraoptic nucleus (SON) 99-102. 
Although the exact role of these NTS projections in influencing food intake is unclear, 
terminal fibres have been identified on CRH100 and TRH104 containing neurones in the 
PVN. Recent evidence also suggests a role for prolactin-releasing peptide neurones in 
the NTS and their projections to the DMN following refeeding in fasted rats105. In 
addition to noradrenergic projections to the PVN, somatostatin106, CART107 and POMC108 
containing neurones within the NTS have also been shown to project to the PVN. 
Brainstem POMC neurones demonstrate signal transducer and activator of 
transcription-3 (STAT-3) activation in response to leptin administration109 and 
administration of leptin into the DVC suppresses food intake110. Finally, approximately 
25% of NTS neurones projecting to the PVN contain preproglucagon derived peptides111. 
Therefore, multiple pathways exist between appetite regulating areas in the 
hypothalamus and brainstem, highlighting the importance of these regions in energy 
homeostasis.  
NTS neurones also receive descending projections from the hypothalamus 
(predominantly PVN and LHA) and central nucleus of the amygdala (CeA) 112. Within the 
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brainstem itself, extensive CCK, galanin and CRH immunoreactive neurones project from 
the NTS and AP to the PBN 98,99,113. Vagal gastric projections also relay to the PBN 
through the caudal NTS114. Acute gastric distension activates c-fos in all areas of the 
brainstem (NTS, AP and DMV)86 and increased electrical activity is seen in the PBN in 
response to gastric balloon dilatation78. Therefore, signals from the periphery have 
pivotal roles in transmitting information via afferent vagal fibres to the caudal 
brainstem or directly to the hypothalamus to modify appetite. 
1.2.1.3 Reward pathways 
 
Reward pathways in the brain involved in feeding behaviour include the nucleus 
accumbens, ventral striatum, ventral tegmental area (VTA), prefrontal cortex and 
hippocampus. CTA and lesioning experiments demonstrate that the orbitofrontal cortex 
and amygdala are important in learning and experiencing food. Furthermore the 
orbitofrontal cortex receives sensory inputs such as taste, smell, sight and feel of food in 
the mouth as well as chemical composition115. Neuroimaging studies in humans have 
shown that pleasant and unpleasant odours activate different regions of the 
orbitofrontal cortex and cingulate gyrus116. If a meal is eaten to satiety, the signal from 
the orbitofrontal cortex decreases and the feeding behaviour changes from acceptance 
of food to rejection. This ability to switch from ‘likeability’ of a food to rejection has been 
associated with leptin signalling117. The VTA is the origin of the dopaminergic cell bodies 
of the mesocorticolimbic dopamine system and widely implicated in drug and natural 
reward circuitry of the brain. Direct administration of leptin into the VTA decreases food 
intake in rats118. Individuals with congenital leptin deficiency are hyperphagic and 
obese119. Leptin treatment in these individuals not only ameliorates their obesity but 
also enables them to discriminate between the ‘liking ratings’ of food in fed and fasted 
states117. 
The mesolimbic dopaminergic system is particularly important in feeding behaviour. 
Following ingestion of highly palatable food, there are increased dopamine levels in the 
nucleus accumbens (NuA) 120. Leptin decreases dopaminergic neuronal firing in ex vivo 
VTA slices121. Ghrelin increases dopamine levels in the NuA 122 and direct injection of 
ghrelin into the NuA and VTA promotes feeding123. Endocannabinoids also increase food 
intake via the cannabinoid CB1 receptor. CB1 receptors are highly expressed in the 
reward centres and modulate dopaminergic signalling in these regions124,125. Blocking 
CB1 receptors using antagonists, such as rimonabant, inhibits food intake and results in 
weight loss in rodents and humans126,127. However, rimonabant has now been 
withdrawn as a treatment for obesity due to psychiatric complications128. It is therefore 
 27 
important when developing anti-obesity treatments, to be aware of the interaction of 
gut hormones with reward centres of the brain and potential side effects these may 
cause.  
1.2.2 Peripheral regulation of energy balance 
 
1.2.2.1 The gut-brain axis 
 
Anticipation of a meal, mechanical stimulation due to the presence of food in the 
stomach and gut nutrient content, stimulate secretion of gut hormones which activate 
signalling pathways from the gut to the brainstem and hypothalamus (the gut-brain 
axis) to terminate food consumption. In addition to direct effects via the circulation, gut 
hormones may also affect food intake via the vagus nerve as previously described. These 
signalling pathways are summarised in figure 1.2. Such ‘anorectic’ hormones include 
PYY, pancreatic polypeptide (PP), CCK, OXM and GLP-1. Circulating levels of these 
hormones rise following a meal and are proportional to the caloric intake and 
composition of a meal129-132. In contrast, ghrelin is an ‘orexigenic’ hormone and initiates 
hunger prior to a meal.  
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Figure 1.2 Signalling pathways between the gut and central nervous system. Gut hormones 
acting via vagal afferents act on the NTS in the brainstem which in turn signals to the 
hypothalamus. Some gut hormones may also act directly on hypothalamic nuclei via the 
circulation. Projections exist between hypothalamic nuclei and the pre-frontal cortex, involved in 
conditioned taste aversion, as well as reward centres such as the amygdala and nucleus 
accumbens. Abbreviations:  Dorsal vagal complex (DVC), peptide tyrosine tyrosine (PYY), 
cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), amygdala (Amyg.), nucleus accumbens 
(NuA), pancreatic polypeptide (PP).  (Reproduced from Simpson et al 2010)133.  
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1.2.2.2 Secretin family peptides 
 
Peptide hormones within the secretin family are expressed in endocrine cells of the 
pancreas, GI epithelium and neurones in the brain. They exert several biological 
functions including regulation of growth, food intake, glucose homeostasis, gut transit 
and digestion and EE134. The secretin family comprises glucagon, GLP-1, GLP-2, glucose-
dependent insulinotropic peptide (GIP), growth hormone releasing hormone (GHRH), 
secretin, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating 
peptide (PACAP). These hormones are structurally related (see figure 1.3) and their 
active site is contained within the N terminal amino acids. They exert their actions 
through the evolutionarily distinct G protein coupled receptor (GPCR) ‘class B’ or 
‘secretin’ family. These receptors consist of a large N-terminal extracellular domain, 
which plays an important role in ligand binding, and seven transmembrane helices with 
intra and extracellular loops followed by an intracellular C terminal domain. In addition, 
there are variations of these receptors as a result of post-translational processing or 
interaction with receptor activity-modifying proteins (RAMPs). Three RAMPs have been 
identified, the presence of which can alter the structural confirmation of the receptor 
and thus ligand binding. The calcitonin-like receptor belongs to the class ‘B’ GPCR 
family. In the presence of RAMP 1, this receptor binds to and is activated by calcitonin 
gene related peptide. However, in the presence of RAMP 2 or RAMP 3, it is activated by 
adrenomedullin 135. RAMP2 also interacts with the glucagon receptor and the PTH1 
receptor, and RAMP3 interacts with the secretin receptor136. The significance of these 
RAMP and receptor pairings are unknown although their presence suggests alternative 
receptor morphology and potential agonists. 
Following binding of secretin family peptides to the GPCR class B family of receptors, 
these hormones activate adenylate cyclase and increase cAMP through downstream 
signalling pathways137. Although each hormone binds to its own respective receptor, at 
high doses, they can bind to other receptors within the family. For example, PACAP 
binds to several GPCRs including PAC1 (highest affinity to PACAP), VPAC1 and VPAC2 
(VIP receptors) but can also bind to the secretin receptor at high doses138.  Due to their 
similarity within the secretin family, these hormones exert similar biological effects in 
the gut including inhibition of gastric acid secretion, increased insulin production and 
delayed gastric emptying. This thesis focuses on two members of the secretin family, 
glucagon and GLP-1, and the regulation of food intake, EE and glucose homeostasis. 
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1.2.2.3 Glucagon-like peptide-1 (GLP-1) 
 
GLP-1, along with glucagon, GLP-2, glicentin, OXM and other peptides are all encoded by 
the preproglucagon gene. The preproglucagon gene is widely expressed in the CNS, 
intestinal L cell and pancreatic α cells139 and encodes a larger precursor called 
proglucagon. The post translational products depend on the tissue-specific presence of 
prohormone convertase (PC). In α cells, the pancreatic action of PC2 produces 
glucagon140 whereas PC 1/3 action in intestinal L cells and the CNS produces GLP-1, 
GLP-2 and OXM141 (Figure 1.4). 
      
Figure 1.4 Post translational products of the preproglucagon gene. Products are dependent 
on site-specific presence of prohormone convertase (PC) 2 and 1/3. Abbreviations: glicentin 
related pancreatic polypeptide (GRPP), intervening peptide (IP), glucagon (Gcg), glucagon-like 
peptide-1 (GLP-1), glucagon-like peptide 2 (GLP-2). 
 
GLP-1 is produced by the post translational processing of proglucagon by PC1 and 3 in 
the intestinal L cells and CNS. Within the L cells of the intestine, GLP-1 is released into 
the circulation but is rapidly degraded by the action of dipeptidyl peptidase IV 
(DPPIV)142  resulting in a half life of just a few minutes. In the brain, preproglucagon 
mRNA expression is exclusively seen in the caudal region of the NTS and overlaps with 
vagal afferent terminals from the gut143,144. GLP-1 receptors are found in the PVN, ARC, 
DMN and SON of the hypothalamus and the AP, NTS and DMV of the brainstem145-148. 
GLP-1 immunoreactive (-ir) fibres are more widespread and have been identified in the 
hypothalamus, particularly the PVN, DMN, SON with lower densities seen in the ARC and 
VMN and the CeA 143,149. Retrograde labelling has identified a large number of GLP-1-ir 
neurones that project from the NTS to the PVN, DMN and SON143,144,150.  
GLP-1R are also extensively found outside the CNS including α,  and  cells of the 
pancreatic islets, liver, lung, heart, kidney, stomach and intestine151,152. GLP-1 and 
GRPP Gcg IP-1 GLP-1 IP-2 GLP-2 COOHNH
GRPP Gcg GLP-1       IP-2 GLP-2IP-1
major proglucagon fragment
PANCREAS
GRPP Gcg IP-1 GLP-2GLP-1 IP-2
INTESTINE AND BRAIN
glicentin
oxyntomodulin
Proglucagon
PC2 PC1/3
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exendin-4 (a GLP-1R agonist) administered ICV or subcutaneous (s/c) increase blood 
pressure and heart rate in rats although this may be a dose dependent effect 153. In 
contrast, increasing evidence suggests beneficial cardiovascular effects following GLP-1 
administration in patients with type 2 diabetes 154,155. 
In humans, intravenous (iv) infusion of GLP-1 reduces food intake in both lean and 
overweight volunteers156,157  and those with type 2 diabetes158. Due to the short half life 
of circulating GLP-1, long acting analogues such as exenatide and liraglutide have been 
developed. Both exenatide and liraglutide cause weight loss in patients with type 2 
diabetes 159,160. Both GLP-1 analogues are now licenced for the use in patients with type 
2 diabetes due to the effects on weight loss and improved glycaemic control161. GLP-1 
lowers blood glucose mainly through its incretin effect and glucose dependent 
stimulation of insulin from pancreatic  cells162. GLP-1 also inhibits glucagon release163 
and delays gastric emptying164. The precise mechanism of GLP-1 induced inhibition of 
glucagon is unclear however it has been postulated that GLP-1 binds to the GLP-1R on 
pancreatic α cells and inhibits glucagon release through a direct mechanism163. 
Alternatively, glucagon may be inhibited indirectly by GLP-1 induced secretion of 
insulin, which itself reduces circulating glucagon. However, GLP-1 is able to suppress 
glucagon release from pancreatic islets in patients with type 1 diabetes that have no 
residual  cell insulin secretion165. 
The GLP-1 analogues, exenatide and liraglutide not only reduce food intake and cause 
weight loss as discussed previously, but they also improve glucose control through the 
release of insulin and inhibition of glucagon166. Similarly, DPPIV inhibitors such as 
sitagliptin, prolong GLP-1 action and reduce glucose in patients with diabetes167. Finally, 
GLP-1 agonists stimulate  cell proliferation and inhibit apoptosis through the release of 
transcription factors, thereby increasing  cell mass168. 
1.2.2.4 Glucagon 
 
Glucagon is a 29 amino acid peptide secreted by the α cells of the pancreas and was first 
discovered by Kimball and Murlin in the 1920s169. Fifty years later, the glucagon 
receptor (GCGR) was identified170. Cloning of the receptor cDNA in 1993 identified it as 
belonging to the class B GPCR family134. Although there is a high degree of homology 
between GLP-1 and glucagon and their receptors, these peptides bind with a high degree 
of selectivity to their respective receptors171. To date, only one GCGR has been identified 
and this is predominantly expressed in the liver and kidney172. Lower levels of GCGR 
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mRNA are found in the heart, lung, adipose tissue, spleen, small intestine, adrenal 
glands, endocrine pancreas and brain172. In the brain, GCGRs have been detected in the 
olfactory tubercle and bulb, hippocampus, anterior pituitary, amygdala, septum, 
medulla, thalamus and hypothalamus173.  
Expression of GCGR in extra-hepatic tissues suggests a broader role of glucagon beyond 
glucose homeostasis. During feeding, gut hormones known to regulate appetite, 
including GLP-1, PYY and PP, are released and signal to the brain to initiate meal 
termination. In rats, circulating glucagon also increases within the first few minutes of 
ingestion, peaks at the end of a meal and gradually returns to premeal levels within 10 
minutes174. This pattern is also seen during sham feeding175 suggesting cephalic neural 
stimuli, rather than an effect of gut nutrients or mechanical gastric distension, account 
for the rise in glucagon. In humans, glucagon is also secreted at the time of meal 
ingestion176,177. However, obese non-diabetic subjects show slower glucagon release 
following a meal compared to lean controls178. This is in contrast to the response seen in 
patients with type 2 diabetes in whom glucagon production in response to 
hypoglycaemia is normal or reduced, yet the secretion of glucagon in response to meals 
is typically exaggerated179. 
Peripherally administered glucagon, whether given by the s/c, intraperitoneal (ip), iv or 
intramuscular (im) route in animals and humans, decreases food intake180-187. In 
contrast, administration of glucagon antibodies increases meal size and duration in 
rats183,188. In obese Zucker rats, higher doses of ip glucagon are required compared to 
lean controls to elicit the same anorectic response189. Consistent with this, repeated ip 
glucagon reduces the ability of the hormone to reduce food intake in rats190. These 
findings suggest a state of ‘glucagon resistance’ in obese animals or tachyphylaxis in 
response to repeated administration, both situations requiring higher doses to elicit an 
anorectic effect.  
The best characterised role of glucagon is in the regulation of glucose homeostasis via 
the activation of liver enzymes controlling gluconeogenesis and glycogenolysis. 
Glucagon release is stimulated by low circulating levels of glucose, certain FFAs and 
amino acids191,192. In contrast, insulin, GLP-1 and somatostatin have an inhibitory effect 
on glucagon secretion193-196. Hypoglycaemia causes the rapid release of glucagon from 
pancreatic α cells via parasympathetic and sympathetic nerves that convey signals from 
the VMN to the islets of Langerhans197. In addition, the liver contains afferent and 
efferent connections from the hypothalamus that are implicated in the control of glucose 
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homeostasis and the regulation of feeding. Stimulation of the VMN increases liver 
glycogenolysis and consequently blood glucose198. In contrast, stimulation of the LHA 
decreases blood glucose via activation of hepatic glycogen synthesis through the 
stimulation of vagal parasympathetic nerves. Blood glucose concentration is also 
influenced by glucocorticoids, adrenaline and hormones such as thyroid hormones, sex 
hormones and growth hormone all of which can modify gluconeogenic enzymes in the 
liver. Once glucagon is released by pancreatic α cells, it enters the bloodstream, where 
its main target is the liver. Circulating glucagon is hydrolysed by DPPIV resulting in a 
short half life of 1-2 minutes199. Clearance of glucagon also occurs at the liver and 
kidney200.  
Glucagon antagonists have been developed in an attempt to reduce hepatic glucose 
output associated with raised glucagon levels seen in patients with type 2 diabetes201. 
Glucagon antagonism in rodent models of obesity, decreases blood glucose 202-204 and 
long term (18 weeks) inhibition of the GCGR using a monoclonal antibody normalises 
blood glucose in DIO mice205. However, these studies show no significant changes in 
food intake or body weight. Furthermore, concern has been expressed regarding the 
administration of glucagon antagonists in patients with type 2 diabetes as native 
glucagon protects against hypoglycaemia206. Lastly, glucagon antagonists stimulate 
hepatic lipogenesis and increase cholesterol levels207, additional effects that are 
undesirable in patients with diabetes. 
The effects of glucagon on glucose homeostasis are well documented however less is 
known about its role in EE and thermogenesis. Glucagon secretion is stimulated by cold 
acclimatisation208 and peripheral administration of glucagon in rats increases oxygen 
consumption and body temperature209. In humans, glucagon increases EE by 15% when 
co-infused with somatostatin210. However, the mechanism through which glucagon 
increases EE is unknown. Two explanations have been proposed211, firstly an increase in 
thermogenesis by brown adipose tissue (BAT) and secondly, futile substrate cycling  
whereby energy-consuming cyclical metabolic pathways are stimulated but with no net 
change in product formation in the liver or other tissues212. 
 In vitro studies suggest that glucagon may increase EE via stimulation of oxygen 
consumption and heat production in BAT213,214. In rats, glucagon administration 
increases whole body oxygen consumption, body temperature, blood flow as well as 
temperature and mass of BAT215,216. Many of these effects are attenuated by propranolol, 
a non-selective  adrenergic receptor blocker, as well as denervation of BAT, suggesting 
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a role for the sympathetic nervous system in increased EE following glucagon 
administration 217,218. Longer-term studies also implicate BAT in glucagon-induced 
thermogenesis. Glucagon infusion via continuous osmotic mini pumps for 5 days (at 
both physiological and pharmacological doses) increases guanosine diphosphate (GDP) 
binding to brown fat mitochondria216. Importantly however, most studies investigating 
the role of glucagon and EE administer pharmacological doses of glucagon which could 
activate the hypothalamic-pituitary-adrenal axis and hence a ‘stress response’. A 
physiological role for glucagon in the regulation of EE remains to be determined.  
1.2.2.5 Gut hormones 
 
1.2.2.5.1 Oxyntomodulin 
Like GLP-1, OXM is secreted from intestinal L cells post-prandially. No specific receptor 
has been identified for OXM. However, OXM acts as an agonist at both the GLP-1R and 
GCGR 219-221. In rodent and human studies, OXM has been shown to reduce food intake 
and body weight, increase EE and improve glucose control220,222,223. In addition, 
following gastric bypass surgery, obese patients exhibit a two fold rise in OXM, GLP-1 
and PYY levels following an oral glucose load compared to controls who had similar 
body weight loss due to dieting 224. These findings suggest that these changes in 
circulating gut hormone levels are due to the surgical procedure rather than weight loss 
and account for the improved glucose profile seen so rapidly following surgery. It has 
been proposed that the effects of OXM on food intake occur mainly via the GLP-1R. Food 
intake and c-fos activation in the ARC following peripheral OXM were blocked by the 
prior administration of exendin(9-39)225. Furthermore, GLP-1R knockout mice do not 
demonstrate reduced food intake following centrally administered OXM219. Peripheral 
OXM also significantly increases c-fos expression in the PVN, AP and NTS. This is 
abolished in GLP-1R but not GCGR knockout mice219. This suggests that the anorectic 
effect of OXM relies on the presence of a functional GLP-1R. However, both GLP-1 and 
OXM increase heart rate in mice. This effect is abolished in GLP-1R knockout mice 
following GLP-1 administration but not OXM226. Therefore, OXM may have effects that 
are independent of the GLP-1R.  
Kosinski et al, have developed a OXM agonist that differs from OXM by only one residue, 
yet has no significant activity at the GCGR227. Chronic treatment with OXM in mice, 
produces significant weight loss compared to the GLP-1R agonist, suggesting a beneficial 
weight lowering effect through GCGR agonism227. Studies in GLP-1R and GCGR knockout 
mice have also demonstrated the important contribution of GCGR agonism in EE and 
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weight loss228,229. Repeated administration of a dual GCGR and GLP-1R agonist results in 
weight loss and reduced food intake in wild-type mice, however this effect is attenuated 
in GCGR knockout mice228. Similarly, administration of a dual glucagon and GLP-1 
receptor agonist for one month to DIO mice, significantly decreases food intake, body 
weight and fat mass and increases EE compared to controls229. These effects are still 
evident following administration in GLP-1R knockout mice229. Therefore OXM provides a 
unique model of dual receptor agonism, causing weight loss through a reduction in food 
intake via the GLP-1 receptor and increased EE via the GCGR. 
1.2.2.5.2 Peptide tyrosine tyrosine (PYY) 
PYY is a member of the pancreatic polypeptide (PP) fold family of peptides released by 
L-cells in the gut into the circulation following a meal. Members of the PP-fold family 
include NPY, PYY and PP which share a common tertiary structure called the PP-fold and 
are involved in food intake regulation. PYY is a 36 amino acid peptide and cleaved at the 
N-terminus by DPPIV to create the truncated form PYY3-36. Full length PYY binds to the 
GPCRs Y1, Y2 and Y5. PYY3-36 has highest affinity for the Y2 receptor and is able to cross 
the BBB freely by a non-saturable mechanism230. The Y2 receptor is an inhibitory 
presynaptic receptor highly expressed on ARC NPY neurones12. NPY neurones also 
release GABA which causes tonic inhibition of POMC neurones231. Therefore the 
anorectic action of PYY occurs through inhibition of NPY neurones and reduction of 
GABA-mediated inhibition of POMC neurones. 
PYY is released into the circulation following a meal, with levels rising to a plateau after 
1-2 hours and remaining elevated for up to 6 hours129. The rise in PYY levels is 
proportional to caloric intake and meal composition, so that fatty meals result in a 
higher rise compared to protein or carbohydrate meals232. PYY 3-36 reduces food intake 
and body weight in rodents and humans233,234 and improves insulin sensitivity in rodent 
models of DIO 235. In obese subjects, the rise in PYY following a meal is blunted resulting 
in impaired satiety and hence greater food intake236.  
In addition to a hypothalamic effect of PYY 3-36, there is evidence that PYY 3-36 also acts at 
the brainstem. Y2 receptors are found in important brainstem regions involved with 
appetite control such as the AP and NTS 88,237. Peripheral administration of PYY 3-36 
causes c-fos activation in these areas238  and lesioning of the brainstem-hypothalamic 
neuronal pathways or vagotomy abolishes the anorectic effects of peripheral PYY 3-36  
87,88. It therefore appears that PYY 3-36 can also exert an anorectic affect via the vagus 
nerve to the brainstem, which in turn has connections to the hypothalamus.  
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1.2.2.5.3 Pancreatic polypeptide (PP) 
PP is secreted by PP cells in the pancreatic islets of Langerhans following a meal and 
circulating levels are proportional to calories ingested. Peripheral injection of PP in 
mice239, dogs240 and humans241 dose-dependently reduces food intake. Transgenic mice 
which overexpress PP are lean and demonstrate reduced food intake242. In human 
studies, iv infusion of PP causes a significant reduction in hunger and food intake 243. 
These anorectic effects are thought to be principally mediated through the Y4 receptor 
since the effect is abolished in Y4 receptor knockout mice244. Ip administration of PP 
causes c-fos activation in the AP and NTS of the brainstem and ARC, PVN, DMN, VMN and 
LHA of the hypothalamus245. Y4 receptors are highly expressed in all these regions246.  
1.2.2.5.4 Cholecystokinin 
CCK was the first gut hormone shown to have an effect on food intake247. CCK is released 
from I cells of the small intestine and levels rise rapidly following a meal, reaching a 
peak within 15 minutes248. Peripheral administration of CCK reduces food intake in 
rodents and humans247,249. Although there are two CCK receptors: CCK1 and CCK2, the 
anorectic effect appears to be mediated through the CCK1 receptor. CCK 1 receptor 
knockout rats are obese and ip injection of a CCK1 antagonist results in weight gain250. 
However, feeding studies to date have been conflicting and although CCK infusions in 
rodents decreases meal size, some reports have found a compensatory increase in meal 
frequency251. The CCK2 receptor may also have a minor role since CCK2 receptor 
knockout mice are hyperphagic and have increased body weight compared to wild 
types252. However, the anorectic effect following peripheral administration of CCK is 
retained in CCK2 receptor knockout mice253 and both agonists and antagonists at the 
CCK2 receptor show no effect on food intake254,255.  
Ip administration of CCK increases c-fos expression in the DMN and CART neurones in 
the PVN256,257. Direct administration of CCK into the DMN decreases food intake258 and 
down regulates NPY gene expression64,250. The anorectic effect of CCK is abolished 
following vagotomy259  suggesting that vagal afferent fibres signalling to the DVC in the 
brainstem are responsible for the reduction in food intake260.  
1.2.2.5.5 Ghrelin 
Unlike other gut hormones, ghrelin initiates hunger prior to a meal and increases food 
intake261,262. Ghrelin is produced by the stomach and is an endogenous ligand for the 
GHS-R1 receptor. Ghrelin-ir neurones are found adjacent to the 3rd ventricle in the brain 
and between the DMN, VMN, PVN and ARC in the hypothalamus263. Furthermore, ghrelin 
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neurones have terminals on hypothalamic NPY/AgRP, POMC and CRH neurones in 
addition to orexin fibres in the LHA263-265. It appears that the orexigenic effect of ghrelin 
is mediated predominantly through NPY/AgRP ARC neurones. Peripheral 
administration of ghrelin stimulates c-fos expression in ARC NPY/AgRP neurones and 
increases hypothalamic NPY mRNA expression261. Ghrelin-induced feeding is abolished 
by central administration of NPY and AgRP antibodies and antagonists in rats261 and in 
NPY and AgRP null mice266. 
In addition to effects on ARC NPY/AgRP neurones, ip administration of ghrelin also 
stimulates c-fos expression in the PVN267. Direct injection of ghrelin into the PVN 
stimulates food intake268. This effect is attenuated by pre-treatment with a melanocortin 
agonist 268 or s/c rimonabant, an endocannabinoid CB1 receptor antagonist269. In 
addition, ghrelin does not induce an orexigenic effect in CB1 receptor knockout mice270. 
This suggests that the orexigenic effect of ghrelin is dependent on the endocannabinoid 
system, with possible modulation of anorectic neurotransmitters such as -MSH. 
1.2.2.6 Leptin 
 
Leptin is secreted by adipocytes and circulates at concentrations proportional to fat 
mass. Leptin administration in rodents and humans decreases food intake and body 
weight271-273. However large amounts of adipose tissue resulting in high circulating 
levels of leptin, leads to leptin resistance and a lack of expected anorectic effect274. 
Rodents and humans lacking leptin are obese and hyperphagic, although this can be 
ameliorated by leptin administration275-277. Leptin is able to cross the BBB and bind to 
the leptin receptor (Ob-Rb) in the hypothalamus278. The predominant effects of leptin on 
food intake and EE are mediated in the ARC, causing activation of anorectic POMC 
neurones and inhibition of orexigenic AgRP/NPY neurones34,231. Leptin also decreases 
MCH and orexin and increases CRH gene expression in the hypothalamus279-281 and 
leptin administration appears to modulate ghrelin signalling in the ARC262. Although 
reduction of food intake and body weight by leptin is largely attributed to its 
hypothalamic actions, administration of leptin into the 4th ventricle or DVC of the 
brainstem, have similar anorectic effects282. In addition, direct injection of leptin into the 
NTS increases STAT3 phosphorylation (transcription activator downstream of the leptin 
receptor) in the ARC and VMN282. Since vagotomy in rats does not attenuate the 
anorectic response to peripherally administered leptin283, it is unclear what the role of 
leptin in the brainstem may be. Peripheral administration of leptin increases c-fos 
activation in the NTS283, where vagal afferent fibres terminate. It has been suggested 
that leptin may interact with anorectic gut hormone pathways signalling via the vagus 
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nerve. The leptin receptor is co-expressed with the CCK-1 receptor in the rat nodose 
ganglion284 and a subset of gastric vagal afferents which are unresponsive to leptin 
alone, become leptin sensitive after prior treatment with CCK285.  Furthermore, the 
anorectic response following ICV leptin administration, is blocked by ip devazepide, a 
CCK1 receptor antagonist286. These findings suggest that leptin acting at the brainstem 
to reduce food intake requires intact CCK signalling286. Conversely, in rodents, central or 
peripheral leptin pretreatment enhances CCK-induced anorexia272,287,288 suggesting a 
synergistic mechanism between leptin and CCK in the control of food intake at the level 
of the brainstem. 
1.2.2.7 Insulin 
 
Insulin also acts in the brain as an adiposity signal. Like leptin, it is able to cross the BBB 
and reduces food intake and increases EE 289. Insulin inhibits NPY/AgRP neurones in the 
ARC17. However, the anorectic effects of insulin may also reflect an interaction with the 
melanocortin system. Insulin receptors are present on ARC POMC neurones and ICV 
administration of insulin increases ARC POMC mRNA expression290. Furthermore, the 
anorectic actions of insulin are blocked by melanocortin antagonists17,290. 
 
1.3 Regulation of energy expenditure and body weight 
EE is the amount of work required by the body to sustain vital functions such as 
thermogenesis, physical activity, cardiac function and respiration. Total EE can be 
divided into three main components. Firstly, the basal metabolic rate (BMR) which is the 
minimum energy required by the body at rest to ensure function of cells and tissues. 
This represents approximately 60-75% of total EE and depends largely on body weight 
and body composition. Secondly, physical activity on average accounts for 15-30% of 
total daily EE. Finally, energy is also expended through adaptive thermogenesis in 
response to cold, food and physical activity. All three components of EE are tightly 
regulated, predominantly by central circuits in the brainstem and hypothalamus in 
addition to peripheral tissues including skeletal muscle and BAT. 
1.3.1 Central regulation of energy expenditure 
 
1.3.1.1 Cold induced thermogenesis 
 
For an organism to maintain a constant core body temperature despite changes in 
environmental temperature, it must be able to adapt its heat production accordingly. 
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Following exposure to cold, autonomic and hormonal responses activate a number of 
heat saving mechanisms including cutaneous vasoconstriction to conserve heat in the 
body core, piloerection, and shivering. However, animals are able to adapt to prolonged 
cold exposure and as the initial heat produced by shivering in skeletal muscle declines291  
other thermogenic mechanisms begin to take effect in tissues such as BAT and skeletal 
muscle292,293.  
Thermoreceptors in the skin transmit sensory information via the spinal dorsal horn to 
the lateral PBN in the pons and subsequently to the medial preoptic area (MPO) of the 
hypothalamus294. Inhibition of MPO neurones completely blocks the activation of BAT 
thermogenesis and the increases in EE and heart rate seen following skin cooling295. 
Although the precise mechanism is unknown, it is thought that afferent signals from 
thermoreceptors result in excitation of neurones from the MPO to the DMN and the 
rostral raphe pallidus nucleus (rRPn) in the brainstem295. Inhibition of neurones in the 
DMN blocks cold-evoked excitation of BAT sympathetic nerve activity and 
thermogenesis296 in addition to shivering thermogenesis297. Since neurones in the DMN 
have not been found to project directly to sympathetic preganglionic neurones but do 
project to the rRPN, it is thought that increased BAT thermogenesis is due to excitation 
of rRPN neurones via the DMN298. The rRPN is located in the brainstem medulla, a key 
area containing sympathetic premotor neurones. Retrograde tracing techniques indicate 
that interscapular BAT sympathetic premotor neurones project to the rRPn and PVN299. 
Stimulation of rRPN neurones using glutamate agonists and GABAA receptor antagonists, 
increases BAT sympathetic nerve activity outflow and thermogenesis300,301. The rRPn 
also has projections to skeletal muscle, and increases in muscle electromyography 
(EMG) activity and shivering are seen following excitation of rRPn neurones suggesting 
a role for rRPn neurones in shivering thermogenesis302,303.  
Within the inner mitochondrial membrane of BAT adipocytes, a specialized proton 
transport channel is located, called uncoupling protein-1 (UCP-1)304,305. Under normal 
circumstances in most tissues, the oxidation of fuel substrates results in mitochondrial 
ATP production through oxidative phosphorylation. Oxidative phosphorylation is driven 
by an electrochemical gradient across the mitochondrial inner membrane whereby 
protons move down the gradient and enter the mitochondrial matrix through ATP 
synthase. In BAT, the presence of UCP-1 protons bypass ATP synthase and the energy of 
the electrochemical gradient is dissipated as heat. Two UCP-1 homologues, UCP-2306 and 
UCP-3307, have also been identified, with 59 and 57% homology to UCP-1, respectively. 
Both homologues demonstrate proton transport activity suggesting they may play a role 
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in adaptive thermogenesis. However, despite having a similar action to UCP-1, their 
distributions are far more widespread. UCP-2 is present in many organs and cell types at 
varying levels and UCP-3 is predominantly expressed in skeletal muscle308. 
Furthermore, expression of UCP-2 and UCP-3 is up-regulated during fasting309,310, a state 
normally associated with reduced EE.   
During cold acclimatisation, hypothalamic activation of the sympathetic nervous system 
(SNS) innervating BAT increases noradrenaline (NA) which binds to 3-
adrenoreceptors. Adrenergic stimulation activates the production of cAMP, which 
activates UCP-1 in addition to inducing lipolysis. The resulting increase in FFAs 
following lipolysis enhances UCP-1 activity. Although the precise interaction between 
FFAs and UCP-1 is not yet known, two mechanisms have been proposed. Firstly, it is 
thought UCP-1 may directly transport protons from the intermembrane space to the 
matrix, with carboxyl groups from FFAs acting as cofactors311. However, an alternative 
mechanism suggests that FFAs cross the inner membrane causing proton dissociation 
and UCP-1 subsequently transports the resulting FA anions back across the 
membrane293,312. This ‘cycling’ of FFAs drives uncoupling of oxidative phosphorylation 
and the dissipation of energy as heat (Figure 1.5). 
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Figure 1.5 Thermogenesis in brown adipose tissue. Signals from the hypothalamus activate 
the sympathetic nervous system (SNS) resulting in the release of noradrenaline (NA). In brown 
adipocytes, NA binds primarily to 3-adrenoreceptors (3). Adrenergic stimulation activates the 
production of cAMP, which in turn induces lipolysis. The resulting increase in free fatty acids 
(FFAs) further enhances UCP-1 activity. This results in the uncoupling of oxidative 
phosphorylation and the dissipation of energy as heat. Abbreviations: α1 adrenoreceptor (α1), 
stimulatory G protein (Gs), adenylate cyclase (AC), cyclic adenosine monophosphate (cAMP),  
triglycerides (Tg), uncoupling protein-1 (UCP-1), thyroid hormone (TH), 2-iodothyronine 
deiodinase (D2), thyroxine (T4), tri-iodothyronine (T3), heart rate (hr), free fatty acid (FFA), 
sympathetic nervous system (SNS), noradrenaline (NA). 
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1.3.1.2 Sympathetic nervous system (SNS) 
 
The SNS is a well known activator of adaptive thermogenesis and is controlled centrally 
by the hypothalamus and brainstem. Stimulation of the SNS results in the release of NA 
from synaptic nerve terminals and binding to β3-adrenergic receptors in BAT to 
promote UCP-1 production. In addition, stimulation of α1 adrenergic receptors by NA 
increases thyroid hormone activation of UCP-1 in BAT (see section 1.3.2.2). Finally, SNS 
stimulation of the heart increases heart rate and blood flow to organs. The role of the 
SNS in adaptive thermogenesis has been supported by studies using SNS blockers313,314, 
β-adrenergic receptor agonists313,314 and in mice lacking NA315. Peripheral 
administration of hexamethonium, an antagonist at the nicotinic acetylcholine receptor 
in sympathetic and parasympathetic ganglia, prevents the rise in oxygen consumption 
following cold exposure in rats314. In contrast, atropine, an antagonist at the muscarinic 
receptors of the parasympathetic nervous system (PNS), did not have this effect, 
implying a role for the SNS but not PNS in thermogenesis314. Similarly, infusion of NA 
increases oxygen consumption and core body temperature in rats316. Furthermore, beta-
dopamine hydroxylase knockout mice are unable to synthesise NA or adrenaline and 
have lower core body temperatures 315. These findings highlight the importance of the 
SNS and the effects of catecholamines in thermogenesis. 
1.3.2 Peripheral regulation of energy expenditure 
 
1.3.2.1 Diet induced thermogenesis 
 
Diet induced thermogenesis is the short term increase in EE observed in response to 
food intake and accounts for approximately 10% of total EE. EE rises following ingestion 
of food but declines during periods of starvation317,318. Heat production arises from the 
digestion, absorption and storage of food.  
 
1.3.2.2 Brown adipose tissue (BAT) 
 
BAT, in contrast to white adipose tissue (WAT), is involved in the production of heat 
rather than storage although both are derived from mesenchymal stem cells319. 
Adipocytes in BAT contain large number of mitochondria and high expression of UCP-1. 
BAT is well recognised to have an important role in the maintenance of body 
temperature in animals and human neonates320,321. Increased BAT activity in rodents 
promotes EE, reduces adiposity and protects mice from DIO 322,323. Recent studies using 
positron emission tomography-computed tomography (PET-CT) have shown that BAT is 
also present in human adults, with reduced activity seen with increasing obesity324. In 
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most mammals, BAT is predominantly found in the interscapular region and axillae325, 
although in mice it has also been found in small amounts in skeletal muscle326. In 
addition, adipocytes in WAT have been shown to differentiate into BAT in response to 
cold or prolonged -adrenergic stimulation322. Furthermore, epidydimal WAT 
adipocytes in rats chronically treated with rosiglitazone (a PPAR gamma agonist) share 
BAT-type characteristics, show increased UCP-1 expression and are known as ‘brite’ 
(brown-in-white) or ‘beige’ adipocytes327.  Finally, the isolation of ‘beige’ cells from WAT 
in mice have been reported which have a distinct gene expression profile from brown or 
white adipocytes. Despite showing low basal levels of UCP1, they respond to cAMP with 
raised UCP-1 expression328.  
 
1.3.2.3 Hypothalamic-pituitary-thyroid axis 
 
The hypothalamo-pituitary-thyroid (HPT) axis has been shown to play an important 
role in regulating EE. Thyrotropin-releasing hormone (TRH), synthesised in the PVN, 
reaches target cells in the anterior pituitary via the pituitary portal vein to stimulate the 
release of thyroid-stimulating hormone (TSH) into the circulation.  TSH in turn 
stimulates the release of thyroid hormone (TH) from the thyroid gland. TH is a key 
modulator of adaptive thermogenesis. Even a modest increase in TH can result in 
thermogenesis, whereas the opposite effect is observed when TH levels are reduced329. 
However, the precise mechanism through which TH stimulates thermogenesis is not 
fully understood.  
A large number of TH receptors are expressed on BAT tissue330 and TH appears to 
directly stimulate transcription of the UCP-1 gene331. UCP-1 gene expression can also be 
regulated indirectly by 2 iodothyronine deiodinase (D2), an enzyme which catalyses the 
conversion of inactive TH (T4/thyroxine) to the active form (T3/tri-iodothyronine)332. 
D2 is highly expressed in BAT and is activated by the SNS via 1-adrenergic receptors333.  
1.3.2.4 Skeletal muscle 
 
Unlike rodents and newborns, adult humans have very little BAT suggesting the 
presence of other thermogenic mechanisms. Skeletal muscle contributes up to 40% of 
total body mass and accounts for approximately 20-30% of total resting oxygen 
uptake334. In addition, up to 50% of adrenaline-induced thermogenesis in humans has 
been demonstrated to originate from skeletal muscle335. In humans, mitochondrial 
respiration is decreased in skeletal muscle of patients with type 2 diabetes and those 
who are obese336,337. 
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Despite these findings, the precise mechanism through which skeletal muscle dissipates 
heat is unknown.  UCP-3 expression appears to be mainly limited to skeletal muscle 
suggesting a role in skeletal muscle thermogenesis. Mice overexpressing UCP3 are 
leaner and more insulin sensitive338 despite being hyperphagic339. Consumption of a 
high fat diet in rodents increases UCP-3 mRNA levels in skeletal muscle340. Over-
expression of UCP-3 in transgenic mice results in mitochondrial uncoupling in skeletal 
tissue and resistance to DIO when fed a high fat diet341. Interestingly, a newly identified 
protein named irisin, is secreted by skeletal muscle in mice and stimulates UCP-1 
expression and BAT-type differentiation in WAT 342. Circulating levels of irisin increase 
in mice and humans following exercise342. In addition,  raised levels of plasma irisin in 
mice fed a high fat diet, increases EE, weight loss and improves glucose control342. These 
findings suggest that in response to excessive energy intake, increased expression of 
UCP-3 and production of irisin in skeletal muscle increases EE by stimulating 
thermogenesis in skeletal muscle, BAT and WAT.  
 
1.4 Summary 
Obesity is increasingly prevalent and associated with several disease states that 
decrease life expectancy. There are no effective pharmacological agents that reduce 
body weight long-term and those currently on the market, have many unwanted side 
effects. Body weight is maintained by complex mechanisms involved in the regulation of 
food intake and EE. Following a meal, gut hormones signal to the brain via the 
circulation and vagus nerve. ‘Anorectic pathways’ within the hypothalamus and 
brainstem signal to other areas within the brain including reward centres, resulting in a 
feeling of fullness and meal termination. In addition, adiposity signals such as leptin 
signal to the brain to convey information about energy reserves.  
Body weight is also controlled through EE. Following a meal, EE increases to ‘burn off’ 
calories consumed. EE is also increased following cold acclimatisation in order to 
produce heat. Thermoreceptors in the skin signal to key areas in the brain which in turn 
activate peripheral tissues such as BAT and skeletal muscle to increase thermogenesis. 
Although the precise mechanisms through which thermogenesis occurs is poorly 
understood, over the past few decades research has focused on mitochondrial 
uncoupling proteins that play a major role in energy homeostasis. 
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GLP-1 is secreted from the gut following a meal and signals to the brain to reduce food 
intake. Long-acting analogues of GLP-1 are used in patients with type 2 diabetes to 
improve glucose control and promote weight loss.  Glucagon also reduces food intake. 
However, evidence suggests a predominant role for glucagon in increasing EE. The 
combination of glucagon and GLP-1 has not previously been investigated and could offer 
a novel dual mechanism through which weight loss could be sustained. This thesis 
therefore focuses on the effects of glucagon and GLP-1 independently, and in 
combination, on food intake, EE and glucose homeostasis. 
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1.5 Hypotheses 
Gut hormones are important in the regulation of energy homeostasis and body weight. 
This thesis focuses on the role of glucagon and GLP-1 as members of the secretin family 
of peptides, in the regulation of food intake, EE and glucose homeostasis.  
Specifically, I hypothesise that: 
 Co-administration of glucagon and GLP-1 in mice acutely reduces food intake to 
a greater degree than each hormone alone, and that these effects are mediated 
by specific interaction with satiety centres in the hypothalamus and brainstem. 
 Chronic co-administration of novel glucagon and GLP-1 analogues in DIO mice 
reduces body weight and improves glucose homeostasis, to a greater degree 
than each analogue alone, and that this effect is due to reduced food intake and 
increased EE.  
 Co-administration of glucagon and GLP-1 reduces food intake, increases EE and 
maintains normoglycaemia following infusion in overweight human volunteers. 
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1.6 Aims 
In this series of investigations, I aimed to: 
 
 Investigate the acute effects of co-administration of glucagon and GLP-1 in mice, 
on food intake and c-fos expression in the hypothalamus and brainstem. 
 Investigate the chronic effects of co-administration of novel glucagon and GLP-1 
analogues on food intake, body weight and glucose homeostasis in DIO mice. 
 Investigate the effect of co-administration  of glucagon and GLP-1 on food intake, 
EE and glucose homeostasis in overweight human volunteers. 
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CHAPTER 2:  
 
THE EFFECTS OF CO-
ADMINISTRATION OF GLUCAGON 
AND GLP-1 ON ENERGY 
HOMEOSTASIS IN RODENTS 
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2.1 Introduction  
Glucagon and GLP-1 are both products of the preproglucagon gene which is found in the 
CNS, in intestinal L cells and pancreatic α cells139. In the brain, preproglucagon mRNA 
expression is exclusively seen in the caudal region of the NTS (cNTS) and overlaps with 
vagal afferent terminals from the gut143,144. Although glucagon opposes the action of 
GLP-1 on glucose homeostasis, both hormones share an anorectic effect. Peripherally 
administered glucagon decreases food intake and body weight in both rodents and 
humans181,182,184,187,343. Conversely, administration of glucagon antibodies increases meal 
size in rats183,188. GLP-1 receptor agonists are licensed for the treatment of type 2 
diabetes mellitus344. In addition to improving glycaemia159, they reduce appetite, 
producing modest weight loss159,160.   
GLP-1 is released into the circulation following a meal in proportion to the calories 
consumed132. Peripheral administration of GLP-1 in mice and rats reduces food intake345 
and increases c-fos-ir in the brainstem and the PVN, but not in the ARC87,219,225. 
Vagotomy or ablation of the brainstem-hypothalamus pathways attenuates the 
reduction in food intake seen following peripheral GLP-1 administration 87,346. This 
suggests that peripheral effects are predominantly mediated via the brainstem. 
However, central administration of GLP-1 to rats also inhibits food intake 346 and 
activates c-fos expression in the ARC, amygdala and PVN346,347. This anorectic effect is 
abolished in rats with ARC lesions induced by s/c monosodium glutamate 147. In 
addition, intra-ARC injection of exendin(9-39) (a GLP-1R antagonist) diminishes the 
anorectic effects of centrally but not peripherally administered GLP-1225. Therefore, the 
anorectic effect of GLP-1 appears to depend on the mode of administration. Although the 
precise mechanism of GLP-1 induced anorexia is unknown, GLP-1R mRNA is densely 
expressed in the ARC and is found in over 60% of ARC neurones that also express POMC 
mRNA 348,349. Furthermore, ICV administration of exendin-4, a GLP-1R agonist, activates 
α-MSH/POMC neurones in the ARC350. These findings suggest that activation of the 
melanocortin system in the brain may be responsible for the anorectic effect of GLP-1. 
In rats, circulating glucagon also increases within the first few minutes of ingestion, 
peaks at the end of a meal and gradually returns to pre-meal levels within 10 minutes174. 
This pattern is also seen during sham feeding175 suggesting cephalic neural stimuli, 
rather than an effect of gut nutrients or mechanical gastric distension, account for the 
rise in glucagon. In humans, glucagon is also secreted at the time of meal ingestion176,177. 
Peripherally administered glucagon, whether given by the s/c, ip, iv or im route in 
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animals and humans, decreases food intake180-187. In contrast, administration of 
glucagon antibodies increases meal size and duration in rats183,188.The glucagon 
anorectic signal appears to reach the brain via the vagus nerve since total 
subdiaphragmatic vagotomy, selective hepatic vagotomy or lesions in the AP and NTS all 
prevent its anorectic effect181,351-353. However, the mechanism by which glucagon 
generates a vagal afferent signal is unknown and GCGRs have not been identified on 
vagal sensory neurones. This suggests an indirect mechanism perhaps through the 
release of other hormones. It has been proposed that glucagon reduces food intake 
indirectly through changes in circulating glucose levels, insulin secretion or another 
unknown mechanism190,354. The satiety effect of glucagon may depend on its 
glycogenolytic and hyperglycaemic effects, since glucagon inhibits feeding less potently 
when liver glycogen is reduced by prolonged fasting354. However, the stress induced by 
such a prolonged fast and the subsequent hunger may override the anorectic effects of 
glucagon. Furthermore, hyperglycaemia alone does not reduce food intake since iv 
glucose infusions do not inhibit feeding in monkeys, dogs or rats 355-357.  In addition, 
glucagon does not suppress food intake in sham fed animals despite marked 
hyperglycaemia358. Previously it was thought that the anorectic effect of glucagon was 
mediated by an increase in insulin secretion190. However, the anorectic effects of hepatic 
portal vein glucagon infusion in rats are not affected by co-administration with insulin 
or insulin antibodies359. Alternatively, glucagon may cause activation of a stress 
response and stimulation of the SNS or aversive signals such as nausea. CTA studies in 
response to glucagon administration have not been described, however ip glucagon 
reduces food intake in rats without affecting the normal behavioural sequence of 
satiety182. 
Despite these findings, the mechanisms through which GLP-1 or glucagon exert their 
anorectic effects are still unknown. Historically, the deleterious effect of unopposed 
glucagon on glucose homeostasis has discouraged study of the mechanism by which 
glucagon reduces appetite. In particular, the pattern of neuronal activation in the CNS 
after peripheral administration of glucagon has not been described. The individual 
anorectic effects of GLP-1 and glucagon are attenuated by vagotomy or by ablation of 
brainstem-hypothalamic pathways suggesting a peripheral mechanism of action 
mediated by the vagus nerve87,181,346,351-353. However, like other gut hormones, it is 
possible that glucagon and GLP-1 also act directly via the circulation and an incomplete 
BBB at the hypothalamus and brainstem360. Central administration of GLP-1 in rodents 
also inhibits food intake and GLP-1R mRNA is densely expressed in the ARC 348,349. 
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Similarly, central administration of glucagon in animals, reduces food intake361-363 and 
although much lower levels of GCGR mRNA are detected in the brain compared to the 
periphery, CNS GCGR mRNA expression is strongest in the hypothalamus and 
amygdala173,364. 
Therefore, my aim was to establish whether glucagon and GLP-1, whilst evolutionarily 
similar, cause c-fos activation in distinct areas within the brain to exert an anorectic 
effect. In order to investigate the relationship between the anorectic effects of glucagon 
and GLP-1, I have studied their individual and combined effects on acute food intake in 
mice. I used c-fos immunohistochemistry to characterise neuronal activation following 
the administration of glucagon and GLP-1. My aim was to determine whether these two 
hormones act via distinct pathways and whether lower doses of each individual 
hormone could be administered in combination to cause a significant reduction in food 
intake. In addition, I studied the effect of glucagon and GLP-1 co-administration on 
circulating glucose. My aim was to determine whether co-administration of low doses of 
glucagon and GLP-1 was associated with a change in plasma glucose concentration.  
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2.2 Hypotheses and Aims 
2.2.1 Hypotheses  
 
I hypothesised that: 
 
 glucagon and GLP-1 administration decreases food intake in a dose dependent 
manner. 
 
 co-administration of glucagon and GLP-1 causes a greater reduction in food 
intake than each hormone alone. 
 
 co-administration of glucagon and GLP-1 ameliorates the rise in glucose 
observed following glucagon alone. 
 
 peripheral administration of glucagon and GLP-1 activates distinct areas in the 
brain to reduce food intake. 
 
 
 
 
2.2.2 Aims 
 
To investigate: 
 the anorectic effect of peripheral glucagon administration at different doses, in 
fed and fasted states and at different periods during the light and dark phase of 
feeding. 
 the effects of glucagon and GLP-1 co-administration on food intake and glucose 
levels at sub-anorectic doses. 
 which areas in the brainstem and hypothalamus are activated by peripheral 
administration of glucagon. 
 which areas in the brainstem and hypothalamus are activated by sub-anorectic 
doses of glucagon and GLP-1 in combination.  
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2.3 Materials and Methods 
 
2.3.1 Peptide synthesis 
 
Human glucagon and GLP-1 were purchased from Bachem Ltd. (Merseyside, UK).  
 
2.3.2 Animal husbandry and conditions 
 
All animal procedures undertaken were approved by the British Home Office Animal 
(Scientific Procedures) Act 1986 (Project Licence 70/7236). Adult male C57BL/6 mice 
(Charles River, Margate, UK) weighing 25-30 g were maintained in individual cages 
under controlled temperature (21-23oC) and lights (12:12 hr light-dark cycle, lights on 
at 0700).  Animals were allowed ad libitum access to water and RM1 diet (Special Diet 
Services, Witham, UK) unless otherwise stated.  Animals were regularly handled and 
acclimatised to ip or s/c injections in order to reduce non-specific stress at the time of 
the study. 
 
2.3.3 Investigation of the acute effects of glucagon on food intake in mice  
 
Experiments were carried out during the early light phase (0800-1000), after fasting 
from 1600 the preceding day unless otherwise specified. Randomisation of treatment 
allocation was stratified by body weight. All mice were injected (maximum volume 50 
µl) within a single 30 minute period, with individual injection times noted, then 
returned to their home cages with a known amount of food. Food was reweighed at 30, 
90 and 180 minutes post injection. Doses of glucagon administered are provided for 
each experiment and are based on previous studies185,365.  
 
2.3.4 Investigation of the acute effects of GLP-1 on food intake in mice  
 
Experimental procedures were performed as described in section 2.3.3. Based on 
previous studies 345,366, mice received s/c GLP-1 at 3, 10, 30, 50, 100 or 600 nmol/kg or 
saline (n=6). 
 
2.3.5  Investigation of the acute effects of glucagon and GLP-1 co-
administration on food intake in mice 
 
Experimental procedures were carried under identical conditions as described in 
section 2.3.3. Based on the results of the dose response studies (section 2.4.1 and 2.4.2), 
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each mouse received two s/c injections, one of 30nmol/kg glucagon or saline, and the 
other of 10 nmol/kg GLP-1 or saline, in quick succession (n=6).  
 
2.3.6 Investigation of the acute effects of glucagon and GLP-1 co-
administration on glucose homeostasis in mice 
 
Experiments were carried out during the early light phase (0800-1000) in ad libitum fed 
mice. This was to ensure minimal hepatic glycogen depletion due to an overnight fast. 
Randomisation of treatment allocation was stratified by body weight. On the basis of 
results of the dose response studies, each mouse received two s/c injection, 
saline/saline, saline/glucagon (30 nmol/kg), saline/GLP-1 (10 nmol/kg) or glucagon 
(30 nmol/kg)/GLP-1 (10 nmol/kg) in combination. All mice were injected (maximum 
volume 50 µl) within a single 15 minute period, with individual injection times noted, 
then returned to their home cages and food removed. Tail tip capillary glucose 
measurements were taken at -30, 0, 15, 30 and 60 minutes post injection and measured 
using a hand held glucometer (Contour glucometer, Bayer Diabetes Care, UK). 
 
2.3.7 Tissue preparation and c-fos immunohistochemistry   
 
Experiments were carried out during the early light phase (0800-1000) in mice fasted 
from 1600 the preceding day. Animals were group housed (n=5/cage, weighing 20-25g) 
and for two weeks prior to experimentation, mice were handled on a daily basis and 
sham injected on at least three separate occasions. Mice (n=5-6 per group) were injected 
with a maximum volume of 50 µl s/c of either saline or peptide and immediately 
returned to their cages. Ninety minutes later, mice were injected with 0.4 mls ip 
pentobarbitone (Euthatal, Merial Animal Health Ltd, Harlow, UK) prior to decapitation. 
Whole brains were rapidly removed and immediately placed in formaldehyde solution 
(Sigma-Aldrich, UK). After 24 hours the brains were transferred to falcons containing 
40% sucrose solution (Sigma-Aldrich, UK) in which they remained for 3-4 days. The 
brains were then snap frozen in isopentane (VWR, UK) which had been cooled in liquid 
nitrogen (BOC, UK) and the brains stored at -80oC. Coronal sections through the 
brainstem and hypothalamus were cut at 40 µm using a sled microtome. Free floating 
sections were stored at -20oC in 24 well plates containing antifreeze solution (0.02M 
phosphate buffer solution (PBS), glycerol (VWR, UK), ethylene glycol (Sigma-Aldrich, 
UK)) until c-fos immunohistochemistry was undertaken. 
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c-fos immunohistochemistry 
Free floating sections were transferred to mesh wells in holding trays containing 0.01M 
PBS (Invitrogen, UK). After being washed three times in 0.01M PBS, slices were placed in 
methanol (VWR, UK) containing 0.6% hydrogen peroxide for 15 minutes to quench 
endogenous peroxidases. Following a further three washes in 0.01M PBS, slices were 
immersed in blocking solution in order to block endogenous proteins, comprising 0.01M 
PBS with 3% goat serum and 0.25% Triton X (BDH, UK) for 2 hours. These slices were 
then transferred to wells containing the above blocking solution with 1:20,000 rabbit 
anti c-fos antibody (Merck Chemicals Ltd, Nottingham, UK) and left to incubate on a 
shaker overnight. The following day, sections were washed three times in 0.01M PBS 
with 0.05% Tween (VWR, Lutterworth, UK) (PBST) followed by a 2 hour incubation in 
secondary antibody solution, comprising 0.01M PBS with 0.3% bovine serum albumin 
(Sigma-Aldrich, UK), 0.25% Triton-X and biotinylated anti-rabbit IgG (1:400 
concentration) (Vector Laboratories, Peterborough, UK). This was followed by a further 
3 washes in PBST  and then one hour incubation in avidin-biotin peroxidase complex 
(ABC) solution (Vector Laboratories, UK). This was made up using 1:200 dilution of both 
avidin and biotin in 0.05M TrisHCl (pH 7.6). Following the one hour incubation, slices 
were washed three times in PBST before transferring to holding wells containing 0.01M 
PBS with 1% diaminobenzedine tetrahydrochloride (50mg/ml) (Sigma-Aldrich, UK) and 
0.01% hydrogen peroxidase. Sections were closely observed during the staining 
procedure and transferred to trays containing 0.01M PBS in order to terminate the 
reaction. Following two washes in PBS, sections were mounted onto polylysine-coated 
slides and left to dry overnight. The next morning, the sections were dehydrated 
through a series of graded ethanols and finally xylene (VWR, UK), prior to mounting 
with DPX and cover slips. The slides were left to dry prior to visualising under a 
microscope and the number of c-fos positive nuclei counted manually. Data are 
presented as the mean and standard error of the mean (SEM) number of c-fos positive 
cellular nuclei across a hypothalamic or brainstem nucleus as defined in a mouse brain 
atlas367. In the hypothalamus the following nuclei were studied: ARC, PVN, DMN, VMN 
and LH. 
 
2.3.8 Investigation of the acute effects of glucagon on c-fos 
immunoreactivity in the brainstem and hypothalamus 
  
Experiments were carried out during the early light phase (0800-1000) in mice fasted 
from 1600 the preceding day. Animals were group housed (n=5/cage, weighing 20-25g) 
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and for two weeks prior to experimentation, mice were handled on a daily basis and 
sham injected on at least three separate occasions. Mice (n=5-6 per group) were injected 
with a maximum volume of 50 µl s/c of either saline or glucagon (30, 100, 300, 500 and 
750 nmol/kg) and immediately returned to their cages. Ninety minutes later, mice were 
injected with 0.4 mls ip pentobarbitone (Euthatal, Merial Animal Health Ltd, Harlow, 
UK) prior to decapitation. Tissue preparation and c-fos immunohistochemistry was 
subsequently performed as described in section 2.3.7.  
 
2.3.9  Investigation of the acute effects of GLP-1 on c-fos immunoreactivity 
in the brainstem and hypothalamus  
 
Experimental procedures were performed as described in section 2.3.8. Mice were 
injected with s/c saline or GLP-1 (3, 30, 50, 100 and 600 nmol/kg). 
 
2.3.10 Investigation of the acute effects of glucagon and GLP-1 co-
administration on c-fos immunoreactivity in the brainstem and 
hypothalamus  
 
Experimental procedures were performed as described in section 2.3.8. Based on results 
from the dose response studies (section 2.4.1 and 2.4.2), each mouse received two s/c 
injections, one of 30 nmol/kg glucagon or saline, and the other of 10 nmol/kg GLP-1 or 
saline, in quick succession (n=6). 
 
2.3.11 Statistical analysis 
 
All data are expressed as mean ± SEM unless specified. Data from acute feeding and c-fos 
immunohistochemistry were analysed using one-way ANOVA followed by Dunnett’s 
post test. Data comparing co-administration of glucagon and GLP-1, each hormone alone 
and saline controls was analysed using one-way ANOVA with Bonferroni multiple 
comparison test. Data from circulating glucose levels following administration of 
glucagon and GLP-1 alone and in combination was analysed using two-way repeated 
measures ANOVA with Bonferroni post test. In all cases, values of p<0.05 were 
considered statistically significant. 
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2.4 Results 
2.4.1 Investigation of the acute effects of glucagon on food intake in mice  
 
This study was performed in mice fasted from 1600 the preceding day. Mice received 
s/c glucagon (500, 750 or 1000 nmmol/kg) or saline at the onset of the light phase.  
Glucagon significantly reduced food intake in fasted mice within the first 30 minutes 
(mean food intake: 0.50±0.06 [saline] vs. 0.26±0.05g [500 nmol/kg], p<0.05 vs. saline; 
0.12±0.03g [750 nmol/kg], p<0.01 vs. saline; 0.23±0.11g [1000 nmol/kg], p<0.05 vs. 
saline; n=6 per group. Fig. 2.1). There were no significant effects on food intake at 
subsequent time points. 
The experiment was repeated under a series of different conditions to ascertain the 
optimal protocol to demonstrate the anorectic effect of glucagon. It has previously been 
postulated that duration of fasting may affect the anorectic response to glucagon190,368 
and therefore this was also studied. In addition, I wanted to determine the appropriate 
conditions to undertake c-fos immunohistochemistry studies. The experimental 
conditions were: 
 ad libitum fed mice at the onset of the light phase (figure 2.2), 
 mice fasted from 0600 on the day of the study and injected midway through the 
light phase (figure 2.3), 
  ad libitum fed and mice fasted from 0600, injected at the onset of the dark phase 
(figure 2.4).  
There was no anorectic effect in fed mice following injection of glucagon whether 
injected at the onset of the light or dark phase (figure 2.2 and 2.4 respectively). In 
contrast, the anorectic effect of glucagon was seen within the first 30 minutes in mice 
fasted from 0600 and injected midway through the light phase (mean food intake: 
0.25±0.02 [saline] vs. 0.07±0.01g [500 nmol/kg] , p<0.01 vs. saline; 0.13±0.03g [750 
nmol/kg], p<0.01 vs. saline; 0.09±0.02g [1000 nmol/kg], p<0.01 vs. saline; n=6 per 
group, fig. 2.3). Similarly, glucagon significantly reduced food intake within the first 30 
minutes in mice fasted from 0600 and injected at the onset of the dark phase (mean food 
intake: 0.47±0.04 [saline] vs. 0.12±0.06g [500 nmol/kg], p<0.01 vs. saline; 0.10±0.04g 
[750 nmol/kg], p<0.01 vs. saline; 0.04±0.01g [1000 nmol/kg], p<0.01 vs. saline; n=6 per 
group, fig. 2.4). 
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Figure. 2.1 The acute effect of glucagon on food intake in fasted mice at the onset of the 
light phase. Study performed in mice fasted from 1600 the day before. Mice received s/c 
injection at the onset of the light phase of saline (controls), glucagon 500, 750 or 1000 nmol/kg. 
Food intake was measured at 30, 90 and 180 minutes following injection. Results expressed as 
mean ± SEM. Data were analysed using one way ANOVA with Dunnett’s post test. *p<0.05, 
**p<0.01 versus controls. n=6/group. 
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Figure. 2.2 The acute effect of glucagon on food intake in fed mice at the onset of the light 
phase. Study performed in ad libitum fed mice at the onset of the light phase (0800-1000). Mice 
received s/c injection of saline (controls), glucagon 500, 750 or 1000 nmol/kg. Food intake was 
measured at 30, 90 and 180 minutes following injection. Results expressed as mean ± SEM. Data 
were analysed using one way ANOVA with Dunnett’s post test. n=6/group. 
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Figure. 2.3 The acute effect of glucagon on food intake in fasted mice midway through the 
light phase. Study performed in mice fasted from 0600 on the day of the study and injected 
midway through the light phase (1400). Mice received s/c injection of saline (controls), glucagon 
500, 750 or 1000 nmol/kg. Food intake was measured at 30, 90 and 180 minutes following 
injection. Results expressed as mean ± SEM. Data were analysed using one way ANOVA with 
Dunnett’s post test. **p<0.01 versus controls. n=6/group. 
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Figure.2.4 The acute effect of glucagon on food intake in fed and fasted mice at the onset of 
the dark phase. Study performed in ad libitum fed and daytime fasted (from 0600 on day of 
study) mice, injected at the onset of the dark phase (1900). Mice received s/c injection of saline 
(controls), glucagon 500, 750 or 1000 nmol/kg. Food intake was measured at 30, 90 and 180 
minutes following injection. Results expressed as mean ± SEM. Data were analysed using one way 
ANOVA with Dunnett’s post test. **p<0.01 versus controls. n=6/group. 
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In order to determine the minimum effective dose of glucagon in reducing food intake, 
an acute feeding study was performed following a range of doses of glucagon. Mice were 
fasted from 1600 the day before and injected at the onset of the light phase (Fig. 2.5). 
This timing was chosen in order to perform the c-fos immunohistochemistry protocol 
(section 2.3.7) during the light phase for practical reasons and in order to reduce stress 
to the mice which could occur if moving animals around during the onset of the dark 
phase. 
Consistent with my previous study, the anorectic effect of glucagon was observed within 
the first 30 minutes only. The lowest effective dose in reducing food intake was 100 
nmol/kg (mean food intake: 0.56±0.04 [saline] vs. 0.30±0.06g [100 nmol/kg], p<0.01 vs. 
saline; n=6/group, fig. 2.5A).  
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Figure. 2.5 Dose response study of the acute effect of glucagon on food intake. Study 
performed at the onset of the light phase in mice fasted from 1600 the day before. Mice received 
s/c injection of saline (controls) or glucagon (3, 10, 30, 100, 300, 500, 750 nmol/kg). Food intake 
was measured at 30, 90 and 180 minutes following injection. Results expressed as mean ± SEM. 
Data were analysed using one way ANOVA with Dunnett’s post test.  **p<0.01, *** p<0.001 versus 
controls. n=6/group. 
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2.4.2 Investigation of the acute effects of GLP-1 on food intake in mice 
 
Previous studies have investigated the effects of GLP-1 on food intake under different 
experimental conditions in rodents 345,369,370. The acute effects of GLP-1 on food intake 
were investigated under identical experimental conditions as described following 
glucagon administration in figure 2.5. A similar protocol was used by Neary et al, in 
which an acute anorectic effect was shown following GLP-1 administration at the onset 
of the light phase in mice fasted for 20 hours345.  
S/c GLP-1 decreased food intake within 30 minutes following administration (Fig. 2.6 
A). The highest dose investigated (600 nmol/kg) produced an anorectic effect which 
persisted at 90 minutes post-injection. Following administration of GLP-1 at doses lower 
than 600 nmol/kg, the anorectic effect was not observed by 90 minutes post injection 
(Fig. 2.6 B). The lowest effective dose of GLP-1 was 30 nmol/kg (mean food intake: 
0.49±0.03g [saline] vs. 0.23±0.03g [30 nmol/kg], p<0.01; n=6/group, fig 2.6 A).  
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Figure 2.6. Dose response study of the acute effect of GLP-1 on food intake in fasted mice. 
Study performed at the onset of the light phase in mice fasted from 1600 the day before. Mice 
received s/c injection of saline (controls) or GLP-1 (3, 10, 30, 50, 100, 300, 600nmol/kg). Food 
intake was measured at 30, 90 and 180 minutes following injection. Results expressed as mean ± 
SEM. Date were analysed using one way ANOVA with Dunnett’s post test.  * p<0.05, **p<0.01, 
***p<0.001 versus controls. n=6/group. 
0-30 mins
Saline 3 10 30 50 100 300 600
0.0
0.2
0.4
0.6
0.8
1.0
**
***
*** ***
GLP-1 (nmol/kg)
 A
Fo
od
 in
ta
ke
 (
g)
30-90 mins
Saline 3 10 30 50 100 300 600
0.0
0.2
0.4
0.6
0.8
1.0
*
GLP-1 (nmol/kg)
B
Fo
od
 in
ta
ke
 (
g)
90-180 mins
Saline 3 10 30 50 100 300 600
0.0
0.2
0.4
0.6
0.8
1.0
GLP-1 (nmol/kg)
C
Fo
od
 in
ta
ke
 (
g)
 67 
2.4.3 Investigation of the acute effects of glucagon and GLP-1 co-
administration on food intake in mice  
 
In order to establish whether co-administration of glucagon and GLP-1 had an additive 
effect on reducing food intake, a sub-threshold dose of each peptide was administered 
alone and in combination. Mice were fasted from 1600 the preceding day and injected at 
the onset of the light phase, as dose response studies following glucagon and GLP-1 
administration alone were performed under these experimental conditions. Based on 
the results from studies 2.4.1 and 2.4.2 these sub-anorectic doses were: glucagon 30 
nmol/kg and GLP-1 10 nmol/kg. Higher doses in combination were also studied to 
investigate anorectic doses as shown in studies 2.4.1 and 2.4.2. The medium dose was 
chosen to reflect the lowest anorectic dose found. The high dose was used as a positive 
control (glucagon 750 nmol/kg and GLP-1 300 nmol/kg).   
At sub-anorectic doses, administration of glucagon or GLP-1 alone did not significantly 
reduce food intake compared to saline in the first 30 minutes (fig. 2.7 A). However, co-
administration of GLP-1 and glucagon at these doses significantly reduced food intake 
(mean food intake: 0.39±0.06 [saline] vs. 0.24±0.06g [GLP-1 10 nmol/kg], p=0.64 vs. 
saline; 0.42±0.07g [glucagon 30 nmol/kg], p=1.0 vs. saline; 0.08±0.06g [GLP-1 10 
nmol/kg and glucagon 30 nmol/kg], p<0.01 vs. saline; n=6/group, fig 2.7A). 
Higher doses of glucagon (750 nmol/kg) and GLP-1 (30 nmol/kg and 300 nmol/kg) 
alone, significantly reduced food intake compared to saline controls. At all three dose 
ranges (glucagon: 30, 100 and 750 nmol/kg; GLP-1: 10, 30 and 300 nmol/kg), the 
combination of glucagon and GLP-1 significantly reduced food intake to a greater extent 
than saline controls or glucagon (LD and MD) but not GLP-1 (fig. 2.7A). At later time 
points, no significant changes in food intake were seen following administration of GLP-
1, glucagon or GLP-1 and glucagon in combination at any dose range. 
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Figure 2.7. Studies of the effects of co-administration of glucagon and GLP-1 on food 
intake. Study performed at the onset of the light phase in mice fasted from 1600 the day before. 
All mice received two s/c injections in quick succession of either: saline/saline; saline/glucagon 
low dose (LD) 30 nmol/kg, medium dose (MD) 100 nmol/kg or high dose (HD) 750 nmol/kg;  
saline/GLP-1 (10 LD, 30 MD, 300 HD nmol/kg) or glucagon/GLP-1 (at the same doses). Food 
intake was measured at 30 (Fig. 2.7 A), 90 (Fig. 2.7B) and 180 minutes (Fig. 2.7C) following 
injection. Columns presented as GLP-1 alone (GLP-1), glucagon alone (GCG) or in combination 
(GLP-1+GCG). Results expressed as mean ± SEM. Data were analysed using one way ANOVA with 
Bonferroni multiple comparison test *p<0.05, **p<0.01, *** p<0.001 versus saline (controls); 
#p<0.05, ###p<0.001 versus glucagon alone. n=6/group. 
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2.4.4 Investigation of the acute effects of glucagon and GLP-1 co-
administration on glucose homeostasis in mice.  
 
On the basis of the feeding studies, the effect of sub-anorectic doses of glucagon and 
GLP-1 co-administration on circulating glucose levels was studied. At a dose of 30 
nmol/kg, glucagon alone significantly increased glucose levels within 15 minutes 
following injection (mean glucose: 7.2  0.4 [saline] vs. 9.2  0.4 mmol/l [glucagon], 
p<0.001 vs. saline, n=8-9/group, fig. 2.8). Glucose levels following GLP-1 alone (10 
nmol/kg) showed no significant differences to saline controls at any time points.  
Co-administration of glucagon and GLP-1 ameliorated the rise in glucose in response to 
glucagon alone and glucose levels were indistinguishable from saline controls (mean 
glucose: 9.2  0.4 [glucagon] vs. 7.6  0.3 mmol/l [glucagon and GLP-1 co-
administration], p<0.01 vs. glucagon alone, n=8-9/group, fig 2.8).  
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Figure. 2.8 Studies of the effects of co-administration of glucagon and GLP-1 on circulating 
glucose levels. Experiments were performed during the early light phase (0800-1000) in ad 
libitum fed mice. All mice received two s/c injections in quick succession of either: saline/saline; 
saline/glucagon (30 nmol/kg), saline/GLP-1 (10 nmol/kg) or glucagon (30 nmol/kg)/GLP-1 (10 
nmol/kg). Glucose measurements were taken at -30, 0, 15, 30 and 60 minutes post injection. Data 
were analysed using two-way repeated measures ANOVA with Bonferroni post test. *** p<0.001 
versus saline (controls); #p<0.05, ###p<0.001 versus GLP-1 alone, $ p<0.05, $$ p<0.01 versus 
glucagon and GLP-1 co-administration. n=9/group. 
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2.4.5 Investigation of the acute effects of glucagon on c-fos 
immunoreactivity in the brainstem and hypothalamus  
 
This study was conducted to determine whether the dose-dependent reduction in food 
intake seen following glucagon administration in previous feeding studies, correlated 
with c-fos-ir in the brainstem and hypothalamus.  
The lowest glucagon dose to produce a significant increase in AP c-fos-ir was 300 
nmol/kg (mean c-fos counts: 7 ± 4 [saline] vs. 81 ± 22 [glucagon 300 nmol/kg], p<0.05 
vs. saline, n=4-5/group, fig. 2.9 A, 2.11A and 2.12). A similar dose-dependent increase in 
c-fos-ir was seen in the cNTS, following glucagon administration (mean c-fos counts: 3 ± 
1 [saline] vs. 108 ± 6 [glucagon 300 nmol/kg], p<0.05 vs. saline, n=4-5/group, fig. 2.9 B, 
2.11A, 2.12). In the PBN there was a significant increase in c-fos-ir at 500 nmol/kg only 
(mean c-fos counts: 16 ± 1 [saline] vs. 63 ± 10 [glucagon 500 nmol/kg], p<0.05 vs. saline, 
n=3-5/group, fig. 2.9 C, 2.11B and 2.12). 
There were no significant differences in the hypothalamic nuclei studied in c-fos-ir 
between saline controls and glucagon at any of the doses administered. In the PVN, 
there was a non-significant trend towards an increase in c-fos-ir (mean c-fos counts: 13 
± 6 [saline] vs. 27 ± 5 [glucagon 750 nmol/kg], p=0.145 vs. saline, n=3-5/group; fig. 2.10 
B). A dose dependent increase in c-fos-ir occurred in the CeA at a dose of 300 nmol/kg 
and above (mean c-fos counts: 12 ± 3 [saline] vs. 107 ± 5 [glucagon 300 nmol/kg], 
p<0.01 vs. saline, n=4-5/group; fig. 2.10F, 2.11C, 2.12).  
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Figure. 2.9 Brainstem c-fos immunoreactivity following increasing doses of glucagon. s/c 
injections of either saline (controls) or glucagon (30, 100, 300, 500, 750 nmol/kg) were 
administered at the onset of the light phase (0800-1000). Animals were decapitated and brains 
removed 90 minutes following injection. c-fos immunoreactivity counts are shown in the area 
postrema (AP) (fig 2.8 A), caudal nucleus tractus solitarius (cNTS) (fig. 2.8 B) and parabrachial 
nucleus (PBN) (fig 2.8 C) of the brainstem. Data were analysed using one-way ANOVA with 
Dunnett’s post test. *p<0.05, **p<0.01, *** p<0.001 versus saline controls. n=3-5/group. 
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Figure. 2.10 Hypothalamic and central nucleus of the amygdala c-fos immunoreactivity 
following increasing doses of glucagon. s/c injections of either saline (controls) or glucagon 
(30, 100, 300, 500, 750 nmol/kg) were performed at the onset of the light phase (0800-1000). 
Animals were decapitated and brains removed 90 minutes following injection.  c-fos 
immunoreactivity counts are shown in the arcuate nucleus (ARC) (fig 2.9A), paraventricular 
nucleus (PVN) (fig. 2.9B), dorsomedial nucleus (DMN) (fig.2.9C ), ventromedial nucleus (VMN) 
(fig. 2.9D), lateral hypothalamus (LH) (fig.2.9E) and central nucleus of the amygdala (CeA) (fig. 
2.9F). Data were analysed using one-way ANOVA with Dunnett’s post test. ** p<0.01, *** p<0.001  
versus saline controls. n=3-5/group 
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A  
B  
C  
Figure. 2.11 Anatomical diagrams illustrating brain regions studied for c-fos expression. 
AP and NTS (Fig 2.10A pink and green respectively), PBN (Fig 2.10B blue) and CeA (Fig. 2.10C 
orange). Reproduced from Franklin and Paxinos mouse brain atlas367.  
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Figure 2.12. Representative photomicrographs of c-fos immunoreactivity 90 minutes after 
subcutaneous saline or glucagon (750 nmol/kg) administration. a: saline nucleus tractus 
solitarius (NTS) and area postrema (AP); b: glucagon NTS and AP, c: saline parabrachial nucleus 
(PBN), d: glucagon PBN, e: saline central nucleus of the amygdala (CeA), f: glucagon CeA. Scale 
bar=0.1mm. 
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2.4.6 Investigation of the acute effects of GLP-1 on c-fos immunoreactivity 
in the brainstem and hypothalamus  
 
GLP-1 increased c-fos-ir in the AP at a dose of 50 nmol/kg and above (mean c-fos 
counts: 6 ± 2 [saline] vs. 87 ± 14 [GLP-1 50 nmol/kg], p<0.001 vs. saline, n=3-5/group; 
fig. 2.13A) and at doses of 30nmol/kg and greater in the cNTS (mean c-fos counts: 19 ± 6 
[saline] vs. 126 ± 17 [GLP-1 30 nmol/kg], p<0.05 vs. saline, n=4-5/group; fig. 2.13 B). In 
the PBN, there was a significant increase in c-fos-ir at 100 nmol/kg (mean c-fos counts: 
53 ± 13 [saline] vs. 104 ± 16 [GLP-1 100 nmol/kg],p<0.05, n=4-5/group, fig. 2.13C).  
 
GLP-1 did not significantly increase c-fos-ir in the hypothalamic ARC, PVN, VMN, DMN or 
LH (fig. 2.14). In the PVN, there was a non-significant trend towards an increase in c-fos-
ir  (mean c-fos counts: 12 ± 8 [saline] vs. 35 ± 10 [GLP-1 600 nmol/kg], p=0.065 vs. 
saline, n=4-5/group; fig. 2.14 B). A dose dependent increase in c-fos-ir was seen in the 
CeA at a dose of 30 nmol/kg and above (mean c-fos counts: 23 ± 3 [saline] vs. 127 ± 10 
[GLP-1 30 nmol/kg], p<0.05 vs. saline, n=4-5/group; fig. 2.14 F). 
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Figure 2.13. Brainstem c-fos immunoreactivity following increasing doses of GLP-1. s/c 
injections of either saline (controls) or GLP-1 (3, 30, 50, 100, 600 nmol/kg) were performed at 
the onset of the light phase (0800-1000). Animals were decapitated and brains removed 90 
minutes following injection. c-fos like immunoreactivity counts are shown in the area postrema 
(AP) (fig 2.11 A), caudal nucleus tractus solitarius (cNTS) (fig. 2.11 B) and parabrachial nucleus 
(PBN) (fig 2.11 C) of the brainstem. Data were analysed using one-way ANOVA with Dunnett’s 
post test.*p<0.05,  ** p<0.01, *** p<0.001  versus saline controls. n=3-5/group. 
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Figure 2.14. Hypothalamic and central nucleus of the amygdala c-fos immunoreactivity 
following increasing doses of GLP-1. s/c injections of either saline (controls) or GLP-1 (3, 30, 
50, 100, 600 nmol/kg) were performed at the onset of the light phase (0800-1000). Animals 
were decapitated and brains removed 90 minutes following injection. c-fos immunoreactivity 
counts are shown in the arcuate nucleus (ARC) (fig 2.12A), paraventricular nucleus (PVN) (fig. 
2.12B), dorsomedial nucleus (DMN) (fig.2.12C ), ventromedial nucleus (VMN) (fig. 2.12D), lateral 
hypothalamus (LH) (fig.2.12E) and central nucleus of the amygdala (CeA) (fig. 2.12F). Data were 
analysed with one-way ANOVA with Dunnett’s post test.*p<0.05,  ** p<0.01, *** p<0.001  versus 
saline controls. n=3-5/group.  
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2.4.7 Investigation of the acute effects of glucagon and GLP-1 co-
administration on c-fos immunoreactivity in the brainstem and 
hypothalamus 
 
c-fos-ir was assessed in the brainstem of mice following injection of saline (controls), 
GLP-1 (10 nmol/kg) or glucagon (30 nmol/kg) either alone or in combination, at the 
onset of the light phase. These doses were chosen as sub-threshold anorectic doses 
following the results of study 2.4.3.  
In the brainstem, administration of either hormone individually did not significantly 
alter c-fos-ir in the AP, cNTS or PBN compared to saline controls. However, GLP-1 and 
glucagon in combination (10 nmol/kg and 30 nmol/kg respectively) significantly 
increased c-fos-ir compared to saline controls in the AP (mean c-fos counts: 7± 3 [saline] 
vs. 46 ± 9 [GLP-1 and glucagon], p<0.01 vs. saline, n=5-6/group, fig. 2.15 A, 2.17).  GLP-1 
and glucagon in combination did not significantly affect c-fos expression in the cNTS or 
PBN compared to saline controls or compared to each hormone administered 
individually (fig. 2.15B, 2.15C, 2.17). 
In the hypothalamus, administration of sub-anorectic doses of either hormone alone or 
in combination did not alter c-fos-ir in any of the nuclei studied (fig. 2.16). However, 
GLP-1 alone and in combination with glucagon, significantly increased c-fos-ir in the CeA 
(mean c-fos counts:103 ± 19 [saline] vs. 218 ± 18 [GLP-1 10 nmol/kg], p<0.001 vs. 
saline; vs. 362 ± 15  [GLP-1 + glucagon], p<0.001 vs. saline, n=5-6/group, fig. 2.16 F, 
2.17). 
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Figure 2.15. Brainstem c-fos immunoreactivity following co-administration of glucagon 
and GLP-1. Mice were fasted overnight and received s/c injections of either saline (controls), 
GLP-1 (10 nmol/kg), glucagon (30 nmol/kg) or of both doses together at the onset of the light 
phase (0800-1000). Animals were decapitated and brains removed 90 minutes following 
injection. c-fos immunoreactivity counts are shown in the area postrema (AP) (fig 2.14A), caudal 
nucleus tractus solitarius (cNTS) (fig. 2.14B) and parabrachial nucleus (PBN) (fig. 2.14 C) of the 
brainstem. One-way ANOVA with Bonferroni multiple comparison test. ** p<0.01 versus controls. 
n=5-6/group. 
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Figure 2.16. Hypothalamic and central nucleus of the amygdala c-fos immunoreactivity 
following co-administration of glucagon and GLP-1. Mice were fasted overnight and received 
s/c injections of either saline (controls), GLP-1 (10 nmol/kg), glucagon (30 nmol/kg) or of both 
doses together at the onset of the light phase (0800-1000). Animals were decapitated and brains 
removed 90 minutes following injection. c-fos immunoreactivity counts are shown in the arcuate 
nucleus (ARC) (fig 2.15A), paraventricular nucleus (PVN) (fig. 2.15B), dorsomedial nucleus 
(DMN) (fig. 2.15C), ventromedial nucleus (VMN) (fig. 2.15 D), lateral hypothalamus (LH) (fig. 
2.15 E) and central nucleus of the amygdala (CeA) (fig. 2.15F). Data were analysed with one-way 
ANOVA with Bonferroni multiple comparison test. *** p<0.001 versus controls, ### p<0.001 
versus GLP-1, $$$  p<0.001 versus glucagon. n=5-6/group. 
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Figure 2.17. Representative photomicrographs of c-fos immunoreactivity 90 minutes after 
subcutaneous administration of saline, GLP-1, glucagon or GLP-1 + glucagon. a-d: nucleus 
tractus solitarius (NTS) and area postrema (AP); e-h: parabrachial nucleus (PBN); i-l: central 
nucleus of the amygdala (CeA). a: Saline b: GLP-1 (10nmol/kg) c: Glucagon (30nmol/kg) d: GLP-1 
(10 nmol/kg) + glucagon (30 nmol/kg) e: Saline f: GLP-1 (10nmol/kg) g: Glucagon (30nmol/kg) 
h: GLP-1 (10 nmol/kg) + glucagon (30 nmol/kg) i: Saline j: GLP-1 (10nmol/kg) k: Glucagon 
(30nmol/kg) l: GLP-1 (10 nmol/kg) + glucagon (30 nmol/kg). Scale bar =0.1mm. 
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2.5 Discussion 
The individual effects of glucagon and GLP-1 on food intake and c-fos 
expression in the hypothalamus and brainstem. 
The studies described in this chapter investigate the acute effects of glucagon and GLP-1, 
individually and in combination, on food intake and c-fos activation in the brain. The 
current work shows that glucagon has an acute anorectic effect on food intake lasting 30 
minutes, which is dose responsive. The anorectic effect following glucagon injection is 
seen in fasted mice, whether administered at the onset of the light phase, midway 
through the light phase or at the onset of the dark phase. In addition, anorectic doses of 
glucagon increase c-fos-ir in the AP, cNTS and PBN of the brainstem and the CeA. 
However, no change in c-fos-ir is seen in the hypothalamic nuclei studied. GLP-1 also 
reduces food intake in a dose-dependent manner and increases c-fos-ir in the AP, cNTS 
and PBN of the brainstem and the CeA. Similarly, there are no significant changes in c-
fos activation in the hypothalamus following GLP-1 administration.  
These results are consistent with previous studies showing that peripheral 
administration of glucagon180-182,184 and GLP-1 87,156,157 alone causes a significant, acute 
reduction in food intake. However, in contrast to previously published studies, the 
anorectic effect of glucagon appears to be irrespective of the time of injection. In rats, 
following a four hour fast, glucagon significantly reduces food intake by almost 50% 
when injected at 1200 and 1600 (mid-late light phase), but not at 2000 (dark phase)190. 
This raises the possibility that the duration of fasting affects the anorectic response to 
glucagon. Geary et al368 fail to demonstrate an anorectic effect in fed rats following 
glucagon injection. However, the same dose significantly reduces food intake following 
an 8, 12, 18 or 24 hour fast. Similarly, portal vein glucagon infusions in sham 
vagotomised rats cause a greater reduction in food intake in eight hour fasted rats 
compared to four hour fasted rats371. These results are likely to reflect how hungry the 
animals are at the time of the study. Animals that have been fasting for a shorter 
duration will be less hungry and therefore any anorectic effect due to glucagon 
administration may not be discernable. Similarly, my results support the absence of an 
anorectic effect following glucagon administration in fed mice368.  
Peripheral administration of glucagon, at doses shown to reduce food intake, increases 
c-fos-ir in the AP, cNTS and PBN of the brainstem and CeA. Currently, there are no 
published data for c-fos expression in the brain following peripheral administration of 
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glucagon. My results indicate that peripheral glucagon administration activates c-fos in 
CNS areas important in the regulation of food intake. Although the central mechanisms 
underlying the anorectic effect of glucagon are unknown, it is likely that the brainstem 
plays an important role in terminating food intake in response to glucagon 
administration. The finding of diminished anorectic response to glucagon in 
vagotomised animals and those with AP and NTS lesions353, suggests that a vagal 
mediated pathway via the brainstem may be the main site of action. It has been 
hypothesised that glucagon acts on sensory afferents in the liver and/or GI tract and a 
glucagon satiety signal is relayed from these sites to the brain via the vagus nerve181. In 
the current study, peripherally administered glucagon induces c-fos-ir in the cNTS, 
which receives signals directly from the vagus nerve originating in the liver and GI 
tract114 and thus is consistent with this hypothesis.  
The lack of c-fos activation in the hypothalamus seen in the current studies also 
supports the hypothesis that the brainstem is the main site of action for the anorectic 
response to glucagon. However, these findings are in contrast to other studies that 
propose hypothalamic involvement. Administration of glucagon into the 3rd ventricle of 
rats, potently reduces food intake suggesting a hypothalamic site of action362. In 
addition, neuronal activation in glucose sensitive neurones in the LH and VMN, is 
suppressed following electrophoretic application of glucagon363. The discrepancy 
between the current results and previous studies could be due to a number of reasons 
including species differences, doses given, route of administration and peptide 
degradation in vivo. Previous studies were undertaken in rats and glucagon 
administered centrally rather than peripherally. Earlier studies have shown that c-fos 
expression following GLP-1 depends on the route of administration. In rats, ICV 
administration of GLP-1 increases c-fos expression exclusively in the PVN and CeA346, 
whereas peripheral administration of GLP-1 increases c-fos expression in the ARC only 
87. Similarly, in one study OXM was shown to inhibit food intake in mice following ICV 
but not ip administration219. Species differences can also account for discrepancies in 
results. Glucagon acutely stimulates adrenocorticotrophin hormone (ACTH) release 
from the pituitary gland in humans372. In contrast, a decrease in ACTH for the first ninety 
minutes is seen in response to glucagon in anaesthetised rats373. Finally, both glucagon 
and GLP-1 are subject to proteolytic degradation in the circulation142,199. This may 
explain why vagal mediated activation of c-fos in the brainstem is apparent, yet direct 
activation of hypothalamic nuclei via the circulation is not seen.  
 85 
It is possible that the anorectic effect of glucagon and GLP-1 is mediated via a ‘stress 
response’ via stimulation of the hypothalamo-pituitary-adrenal (HPA) axis to release 
corticosterone in rodents or sympathetic activation of the adrenal medulla causing 
release of catecholamines. Glucagon, GLP-1 and exendin-4 (a GLP-1R agonist) are known 
to stimulate the HPA axis and SNS in rats, mice and humans374-379. The HPA axis 
modulates food intake initially through the production of CRH in the PVN which 
modulates NPY380 and leptin signalling381 in the hypothalamus. In addition, CRH causes 
release of ACTH from the anterior pituitary which affects food intake and EE in humans 
through the stimulated production of cortisol46. However, if the anorectic effect seen in 
the current studies following either glucagon or GLP-1 administration is due to 
stimulation of the HPA axis, one would expect significant c-fos activation in the PVN382.  
Ascending neuronal projections exist between the NTS and PVN102,383 and noradrenergic 
terminals from the NTS exist on CRH and TRH containing neurones in the PVN104,384. In 
my studies, c-fos-ir increases in the PVN in response to high doses of both glucagon and 
GLP-1, however this fails to reach significance. Furthermore, although the magnitude of 
rise in c-fos counts in the PVN between saline controls and glucagon or GLP-1 appears 
significant, absolute c-fos counts are low making interpretation of results difficult. In 
contrast, the increase in c-fos expression in response to saline and glucagon or GLP-1 in 
the brainstem and CeA, is of much greater magnitude and suggests a meaningful 
comparison. Measuring plasma catecholamines and corticosterone during these studies 
may have been useful in elucidating whether the results reflect activation of a ‘stress 
response’. 
Peripheral injection of GLP-1 individually produces a dose related acute reduction in 
food intake and increases c-fos-ir expression in the AP, cNTS and PBN of the brainstem 
and CeA. This is consistent with a previous study, in which hepatic portal vein infusions 
of GLP-1 increases c-fos-ir in the AP, NTS and CeA in rats 385. Further studies of the 
mechanism through which GLP-1 reduces food intake utilise the prolonged action of 
exendin-4, which is resistant to proteolytic cleavage and therefore has a longer half-life 
in vivo. Peripheral administration of exendin-4 activates c-fos expression in the PVN, 
SON and ARC of the hypothalamus and the AP, NTS and PBN in the brainstem of mice 
219,386,387. Similarly, a recent study shows that peripheral exendin-4 increases c-fos 
expression in the AP and NTS and within the enteric nervous system of the GI tract of 
rats388.  
It is thought that exendin-4 decreases food intake through direct activation of GLP-1Rs 
in the hypothalamus and brainstem via the circulation and an incomplete BBB. However, 
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the finding that c-fos activation occurs in enteric neurones in the gut in response to 
exendin-4 388, suggests that vagal afferents from these enteric neurones signalling to the 
brainstem provide another potential mechanism through which exendin-4 and GLP-1 
reduce food intake. This is supported by the findings that vagotomy attenuates the 
anorectic effect of GLP-1 and diminishes c-fos-ir in ARC neurones in response to GLP-1 
in rats 87. In addition, Hayes et al 146 use a decerebrate rat model to demonstrate that the 
brainstem alone is able to elicit the anorectic response to exendin-4. Furthermore, the 
acute anorectic response to exendin-4 is preserved in AP lesioned rats suggesting that 
the NTS is responsible for processing the signals mediating the anorectic response389. 
These studies are consistent with my results that have shown a significant increase in c-
fos-ir in the NTS following GLP-1 administration. 
The current studies have shown that glucagon and GLP-1 independently increase c-fos-
ir in similar areas within the brain, namely the AP, cNTS and PBN of the brainstem and 
CeA. This was unexpected since OXM, an agonist at both the GCGR and GLP-1R, has been 
previously shown to activate different areas in the hypothalamus compared to GLP-1366. 
This suggests that glucagon and GLP-1 also activate distinct regions in the brain.  
The PBN receives extensive projections from the NTS98 and activation of this pathway 
may be responsible for the c-fos-ir observed in the PBN. Likewise, the CeA receives 
projections from both the PBN and NTS390,391 and c-fos expression in this nucleus is 
stimulated by a range of anorectic stimuli including GLP-186,385. However, the role of the 
CeA in appetite control is uncertain. Kainic acid lesions of the CeA increase food intake 
and body weight in rats 392. Similarly, CeA administration of the GABAA antagonist 
bicuculline, results in increased food intake, whereas the GABAA agonist, muscimol, 
decreases feeding393. These results suggest that the CeA is involved in feeding 
regulation, possibly through the activation of GABAA receptors. The CeA appears to be 
predominantly involved in emotional behaviour, particularly anxiety and conditioned 
fear394. However, the amygdala also has connections with the NTS and DMV in the 
brainstem395. Electrical stimulation of the CeA increases pancreatic exocrine secretion 
and decreases gastric motility, whilst both effects are attenuated by vagotomy396,397. This 
suggests that an anorectic effect due to activation of the CeA may reflect reduced gastric 
emptying via the vagus nerve, thereby causing nausea, rather than increased satiety. 
Therefore, the increase in c-fos-ir in the CeA in response to glucagon or GLP-1 
administration observed in my studies, may represent activation of the NTS-CeA 
pathway. Glucagon and GLP-1 are known to reduce gastric emptying164,398  and this may 
be reflected in my results. Although not investigated in my studies, this could be 
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measured using solid and liquid-phase gastric emptying techniques and paracetamol 
absorption studies to assess gut transit time399,400.  
The effects of co-administration of glucagon and GLP-1 on food intake and 
c-fos activation in the brainstem. 
The current studies show that co-administration of glucagon and GLP-1  reduces  food 
intake at doses that alone have no significant anorectic effect Although glucagon and 
GLP-1 co-administration reduced food intake to a greater extent than GLP-1 alone, this 
did not reach statistical significance. Administration of lower doses of GLP-1 that did not 
reduce food intake compared to saline controls would have been useful to investigate 
this further.  
Co-administration of sub-anorectic doses of glucagon and GLP-1 significantly reduce 
food intake compared to controls and increase c-fos-ir in the AP and CeA. These findings 
suggest that low doses of each hormone, which alone are not anorectic, can be given in 
combination to significantly reduce food intake. Clinically, this is of interest due to the 
common side-effect of nausea and vomiting following GLP-1 administration. Up to two-
thirds of patients treated with GLP-1 agonists report nausea, limiting the dose at which 
these agents can be administered401,402. Co-administration of glucagon and GLP-1 has 
not been investigated in humans. Understanding the neuronal pathways involved in the 
anorectic response to glucagon and GLP-1, both independently and in combination, is 
particularly important since both can cause nausea. If both hormones act through a 
common pathway to reduce food intake, combination therapy may allow lower doses to 
achieve anorexia but still cause significant nausea. Although increased c-fos-ir is 
demonstrated in similar areas of the brain following glucagon and GLP-1 administration, 
there may be differences in the specific neuronal populations activated by GLP-1 and 
glucagon within any of the nuclei studied. A further study using immunohistochemistry 
or another method of characterisation of the neurones activated would help to 
determine whether there is any difference in the pattern of neuronal activation induced 
by these two hormones. 
A further study of c-fos expression following peripheral OXM would be interesting. OXM 
is an agonist at both glucagon and GLP-1 receptors219-221. In mice, peripheral (ip) OXM 
significantly increases c-fos expression in the PVN, AP and NTS219. The current studies 
show increased c-fos-ir in the AP and CeA only, following peripheral (s/c) co-
administration of glucagon and GLP-1. In my studies, sub-anorectic doses of glucagon 
and GLP-1 are administered to ascertain whether there is an anorectic effect on food 
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intake following co-administration compared to each hormone alone. The use of such 
low doses may explain the differences in c-fos expression compared to OXM. 
Alternatively, these findings may reflect different routes of hormone administration or 
receptor binding and the activating properties of OXM at the glucagon and GLP-1 
receptor compared to the native hormones. The anorectic effect and c-fos-ir distribution 
seen following peripheral OXM administration is abolished in GLP-1R knockout mice, 
but not GCGR knockout mice219. This suggests that the anorectic effect of OXM is 
mediated through the GLP-1 receptor alone. Furthermore, in the hypothalamus, 
peripheral OXM and GLP-1 activate different regions when assessed using manganese-
enhanced magnetic resonance imaging (MEMRI)366. Following peripheral injection of 
OXM in fasted mice, there is reduced signal enhancement in the ARC, PVN and SON, 
whereas GLP-1 causes a reduction in the PVN only. In the brainstem, GLP-1 and OXM 
administration individually increases signal intensity in the AP366. Surprisingly, there is 
no change in c-fos expression in the hypothalamus or NTS of the brainstem following 
OXM. These results are consistent with my findings following glucagon and GLP-1 co-
administration.  
In the current studies, glucose levels were measured following sub-anorectic doses of 
glucagon and GLP-1, independently and in combination. The acute rise in glucose in 
response to glucagon was attenuated by the co-administration of GLP-1. Although not 
investigated, this effect was assumed to be secondary to GLP-1-mediated insulin release 
from pancreatic  cells. These findings suggest that glucagon and GLP-1 co-
administration may be of therapeutic value in achieving weight loss due to an additive 
anorectic effect, without compromising glucose control. 
In conclusion, the current studies demonstrate that neurones in the brainstem and 
amygdala are activated by anorectic doses of glucagon, and that the pattern of activation 
is indistinguishable from GLP-1. Furthermore low, sub-anorectic doses of glucagon and 
GLP-1 in combination inhibit food intake and increase c-fos-ir in the AP and CeA. 
Overall, these findings suggest that GLP-1 and glucagon receptor co-agonism may have a 
greater satiating effect than agonism of the GLP-1R or GCGR alone. This dual approach in 
targeting both the glucagon and GLP-1 receptor systems may offer additional benefits in 
an obesity treatment compared to GLP-1 alone due to increased anorectic effect.  
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3.1 Introduction 
The naturally occurring gut hormone, OXM, is an agonist at both the glucagon and GLP-1 
receptor219-221 and has been shown to have beneficial effects on food intake220,222,225, 
EE223 and glucose homeostasis403. However, using this hormone alone as a therapeutic 
agent does not allow modification of the extent of co-agonism at each receptor. Study of 
the effects of glucagon and GLP-1 administered individually and in combination, on food 
intake, EE and glucose homeostasis may enable identification of the most beneficial ratio 
of glucagon to GLP-1 receptor agonism to increase EE and reduce food intake, with 
minimal side effects, whilst improving glycaemic control. In doing so, this approach may 
lead to new therapies for overweight patients with type 2 diabetes that have advantages 
above clinically used GLP-1 agonists alone. However, this requires longer term studies 
to investigate whether the acute effects of these therapies are sustained and lead to 
significant weight loss. 
The previous chapter focused on the investigation of glucagon and GLP-1 alone, and in 
combination on food intake, glucose homeostasis and activation of key areas within the 
brain involved with appetite. Both glucagon and GLP-1 have short half-lives of several 
minutes due to enzymatic breakdown within the circulation by DPPIV142,199. In order to 
study long term effects of these peptides in animals, this would necessitate frequent and 
multiple injections in order to achieve raised circulating levels over a 24 hour period, 
potentially leading to stress and disturbance of normal activity. Previous research 
groups have developed analogues containing the amino acid sequences of both glucagon 
and GLP-1 in a single peptide, which bind and activate their respective receptors228,229. 
Chronic administration of these analogues in DIO mice increases weight loss through a 
simultaneous reduction in food intake and increased EE, whilst improving glucose and 
lipid control228,229. All of these findings are of potentially therapeutic benefit to obese 
patients with diabetes in whom multiple agents are often required to control these 
aspects. In the Department of Investigative Medicine, Imperial College, our laboratory 
has designed long-acting glucagon and GLP-1 analogues to investigate the effects on 
food intake, EE, glucose homeostasis and lipid control. The work outlined in this chapter 
focuses on the effects of specific analogues on energy homeostasis. 
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The role of glucagon and GLP-1 in the control of food intake 
Peripheral administration of both glucagon and GLP-1 reduces acute food intake as 
described in chapter 2. GLP-1 analogues have been extensively investigated and cause a 
sustained reduction in food intake leading to modest weight loss in humans (see 
Edwards et al, 2012 for review404). Similarly, glucagon is anorectic in 
rodents181,182,184,185,351. However, whether this effect is apparent following repeated 
administration is unclear. An OXM analogue administered for 14 days in mice causes a 
sustained reduction in food intake compared to a modified OXM analogue which differs 
by only one amino acid but does not bind or activate the GCGR227. This suggests that 
glucagon does reduce food intake following repeated administration.  
The role of glucagon and GLP-1 in the control of energy expenditure (EE) 
Studies investigating the role of GLP-1 and its analogues in the control of EE have been 
conflicting. The administration of exenatide for three months in non-diabetic obese 
humans, causes weight loss and reduced food intake but no change in weight-adjusted 
EE405.  Similarly, once daily administration of the GLP-1R agonist, liraglutide, for four 
weeks, in overweight patients with type 2 diabetes, does not significantly increase 
resting EE406. In support of this finding, ICV injection of GLP-1 in mice increases activity 
of sympathetic nerve fibres innervating interscapular BAT and increases expression of 
genes upregulated by adrenergic signalling and those required for BAT thermogenesis 
(PGC1-α and UCP-1)407. However, in the same study, GLP-1 receptor knockout mice 
show a normal response to cold exposure, suggesting that GLP-1 receptors are not 
essential for the thermogenic response to cold acclimatisation. Although circulating 
catecholamine levels were not measured following ICV injection, the dose of GLP-1 
administered may have stimulated a stress response and activation of the SNS, 
increasing thermogenesis. In healthy volunteers, GLP-1 analogues have been found to 
increase heart rate and cardiac output408,409 and catecholamines during exercise376.  
The evidence for increased EE following glucagon administration is more conclusive, 
although the mechanism is unknown and could also represent a supraphysiological and 
hence stress response. ICV administration of glucagon in mice also increases activity of 
sympathetic fibres innervating BAT and genes involved with adrenergic signalling in 
BAT407. In rats, glucagon administration increases whole body oxygen consumption, and 
body temperature, blood flow to BAT, as well as temperature and BAT mass 215,216. Many 
of these effects are attenuated by propranolol, a non-selective β-adrenergic receptor 
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blocker, as well as denervation of BAT, suggesting a role for the SNS in increased EE 
following glucagon administration217,218. Whether these effects of glucagon and 
increased EE are sustained following repeated administration is unknown. Furthermore, 
should such an increase in EE be sustained, this may not result in reduced body weight. 
Compensatory mechanisms such as increased food intake may override any increased 
EE to maintain stable body weight. 
The role of glucagon and GLP-1 in the control of glucose homeostasis 
Glucagon and GLP-1 have opposing roles in glucose homeostasis when administered 
acutely. GLP-1 is known for its incretin effect, whereby it potentiates glucose-stimulated 
insulin secretion from the pancreas. In contrast, glucagon is best known for its role in 
gluconeogenesis and glycogenolysis in the liver, thereby increasing circulating glucose 
levels (see figure 3.1). Both hormones in combination could therefore exploit the 
beneficial weight lowering effects of glucagon and GLP-1 whilst improving glucose 
control. These effects would depend on the ratio of GLP-1 and GCGR agonism achieved 
by this combination.  
GLP-1 analogues and their use in clinical practice have been extensively investigated. 
Increasingly, longer acting preparations are being developed with the intention that 
effects on weight loss and glucose control will be superior to current preparations. 
However, weight loss with current GLP-1 analogues is modest and patients with type 2 
diabetes frequently require multiple therapies to maintain normal blood glucose levels. 
The investigation of long-term GCGR agonism has only recently received attention, due 
to effects on increased EE and potential for weight loss. In contrast, GCGR antagonists 
have been developed in an attempt to reduce hepatic glucose output attributed with 
raised glucagon levels seen in patients with type 2 diabetes201.  Chronic GCGR agonism 
and the effects on glucose homeostasis and body weight in humans are unknown.  
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Figure 3.1. Simplified diagram depicting the role of glucagon in glycogenolysis and 
gluconeogenesis. Glucagon (GCG) signals through its receptor (GCGR) on the hepatocyte cell 
surface and activates G proteins called Gsα and Gq. Activation of Gq increases intracellular 
calcium ions via phospholipase C and inositol 1,4,5-triphosphate (IP3). Activation of Gsα, leads to 
activation of adenylate cyclase (AC) and increased levels of cAMP with subsequent activation of 
protein kinase A (PKA). Activated PKA phosphorylates and activates glycogen phosphorylase 
kinase which in turn activates glycogen phosphorylase. This latter enzyme phosphorylates 
glycogen promoting its breakdown and the production of glucose-6-phosphate (G-6-P). G-6-Pase 
then converts G-6-P into glucose. Glucagon also upregulates the G-6-Pase gene via a nuclear 
transcription factor coactivator called peroxisome proliferator-activated receptor-γ coactivator-
1α (PGC-1α). Glucagon also promotes glycogenolysis through the inhibition of glycogen synthase 
(not shown). During gluconeogenesis, an important rate-limiting step involves the conversion of  
oxaloacetate to phosphoenolpyruvate (PEP) by phosphoenolpyruvate carboxykinase (PEPCK). 
Glucagon increases PEPCK transcription and activity indirectly through PKA activation and 
upregulation of PGC-1α, which in turn increases transcription of the PEPCK gene. Through a 
series of enzymatic reactions, PEP is converted to fructose-6-phosphate (F-6-P) and 
subsequently G-6-P. Glucagon also increases gluconeogenesis by inhibiting glycolysis. Diagram 
adapted from Jiang and Zhang 2003410. 
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The role of glucagon and GLP-1 in the control of circulating lipids 
Beneficial effects of GLP-1 and its analogues on circulating lipids have been 
demonstrated in patients with type 2 diabetes411. However, it is likely that these effects 
are due, at least in part, to the associated weight loss and improved diabetes control. It is 
unclear whether GLP-1 has any direct effects on circulating lipids. To address this, one 
recent study investigated lipid oxidation in healthy volunteers using a pancreatic clamp 
technique, whereby plasma insulin and glucagon levels were clamped using 
somatostatin and hormone replacement412. During a four hour GLP-1 infusion, lipolysis 
and substrate oxidation remained the same as controls412. In contrast, a study in which 
such a clamp technique was not used, demonstrated that GLP-1 reduced postprandial 
triglyceride levels413. However, this was also accompanied by marked changes in other 
hormones and likely to be due to insulin-mediated inhibition of lipolysis and reduced 
gastric emptying. In contrast, there is now emerging evidence to suggest a beneficial 
effect of insulin sensitisers such as GLP-1 analogues and DPPIV inhibitors in non-
alcoholic steatohepatitis (NASH). NASH is characterised by insulin resistance and 
accumulation of fat within the hepatocytes, and can lead to liver cirrhosis. Exendin-4 
administration in mice reduces apoptosis and increases lipolysis in hepatocytes in 
response to ischaemic reperfusion injury 414. Animal studies have demonstrated that 
GLP-1 protects against NASH by increasing fatty acid oxidation, decreasing lipogenesis 
and improving hepatic glucose metabolism415,416. It is unknown however whether these 
effects occur independently of weight loss and improved glycaemic control, both of 
which also ameliorate NASH. 
A role for glucagon in lipolysis has also had conflicting results. In vitro  and ex vivo 
studies previously suggested a role for glucagon in stimulating an enzyme called 
hormone sensitive lipase (HSL) in adipocytes, causing the hydrolysis of triglycerides 
into glycerol and fatty acids417 (see figure 3.2). In contrast, human in vivo studies, have 
shown very little effect of glucagon infusion on circulating lipid profile. Iv infusion of 
glucagon to healthy human volunteers shows no change in plasma levels of triglycerides 
or FFAs418. Similarly, s/c glucagon infusion in healthy male volunteers does not increase 
glycerol or FFAs at either physiological or supraphysiological levels419.  
However, there may be a role for glucagon in the regulation of hepatic lipid metabolism. 
GCGR knockout mice exhibit defects in hepatocyte lipid oxidation and accumulation of 
excessive lipids420. In addition, s/c glucagon administration to wild-type mice inhibits 
triglyceride synthesis in the liver and stimulates fatty acid oxidation420.  
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This chapter focuses on the effects of long-acting glucagon and GLP-1 analogues on 
acute and chronic food intake, EE and glucose homeostasis in mice. In addition, the 
effects of these analogues on behaviour and brainstem c-fos activation were studied. 
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Figure 3.2. The role of glucagon in the control of circulating lipids. Glucagon binds to its 
receptor in adipocytes, causing increased cAMP and activation of hormone sensitive lipase (HSL). 
HSL hydrolyses triglycerides into glycerol and free fatty acids (FFAs), which are released into the 
circulation and transported to the liver. Depending on the size of the FFA, it either diffuses across 
the cell membrane or is carried by cell surface transporters. Once inside the cell, a CoA group is 
added to the FFA by fatty acyl-CoA synthase forming long chain acyl-CoA. Carnitine 
palmitoyltransferase1 (CPT1) converts this long chain acyl-CoA to long chain acylcarnitine, 
allowing the fatty acid to be transported into the mitochondria via carnitine-acylcarnitine 
translocase (CAT). Within the inner mitochondrial membrane, CPT2 converts the long chain 
acylcarnitine back into long chain acyl-CoA which enters the fatty acid beta-oxidation pathway. 
This pathway involves a series of reactions in which acetyl CoA is cleaved from the fatty acid by 
co-enzyme A. Acetyl CoA then enters Kreb’s cycle to produce NADH and FADH2 which are used in 
the electron transport chain to produce ATP and hence energy. Acetyl-CoA carboxylase (ACC) is a 
key enzyme involved in fatty acid beta oxidation and fatty acid synthesis. ACC catalyses the 
carboxylation of acetyl-CoA producing malonyl-CoA which can be used as a substrate for fatty 
acid synthesis. Malonyl-CoA also inhibits CPT1, thereby blocking mitochondrial fatty acid 
synthesis. In mammals, two isoforms of ACC are found, ACC1 and ACC2. ACC1 maintains 
regulation of fatty acid synthesis and is highly expressed in adipose tissue. In contrast ACC2 
mainly regulates fatty acid oxidation and is found in highly metabolic organs such as skeletal 
muscle and heart. Both ACC1 and ACC2 are found in the liver where fatty acid oxidation and 
synthesis is important. Adapted from Fillmore et al 2012 421. 
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3.2 Hypothesis and aims 
 
3.2.1 Hypothesis 
 
I hypothesised that dual glucagon/GLP-1 analogues and co-administration of glucagon 
and GLP-1 analogues reduce food intake and increase EE causing weight loss and 
improved glucose homeostasis in mice.  
 
3.2.2 Aims 
 
To investigate the effect of glucagon/GLP-1 analogues on: 
 acute food intake, behaviour and c-fos activation in the brainstem of lean mice 
 chronic food intake, body weight, glucose homeostasis and markers of EE in DIO 
mice 
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3.3 Materials and Methods 
 
3.3.1  Investigation of the acute effects of a long acting dual glucagon and 
GLP-1 analogue G(X) on food intake and c-fos immunoreactivity in the 
brainstem in mice. 
 
3.3.1.1 Peptides 
 
Human glucagon, human GLP-1 and exendin-4 were purchased from Bachem Ltd. 
(Merseyside, UK). A dual glucagon/GLP-1 analogue, G(X), was designed by Prof. Stephen 
R. Bloom, Dept Investigative Medicine, Imperial College, London. Analogues were 
custom synthesised using solid phase peptide synthesis (SPPS) methodology (Bachem 
Ltd). Peptide purity was determined by reverse-phase high performance liquid 
chromatography (HPLC) and by Matrix-assisted laser desorption ionization mass 
spectroscopy (MALDI-MS). Work involving receptor binding assays, cAMP activation 
and feeding studies of the glucagon/GLP-1 analogue G(X) was undertaken by other 
members of the research team. These results and the amino acid sequence of G(X) is 
found in Appendix B. G(X) contains identical amino acid sequences to glucagon from 
positions 1 to 16 with the exception of a serine to aminoisobutyric acid (AIB) 
substitution at position 2. AIB is structurally similar to alanine except for a methyl group 
in place of a hydrogen at the alpha-carbon leading to changes in helix formation and 
reduced DPPIV cleavage229. From positions 16-39, amino acid substitutions have been 
made to resemble exendin-4, including a Trp-cage at the C-terminal (amino acids 32-
39). Although evidence has been conflicting, it is thought that the Trp-cage may increase 
the binding affinity of exendin-4 to the GLP-1R422. However, the EC50 values 
demonstrate that G(X) binds and activates the GCGR and GLP-1 receptors with low 
affinity (appendix B). Despite these findings, initial pilot data from other members in the 
department found that G(X) dose-dependently reduced food intake. Furthermore, the 
anorectic action persisted for up to eight hours at the highest dose administered and 
suppressed food intake by almost 85% compared to saline controls over this time 
period (see appendix B4). However, subsequent studies demonstrated that G(X) was 
less effective than exendin-4 at reducing food intake when administered at the same 
dose. Therefore, further analogues were developed that were also biologically active but 
were specific for the GLP-1R or GCGR (G(Y) and G(Z) respectively (see appendix B).  
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3.3.1.2 Animals 
 
All animal procedures undertaken were approved by the British Home Office Animal 
(Scientific Procedures) Act 1986 (Project Licence 70/6402). 
Adult male C57BL/6 mice (Charles River, Margate, UK) weighing 25-30 g were 
maintained in individual cages under controlled temperature (21-23oC) and lights 
(12:12 hr light-dark cycle, lights on at 0700).  Animals were allowed ad libitum access to 
water and RM1 diet (Special Diet Services, Witham, UK) unless otherwise stated.  
Animals were regularly handled and acclimatised to ip or s/c injections in order to 
reduce non-specific stress at the time of the study. 
 
3.3.1.3 Investigation of the acute effects of a long-acting glucagon and GLP-1 
analogue G(X) on food intake in mice 
 
Experiments were carried out during the early light phase (0800-1000), in C57BL/6 
mice fasted from 1600 the preceding day, unless otherwise stated. Body weights of 
animals were recorded the day before the study in order to randomise mice to each 
group and calculate weight adjusted doses. Specific experimental details are noted for 
each study, but in each case the following was performed: a maximal volume of 0.05 ml 
was injected s/c and mice returned to their home cage with a known amount of food 
following injection.  Food was reweighed at regular intervals post injection. 
3.3.1.4 Investigation of the acute effects of co-administration of exendin(9-39) and a 
long-acting glucagon and GLP-1 analogue G(X) on food intake in mice 
 
In order to elucidate how much of the anorectic effect was due to activation of the GLP-1 
receptor, G(X) was co-administered with the GLP-1 receptor antagonist exendin-4(9-39).  
Experiments were carried out as described in section 3.3.1.3, however two s/c injections 
were administered to each mouse.  The first injection was either ip vehicle or exendin-
4(9-39) at 25000 nmol/kg.  The dose of exendin(9-39) used was based on previous 
studies219,423. Exendin-4(9-39) has previously been shown to bind with at least 10-fold 
lower affinity at the GLP-1R compared to GLP-1 and this high dose was chosen to ensure 
that the majority of GLP-1 receptors were blocked423.  A second s/c injection of either 
vehicle or analogue G(X) (50nmol/kg) was administered 5 minutes later.  This time 
delay was to allow exendin-4(9-39) to disperse through the circulation and bind to the 
GLP-1 receptors before administration of a GLP-1R agonist. Food intake was measured 
at 0.5, 1.5, 3 and 6 hours post injection. 
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3.3.1.5 Investigation of behaviour in mice following administration of a long-
acting glucagon and GLP-1 analogue G(X) 
 
In order to investigate whether the dual glucagon/GLP-1 analogue G(X) caused adverse 
effects, a behaviour study was conducted. Experiments were carried out during the early 
light phase (0800-1000) in mice fed ad libitum. Environmental enrichment was removed 
the day before to ensure adequate visualisation. A maximal volume of 0.2 ml was 
injected ip and mice immediately returned to their cages. LiCl was used as a positive 
control as it is known to induce behavioural abnormalities in mice424. Behavioural 
patterns were monitored continuously for 90 minutes post injection by observers 
blinded to the treatment group. Behaviour was classified into the following categories: 
feeding, grooming, drinking, rearing, hunching, locomotion, burrowing, inactive, pica 
and sleeping. Each mouse was observed for 15 seconds every five minutes. During these 
15 seconds, three behaviours lasting five seconds each were recorded giving a total of 
36 observations per hour. Data are presented as median (interquartile range). 
 
 
3.3.1.6 Investigation of c-fos immunoreactivity in the brainstem following 
administration of a long-acting glucagon and GLP-1 analogue G(X). 
 
Experiments were carried out during the early light phase (0800-1000) in mice fasted 
from 1600 the preceding day. Animals were group housed (n=5/cage, weighing 20-25g) 
and for two weeks prior to experimentation, mice were handled on a daily basis and 
sham injected on at least three separate occasions. Mice (n=5-6 per group) were injected 
with a maximum volume of 50 µl s/c of either saline, glucagon 750 nmol/kg, GLP-1 100 
nmol/kg or G(X) 50 nmol/kg and immediately returned to their cages. Ninety minutes 
later, mice were injected with 0.4 mls ip pentobarbitone (Euthatal, Merial Animal Health 
Ltd, Harlow, UK) prior to decapitation. Tissue preparation and c-fos 
immunohistochemistry was subsequently performed as described in section 2.3.7.   
3.3.2  Investigation of the chronic effects of long acting glucagon and GLP-1 
analogues G(Y) and G(Z) on food intake and body weight in diet induced 
obese (DIO) mice. 
 
3.3.2.1 Peptides 
 
In order to investigate the chronic effects of glucagon and GLP-1 separately, two 
analogues (G(Y) and G(Z)) were designed with specificity towards the GLP-1R or GCGR 
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respectively. These analogues were designed by Prof. Stephen R. Bloom, Dept 
Investigative Medicine, Imperial College, London. Analogues were custom synthesised 
using SPPS methodology (Bachem Ltd). Peptide purity was determined by  reverse-
phase HPLC and by MALDI-MS. Receptor binding assays, cAMP activation, 
pharmacokinetic profiles and acute feeding studies of the glucagon and GLP-1 analogues 
were undertaken by other members of the research team. These results and the amino 
acid sequences of G(Y) and G(Z) are found in Appendix B. G(Y) contains the same amino 
acids as glucagon up to position 14, with the exception of Lys→His12. Subsequent amino 
acids are based on the structure of exendin-4 with the exception of the Trp-cage which 
is not included. Previous studies have demonstrated that amino acids in position 2, 3, 10 
and 12 in glucagon are key in maintaining GCGR activity425. Therefore substitution of Lys 
at position 12 may partly explain why G(Y) predominantly activates the GLP-1R and not 
the GCGR. In addition, the Ser→Glu16 is likely to impact on the protein structure since 
serine at position 16 of glucagon is important in helix formation229. In contrast, G(Z) is 
identical to glucagon with the exception of three amino acid changes at positions 20, 21 
and 27. Both G(Y) and G(Z) have an amidated C-terminal to avoid introducing a charged 
group which can affect peptide solubility. 
 
The EC50 values demonstrate that G(Y) binds and activates predominantly the GLP-1R, 
whereas G(Z) is specific for the GCGR (see appendix B). Both peptides show prolonged 
pharmacokinetic profiles in rats compared to native glucagon or GLP-1. G(Y) 
significantly decreased food intake compared to saline controls by 30% over 24 hours 
(appendix B4). G(Z) reduced food intake for the first 4 hours by almost 40% compared 
to saline controls however cumulative food intake thereafter was not significantly 
reduced compared to saline controls. The vehicle used was 1:1 zinc chloride: saline 
solution. At pH <5.5, the charged histidines in the analogue do not interact with the zinc 
ions in solution, however upon injection (pH of the skin is approximately 7.4), the 
charged histidines in the peptides bind to the zinc ions. This histidine-zinc binding 
causes precipitation of the peptide and the formation of a subcutaneous depot426. This 
results in longer lasting peptide action. 
 
3.3.2.2 Animals 
 
All animal procedures undertaken were approved by the British Home Office Animal 
(Scientific Procedures) Act 1986 (Project Licence 70/6402). Adult (aged 8 weeks old) 
male C57BL/6 mice (Charles River, Margate, UK) with an initial mean body weight of 
25g were group housed for 8 weeks followed by two weeks singly housed. Individual 
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cages were maintained under controlled temperature (21-23oC) and lights (12:12 hr 
light-dark cycle, lights on at 0700).  Animals were allowed ad libitum access to water 
and high fat diet (60% kcal from fat, Research Diets, New Jersey). Animals were 
regularly handled and acclimatised to s/c injections in order to reduce non-specific 
stress at the time of the study. At the start of the study the mice had a mean body weight 
of 38g (36-45g), which is approximately 25% more than the average weight of a mouse 
at 18 weeks old fed a chow diet427.  
 
3.3.2.3 Investigation of the effects of chronic administration of long acting 
glucagon and GLP-1 analogues on food intake and body weight  
 
Mice were maintained in individual cages as described in section 3.3.2.2. Mice were 
injected s/c once daily at 1500 for 70 days with either vehicle, G(Y) (5 nmol/kg days 1-5, 
10 nmol/kg day 6 onwards), G(Z) 20 nmol/kg days 1-5, 40 nmol/kg days 6-15, 80 
nmol/kg day 16 onwards) or a combination of G(Y) and G(Z) at these same doses. 
Following injection, mice were returned immediately to their cages. Initial doses were 
chosen based on previous acute feeding studies, with lower doses administered initially 
and then increased according to response until day 16. Thereafter doses remained the 
same. Food and body weight were measured every 1-2 days, immediately prior to 
injection.  
 
3.3.2.4 Investigation of glucose homeostasis following chronic administration of 
long acting glucagon and GLP-1 analogues 
 
Mice were maintained in individual cages as described in section 3.3.2.2. and injected 
daily with chosen peptides or vehicle as described in section 3.3.2.3. On day 70, mice 
underwent an ip glucose tolerance test (ipGTT). Due to the number of mice involved, 
this was performed on 3 consecutive days so that the test could be undertaken at the 
same time of day (T=0 at 1300). Ad libitum fed mice, were injected with peptide or 
vehicle at 0700 on the day of the study and then fasted until the ipGTT. Blood samples 
were collected at -30, 0, +30, +60, +90 and +120 minutes following ip 2g/kg glucose 
solution. Blood samples were obtained using tail tipping and serum glucose measured 
using a handheld glucometer. Blood samples were also taken at -30, +30, +60 and +120 
minutes following glucose injection for measurement of insulin. These insulin samples 
were collected in 0.5mls eppendorfs and centrifuged at 10000 rpm for 10 minutes. 
Plasma was then separated using a pipette and stored in 0.5 ml eppendorfs at -20°C 
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until assayed. Insulin samples were assayed in singlet using an insulin ELISA (Millipore, 
UK). 
 
3.3.2.5 Investigation of the effects of chronic administration of long acting 
glucagon and GLP-1 analogues on markers of energy expenditure (EE) and 
gluconeogenesis.  
 
Tissue harvesting 
 
Following the ipGTT, mice were maintained as described in section 3.3.2.3 and 
continued to receive daily s/c injections. On day 73, mice were killed by carbon dioxide 
(C02) asphyxiation and cardiocentesis performed in order to obtain blood samples for 
later analysis of markers of energy homeostasis. Blood samples were collected into 
heparinised eppendorfs and centrifuged at 10000 rpm for 10 minutes. Plasma samples 
were then stored in 2.5 mls eppendorfs at -80°C until further analysis was performed. 
Immediately following cardiocentesis, the following tissues were harvested, weighed 
and snap frozen in liquid nitrogen: interscapular BAT, epidydimal WAT, and liver. In 
order to maintain consistency, both epidydimal WAT deposits were removed and the 
same lobe of liver was harvested in each mouse.  
 
Total RNA extraction 
Real time quantitative polymerase chain reaction (rtPCR) was used to analyse the 
expression of various mRNA sequences in liver, BAT and WAT using TaqMan gene 
expression assays. Genes of interest focused on markers of EE, gluconeogenesis and 
lipid oxidation. All materials for qPCR were supplied by Applied Biosystems, 
Warrington, UK, unless otherwise stated. 
Tissues were harvested as described above. Total RNA was extracted using the Tri-
reagent method according to the manufacturer’s protocol. Using a pestle and mortar, 
samples of liver, BAT or WAT were ground under liquid nitrogen, homogenised in 1 ml 
Tri-reagent and the suspension transferred to 1.5 ml eppendorfs to incubate at room 
temperature for 10 minutes. 100 µls of bromo-chloropropane was then added, mixed 
and incubated for 10 minutes at room temperature. The solution was centrifuged for 10 
minutes at 14,000g at 4C and the upper aqueous phase transferred to an autoclaved 
eppendorf and stored at -20C until all samples from each tissue had been similarly 
processed. 
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To ensure sample purity and absence of DNA, RNA samples were purified using a 
Purelink RNA Mini Kit (Invitrogen, Paisley, UK) and Purelink DNase set (Invitrogen, 
Paisley, UK) and instructions followed according to the manufacturer’s protocol. 
Samples were allowed to thaw and 400 µls 70% ethanol added. Each sample was mixed 
by hand and added to a spin cartridge, prior to centrifugation at 14000g for 15 seconds 
at room temperature. The flow-through was discarded leaving RNA bound to the 
cartridge membrane. The spin cartridge then underwent a series of buffer washes and 
centrifugation, followed by the addition of Purelink DNAse. For each sample the 
following constituents were added to create the Purelink DNase mixture: 8 µls 10x 
DNAse I reaction buffer, 10 µls resuspended DNase and 62 µls RNase free water. 
Samples contained within the spin cartridges were allowed to incubate at room 
temperature for 15 minutes followed by a further buffer wash and centrifugation 
(14000g for 15 seconds). A final wash using 500 µls buffer containing 60% ethanol, was 
added to the cartridge and centrifuged at 14000g for 15 seconds. The flowthrough was 
discarded, leaving the dry membrane with bound RNA which was placed into a recovery 
tube. RNase-free water was added to the membrane in the following quantities 
depending on the tissue collected: liver 70 µls, BAT 50 µls and WAT 30 µls. Samples 
were incubated at room temperature for 1 minute and then centrifuged for 1 minute at 
14000g to elute the RNA from the membrane into the recovery tube. Purified RNA was 
then stored at -20C until all samples from each tissue had been similarly processed. 
Finally, RNA in each sample was quantified using a UV 1101 spectrophotometer 
(Biochrom, Cambridge, UK). A 1:50 dilution of the RNA purified sample was made (2µls 
RNA sample added to 98 µls GDW) and the resultant 100 µls solution placed in a 
disposable quartz cuvette (Brand manufacturers, Germany). The absorbance was read 
at 260nm and 280 nm and the concentration of RNA calculated using the following 
formula: 
Concentration (µg/ml) = (absorbance260 x dilution factor) x 40 
The 280nm reading provided an assessment of the degree of purity of the sample. 50 
µg/ml of total RNA was required for appropriate amplification using rtPCR. Liver sample 
RNA content was above this threshold, however, over 50% of BAT and WAT RNA 
samples were inadequate. For this reason, ethanol precipitation was undertaken on all 
BAT and WAT samples. The RNA samples were mixed with 1µl of glycogen (5mg/ml, 
Ambion, UK), 0.1x volume of 2M sodium acetate and 2.5x volume 100% ethanol, and the 
solution thoroughly mixed by hand. Samples were then incubated at -20C for at least 
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one hour. Samples were subsequently centrifuged for 7 minutes at 14,000g. The 
supernatant was then discarded and the pellet air dried under a fume hood for 2-3 
hours. Pellets were re-suspended in the appropriate volume of GDW to give a final 
concentration of 50 µg/ml and stored at -20C. Liver samples did not undergo ethanol 
precipitation but instead were diluted to give a final concentration of 50 µg/ml. 
 
Reverse transcription of mRNA into cDNA 
In order to undertake rtPCR, mRNA has to be transcribed into its complementary DNA 
sequence (cDNA) by reverse transcription. A High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, UK) was used and the protocol followed according to the 
manufacturer’s instructions. 2X RT Master Mix was prepared using the following 
components: 2 µls 10XRT buffer, 0.8 µls 25X 100mM dNTP mix, 2 µls 10X RT random 
primers, 1 µl Multiscribe Reverse Transcriptase and 4.2 µls RNase free water. 500 ng 
(10 µls of 50µg/ml sample) of each RNA sample was added to 0.5ml eppendorfs 
containing 10µl 2X RT master mix and pipetted several times to mix. Each eppendorf 
was transferred to a thermal cycler (PTC-100 7307 Programmable Thermal Controller, 
MJ Research Inc., US) under the following conditions:  
25C for 10 minutes 
 
37C for 120 minutes 
 
85C for 5 minutes 
 
4C until samples removed 
 
storage at -20C 
rtPCR assay 
During rtPCR, a specific gene is quantified through the use of a reporter-tagged probe, 
which is complementary to the cDNA of interest. The TaqMan probe anneals specifically 
to the complementary sequence. When the probe is intact, the proximity of the reporter 
dye to the quencher suppresses the fluorescence of the reporter. However, addition of 
DNA polymerase cleaves the probe that is hybridised to the complementary sequence, 
causing release of the reporter dye from the quencher and thus fluorescence of the 
reporter. This is illustrated in figure 3.3.  
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Figure 3.3. Schematic diagram representing the mechanism of real time quantitative 
polymerase chain reaction (rtPCR). TaqMan probes consist of a fluorophore (6-
carboxyfluorescein, FAM) attached to the 5’-end of the oligonucleotide probe and a quencher at 
the 3’-end (dihydrocyclopyrroloindole tripeptide minor groove binder, MGB). The PCR cycler’s 
light source under normal conditions excites the fluorophore using Förster-type energy transfer. 
However, close proximity of the quencher to the fluorophore prevents this excitement. The probe 
anneals to a region of interest within DNA which has been amplified using a set of primers. As the 
Taq polymerase extends the primer and synthesises a second strand of DNA the 5’ to 3’ activity of 
the polymerase degrades the probe. This releases the fluorophore from the probe, and hence 
proximity to the quencher, resulting in fluorescence. Therefore, fluorescence detected in rt-PCR 
is directly proportional to the amount of fluorophore and hence DNA template present in the 
sample. Figure reproduced from Koch WH (2004)428.  
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In this study, the following probes were obtained (Applied Biosystems, UK) in order to 
quantify the expression of the relevant genes shown in table 3.1. 
Tissue Gene of interest 
(abbreviation) 
Full name of gene Probe no. 
Liver G-6-Pase Glucose-6-phosphatase Mm00839363_m1 
 PEPCK1 Phosphoenolpyruvate 
carboxykinase 1 
Mm01247058_m1 
 ACC1 Acetyl-coenzyme A 
carboxylase alpha 
Mm01304257_m1 
 FGF-21 Fibroblast growth factor-21 Mm00840165_g1 
BAT UCP-1 Uncoupling protein-1 Mm01244861_m1 
 PPARγ Peroxisome Proliferative 
activated receptor gamma 
Mm01184322_m1 
 PGC1 Peroxisome proliferative 
activated receptor gamma 
co-activator 1 alpha 
Mm01208835_m1 
WAT UCP-1 Uncoupling protein-1 Mm01244861_m1 
 PPARγ Peroxisome Proliferative 
activated receptor gamma 
Mm01184322_m1 
 HSL Hormone sensitive lipase Mm00495359_m1 
 
Table 3.1. Probes used to quantify various genes of interest in liver, brown 
adipose tissue (BAT) and white adipose tissue (WAT) in DIO mice. The full name 
and abbreviation of the gene of interest is given, in addition to the probe number. 
Probes were obtained from Applied Biosystems (UK). 
 
For each rtPCR reaction, the following constituents were added to each well within a 
384 well plate: 10 µl TaqMan Universal PCR Master Mix, 1µl 20x TaqMan Gene 
Expression Probe, 1µl cDNA and 8µls GDW. A gene expression assay targeting the 18S 
ribosomal subunit was used as a control (using 1:5 dilution of sample). Each reaction 
was mixed and centrifuged for 1 minute at 1000g at room temperature to remove 
bubbles from within the reaction mixture. Each plate was then loaded into an rtPCR 
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machine (7900HT Fast Real-Time PCR System, Applied Biosystems, Warrington, UK) 
and PCR performed under the following conditions: 
50C for 2 minutes 
 
95C for 10 minutes 
 
Thermal cycling: 95 C for 15s followed by 60C for 1 minute 
 
Repeated for 40 cycles 
 
 
Each probe was validated prior to experimental procedures, using a randomly selected 
sample from the relevant tissue and compared to 18S control. The amplification data for  
each target gene was normalised to the expression of the 18S endogenous control and 
expressed relative to an internal calibrator (vehicle group sample) using the 2-CT 
method (SDS v2.3 software, Applied Biosystems, UK). This method allows data to be 
expressed as the fold change in gene expression normalised to a reference gene (18S) 
and relative to an internal untreated control.  
Leptin 
Leptin was measured using a mouse leptin ELISA kit (Crystal Chem Inc., USA) and the 
manufacturer’s protocol was followed. The kit uses a sandwich-ELISA method (see 
figure 3.4), in which monoclonal rabbit anti-leptin antibodies are immobilised on the 
surface wells. Guinea-pig anti-mouse leptin IgG antibody is added to each well which 
simultaneously bind to the immobilised plate antibodies and mouse leptin in the sample 
(5 µl added), standard or control solutions. The plate is then incubated overnight at 4°C. 
The following day, a series of washes remove unbound material. Subsequently, 
streptavidin-horseradish peroxidase conjugated to anti-guinea pig IgG antibody is added 
which binds to the guinea pig anti-leptin IgG of the complex immobilised to the 
microplate well. After excess streptavidin-enzyme conjugate is washed away, a 
substrate for horseradish peroxidase is added (3,3’, 5, 5’-tetramethylbenzidine). The 
peroxidase reaction is stopped by the addition of 1N sulphuric acid. Leptin 
concentration was measured spectrophotometrically (Multiskan RC microplate reader, 
Labsystems, Vienna, VA, USA) by the increased absorbancy at 450 and 630 nm. A 
standard curve was constructed and sample concentration derived from this (GraphPad 
Prism 5.0d, GraphPad Software, San Diego, USA).   
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Figure 3.4. Schematic diagram representing mouse leptin ELISA assay protocol.  Rabbit 
anti-leptin antibodies are immobilised on the well plate, to which guinea-pig anti-mouse leptin 
IgG antibodies and mouse leptin sample are added. HRP (horse radish peroxidase)-conjugated 
anti-guinea pig IgG antibody is pipetted into the wells. TMB (tetramethylbenzidine) is added and 
oxidised by the peroxidase present. The reaction is halted by the addition of sulphuric acid, 
causing the solution to turn yellow depending on the concentration of leptin present, and can be 
read using a spectrophotometer. 
 
Free tri-iodothyronine (fT3) 
fT3 was measured using a fT3 mouse ELISA assay (Cusabio Biotech, China) and the 
manufacturer’s protocol was followed. The kit uses a competitive inhibition enzyme 
immunoassay technique, in which monoclonal anti-T3 antibodies are immobilised on 
the surface wells. These antibodies bind to T3 in the sample (50 µl added), standard or 
control solutions. In addition biotin-conjugated T3 is added to the well and incubated 
for 1 hour. During this time, a competitive inhibition reaction occurs between T3 in the 
samples/standards and biotin conjugated T3 with the pre-coated antibody specific for 
T3. After washing, to remove unbound material, streptavidin-horseradish peroxidase is 
added which binds to biotin. After excess streptavidin-enzyme conjugate is washed 
away, a substrate for horseradish peroxidase is added (3,3’, 5, 5’-tetramethylbenzidine). 
The peroxidase reaction is stopped by the addition of 0.3M HCl. Enzyme activity was 
measured spectrophotometrically (Multiskan RC microplate reader, Labsystems, 
Vienna, VA, USA) by the increased absorbancy at 450 nm. A standard curve was 
constructed and sample concentration derived from this (GraphPad Prism 5.0d, 
GraphPad Software, San Diego, USA).   
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Triglycerides 
Triglycerides were measured using a triglyceride quantification kit (Abcam, Cambridge, 
UK). Standard, sample (50 l of 1:10 dilution) and controls were added to a 96 well 
plate. 2l of lipase was added to each well and incubated for 20 mins to convert the 
triglycerides to glycerol and FFAs. The glycerol was then oxidised by the addition of a 
triglyceride reaction mix (OxiRed in DMSO and enzyme mix) and left to incubate for 1 
hour. Enzyme activity was measured spectrophotometrically (Multiskan RC microplate 
reader, Labsystems, Vienna, VA, USA) by the increased absorbancy at 560 nm. A 
standard curve was constructed and sample concentration derived from this (GraphPad 
Prism 5.0d, GraphPad Software, San Diego, USA).   
 
β-hydroxybutyrate 
β-hydroxybutyrate was measured using a quantification kit (Abcam, Cambridge, UK). 
Standard, sample (20 l) and controls were added to a 96 well plate and the volume 
adjusted to 50 ls using the buffer provided. A further 50 ls of enzyme reaction mix 
was added to each well (containing 46 ls buffer, 2 ls hydroxybutyrate dehydrogenase 
and 2 ls substrate mix). Samples were incubated at room temperature for 30 mins and 
enzyme activity measured spectrophotometrically by the absorbancy at 450 nm 
(Multiskan RC microplate reader, Labsystems, Vienna, VA, USA). A standard curve was 
constructed and sample concentration derived from this (GraphPad Prism 5.0d, 
GraphPad Software, San Diego, USA).   
 
3.3.3 Statistics 
All data are expressed as mean ± SEM unless specified. Data from acute feeding studies, 
and c-fos immunohistochemistry were analysed using one-way ANOVA followed by 
Dunnett’s or Tukey’s post test as indicated. Data from the behaviour study were 
analysed using Kruskall-Wallis followed by Mann-Whitney U.  
In the chronic studies, data from cumulative food intake, area under the curve (AUC) for 
glucose and insulin values, tissue mass, mRNA expression and plasma markers of energy 
homeostasis were analysed using one way ANOVA with Tukey’s post test. Data from 
body weight, glucose and insulin values during the ipGTT were analysed using repeated 
measures two-way ANOVA with Bonferroni’s post test. In all cases, values of p<0.05 
were considered statistically significant. 
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3.4 Results 
3.4.1 Investigation of the acute effects of a long acting dual glucagon and 
GLP-1 analogue G(X) on food intake and c-fos immunoreactivity in the 
brainstem in mice. 
 
3.4.1.1 Investigation of the acute effects of a long-acting glucagon and GLP-1 
analogue G(X) on food intake in mice 
 
50 nmol/kg of G(X) was the lowest effective dose to reduce food intake in the first 30 
minutes (mean food intake: 0.41±0.06 [saline] vs. 0.22±0.05g [G(X) 50 nmol/kg], p<0.05 
vs. saline; n=5/group, fig 3.5). At this dose, the anorectic effect lasted three hours and 
caused a complete abolition of food intake (fig 3.5). Exendin-4 (10 nmol/kg) was used as 
a positive control at a dose previously shown to decrease food intake400,429.  
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Figure 3.5. Effects of the long-acting glucagon/GLP-1 analogue G(X) on food intake. Food 
intake was measured following s/c administration of either saline (control), G(X) 10, 50, 100, 500 
nmol/kg. Exendin-4 (10 nmol/kg) was used as a positive control. Food intake was measured at 
30, 90, 180 minutes, 3 hours, 8 hours and 24 hours following injection. Results expressed as 
mean ± SEM. Data were analysed using one way ANOVA with Dunnett’s post test. *p<0.05, 
**p<0.01 versus controls. n=5/group. 
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3.4.1.2 Investigation of behaviour in mice following administration of a long-
acting glucagon and GLP-1 analogue G(X) 
 
 
A behavioural study was undertaken to ascertain whether the reduction in food intake 
seen following the administration of G(X) was due to adverse symptoms. Ad libitum fed 
mice were observed for 90 minutes following injection of glucagon, exendin-4 and G(X) 
at the onset of the light phase. LiCl was used as a positive control as it demonstrates 
adverse behaviour at high doses424. Exendin-4 was used rather than GLP-1 as it has a 
longer half life than GLP-1 and has been used in previously published behavioural 
studies429.  
There was no evidence of major adverse behaviour in response to G(X) or glucagon at 
the doses administered. 
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0-30 minutes     
Behaviour Saline LiCl 
Exendin-4 
10 nmol/kg 
Glucagon 750 
nmol/kg 
G(X) 50 
nmol/kg 
Feeding 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0) 0 (0-0) 
Drinking 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Rearing 1 (1-2) 0 (0-1) 0 (0-1) 0 (0-2) 0 (0-2) 
Locomotion 4 (4-5) 3 (2-4) 2 (1-6) 5 (3-5) 7 (4-8) 
Grooming 5 (4-8) 1 (0-1)* 3 (2-3) 5 (2-6) 2 (2-3) 
Burrowing 3 (0-3) 0 (0-0) 0 (0-0) 4 (0-6) 2 (2-3) 
Hunching 0 (0-0) 11(10-12)** 3 (0-9) 0 (0-2) 0 (0-0) 
Sleeping 0 (0-3) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Pica 0 (0-2) 0 (0-0) 0 (0-0) 0 (0-0) 3 (0-3) 
Inactive 1 (1-2) 2 (1-4) 4 (3-7)* 2 (2-4) 1 (1-3) 
 
30-60 minutes     
Behaviour 
 
Saline 
 
LiCl 
Exendin-4 10 
nmol/kg 
Glucagon 750 
nmol/kg 
G(X) 50 
nmol/kg 
Feeding 0 (0-0) 3 (1-5) 0 (0-2) 3 (3-3) 3 (0-3) 
Drinking 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Rearing 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Locomotion 0 (0-2) 1 (1-2) 1 (0-1) 5 (2-5)* 0 (0-0) 
Grooming 0 (0-0) 4 (2-5)* 0 (0-0) 1 (0-2) 0 (0-1) 
Burrowing 0 (0-1) 0 (0-0) 0 (0-0) 5 (3-6) 1 (1-2) 
Hunching 0 (0-0) 3 (2-6) 9 (4-12) 0 (0-0) 0 (0-3) 
Sleeping 3 (0-8) 0 (0-0) 0 (0-0) 0 (0-0) 7 (0-9) 
Pica 5 (0-6) 2 (2-3) 1 (0-3) 5 (1-5) 1 (0-2) 
Inactive 1 (0-4) 2 (1-3) 4 (0-6) 0 (0-0) 2 (1-7) 
 
60-90 minutes     
Behaviour Saline LiCl 
Exendin-4 10 
nmol/kg 
Glucagon 750 
nmol/kg 
G(X) 50 
nmol/kg 
Feeding 0 (0-0) 6 (3-6)* 0 (0-0) 0 (0-0) 0 (0-0) 
Drinking 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Rearing 0 (0-0) 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-0) 
Locomotion 0 (0-0) 1 (0-1) 0 (0-0) 0 (0-0) 0 (0-3) 
Grooming 0 (0-1) 3 (0-3) 0 (0-0) 3 (3-4)** 0 (0-0) 
Burrowing 0 (0-0) 2 (0-3) 0 (0-0) 0 (0-0) 0 (0-0) 
Hunching 0 (0-0) 0 (0-0) 3 (3-3) 0 (0-0) 0 (0-0) 
Sleeping 
9(9-
17) 0 (0-0)** 6 (6-9) 12 (12-15) 
18(10-
18) 
Pica 0 (0-3) 4 (3-6) 0 (0-0) 0 (0-1) 0 (0-0) 
Inactive 0 (0-0) 3 (3-3) 6 (0-7) 0 (0-0) 0 (0-0) 
 
 
Table 3.2 Behavioural study in fed mice at the onset of the light phase (0800-
1000). ip injections of either saline (controls), LiCl (127 mg/kg), exendin-4 (10 
nmol/kg), glucagon 750 nmol/kg or G(X) 50 nmol/kg were performed and mice 
returned immediately to their cages. Behaviour was recorded for 15 seconds every 5 
minutes, continuously for 90 minutes. Data from this study was subdivided into 0-30 
minutes, 30-60 minutes and 60-90 minutes. Data presented as median (interquartile 
range). Adverse behaviour (pica, hunching and inactivity) highlighted in red. Data were 
analysed using Kruskall-Wallis followed by Mann-Whitney U, *p<0.05, ** p<0.01 versus 
saline treated control. n=5/group. 
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3.4.1.3 Investigation of the acute effects of co-administration of exendin(9-39) and a 
long-acting glucagon and GLP-1 analogue G(X) on food intake in mice 
 
 
In order to establish how much of the anorectic effect of the glucagon/GLP-1 analogue 
G(X) was due to GLP-1 receptor activation, the GLP-1 antagonist exendin(9-39) was 
administered prior to injection of G(X). Exendin(9-39) (25000 nmol/kg) attenuated the 
anorectic effect of G(X) between 30-90 minutes following administration: (mean food 
intake: G(X): 0.06±0.01 [G(X) 50 nmol/kg] vs. 0.51±0.07g [G(X) and exendin (9-39) 
combined], p<0.05 vs. G(X), n=6 per group, fig. 3.6). 
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Figure. 3.6. Effect of exendin(9-39) on food intake following administration of glucagon/GLP-
1 analogue G(X). The study took place at the onset of the light phase (0800-1000) in overnight 
fasted mice. Exendin(9-39) (25000 nmol/kg s/c) or vehicle was injected 5 minutes prior to 
injection of either vehicle or G(X) (50 nmol/kg). Food intake was measured at 0.5, 1.5, 3 and 6 
hours following the second injection. Shaded bars illustrate mice pre-treated with exendin(9-39). 
Results expressed as mean ± SEM. Data were analysed using one way ANOVA with Tukey’s post 
test. **p<0.01,  versus controls, #p<0.05, ##p<0.01 versus G(X) alone. n=6/group. 
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3.4.1.4 Investigation of c-fos immunoreactivity in the brainstem following 
administration of a long-acting glucagon and GLP-1 analogue G(X). 
 
c-fos-ir was assessed in the brainstem of mice following injection of the glucagon/GLP-1 
analogue G(X). The study was performed in fasted mice at the onset of the light phase. 
Glucagon and GLP-1 were used as positive controls at doses shown to increase c-fos-ir in 
previous studies. Glucagon and GLP-1 both increased c-fos-ir in the AP and cNTS at the 
doses administered (mean c-fos counts: AP: 25 ± 4 [saline] vs. 92 ± 14 [GLP-1], p<0.05 
vs. saline; vs. 84 ± 18 [glucagon], p<0.05 vs. saline, n=5/gp; cNTS: 62 ± 22 [saline] vs. 
213 ± 22 [GLP-1], p<0.05 vs. saline; vs. 218 ± 43 [glucagon], p<0.05 vs. saline, n=5/gp, 
fig. 3.7). Following administration of G(X), there was an increase in c-fos-ir in the AP 
compared to saline controls, however this did not reach significance. There were no 
significant differences between saline and G(X) in the cNTS or PBN.  
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Figure 3.7. c-fos immunoreactivity in brainstem following administration of G(X). Mice 
were fasted overnight and injected with either saline (controls), glucagon (GCG) (750 nmol/kg), 
GLP-1 (100 nmol/kg) or G(X) (50 nmol/kg) at the onset of the light phase (0800-1000). Animals 
were decapitated and brains removed 90 minutes following injection. c-fos-ir is shown in the 
area postrema (AP), caudal nucleus tractus solitarius (cNTS) and parabrachial nucleus (PBN) of 
the brainstem. Data were analysed using one-way ANOVA with Dunnett’s post test. *p<0.05 
versus saline controls. n=4-5/group. 
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3.4.2  Investigation of the chronic effects of long acting glucagon and GLP-1 
analogues G(Y) and G(Z) on food intake and body weight in diet induced 
obese (DIO) mice. 
 
3.4.2.1 Investigation of the effects of chronic administration of long acting 
glucagon and GLP-1 analogues on food intake and body weight  
 
G(X) demonstrated an acute anorectic effect in mice. However, it bound and activated 
the GCGR and GLP-1R with poor affinity (Appendix B). Therefore, interpretation of these 
findings and identifying which receptor the anorectic effect was attributable to was 
difficult. My aim was to investigate the chronic effects of GCGR and GLP-1R agonism 
separately and in combination on food intake, glucose homeostasis and EE. Therefore, 
G(Y) and G(Z) were designed to bind and activate predominantly the GLP-1R and GCGR 
respectively. Both analogues were injected once daily alone and in combination for 70 
days. There were no significant differences in cumulative food intake compared to 
controls (Fig 3.8). Neither G(Y) or G(Z) alone significantly reduced body weight 
compared to controls. However, the combination of G(Y) and G(Z) significantly reduced 
body weight compared to saline controls from day 30 onwards despite no change in 
cumulative food intake (mean body weight change: 0.13 ± 0.45 [vehicle] vs. -2.00 ± 
0.46g [G(Y)+G(Z)], p<0.05 vs. vehicle, n=10-12/group, fig 3.9). In addition, co-
administration of G(Y) and G(Z) significantly decreased body weight compared to G(Y) 
and G(Z) alone from day 61 onwards. 
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Figure 3.8 Cumulative food intake in DIO mice following chronic administration of G(Y) 
and G(Z) alone and in combination. Data were analysed using one way ANOVA with Tukey 
post test. (n=10-12/group). 
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Figure 3.9 Body weight in DIO mice following chronic administration of G(Y) and G(Z) 
alone and in combination. Mice were injected daily with vehicle/vehicle, G(Y) (5nmol/kg day 
0-5, 10 nmol/kg day 6 onwards)/vehicle, G(Z) (20 nmol/kg day 0-5, 40 nmol/kg day 6-15, 80 
nmol/kg day 16 onwards)/vehicle or G(Y)/G(Z) at the same doses and body weight (BW) 
measured every 1-2 days for 70 days. BW and %BW change are shown. Data were analysed using 
two way repeated measures ANOVA with Bonferroni post test. *p<0.05, **p<0.01, ***p<0.001 
versus vehicle, #p<0.05, ##p<0.01, ###p<0.001 versus G(Y) and G(Z) in combination. (n=10-
12/group). 
 122 
3.4.2.2 Investigation of glucose homeostasis following chronic administration of 
long acting glucagon and GLP-1 analogues. 
 
 
Fasting plasma glucose values were lowest in the combined G(Y) and G(Z) group and 
highest in the vehicle group although this did not reach statistical significance (mean 
glucose: 8.52 ± 0.49 [vehicle] vs. 3.63 ± 0.12 mmol/l [G(Y) + G(Z)],n=10-12/group, fig. 
3.10, t=-30). Following ip glucose administration, DIO mice injected with vehicle showed 
a rise in glucose from 8.35 ± 0.6  mmol/l (T=0) to 17.7 ± 1.1 mmol/l (t=30 mins).  Mice 
administered G(Y) and G(Z) alone showed a slight rise in glucose but all glucose 
measurements following injection were significantly lower than the vehicle controls. In 
contrast, plasma glucose did not change following a glucose load in mice co-
administered G(Y) and G(Z) (mean AUC: 2291 ± 221 [vehicle] vs. 1362 ±137 [G(Y)], 
p<0.001; vs. 1192 ± 147 [G(Z), p<0.001; vs. 672 ±27 [G(Y)+G(Z)], p<0.001, n=10-
12/group, fig 3.10). 
 
Samples were also collected for serum insulin measurement at t=0, 30, 60 and 120 
minutes following glucose administration. Fasting insulin was highest in the vehicle and 
G(Y) groups suggesting insulin resistance whereas it was lowest in the combined G(Y) 
and G(Z) group (mean insulin: 10.2± 1.3 [vehicle] vs. 2.9 ± 0.6 ng/ml [G(Y)+G(Z)], 
p<0.001; vs. 9.4 ± 1.6 [G(Y)], p>0.05; n=10-12/group, fig 3.11). G(Z) administration 
significantly lowered plasma insulin levels compared to vehicle (mean AUC: 1054 ± 144 
[vehicle] vs. 480 ± 66 [G(Z)], p<0.05, n=10-12/group, fig 3.11).  
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Figure 3.10 Intraperitoneal glucose tolerance test following chronic administration of 
G(Y) and G(Z) alone and in combination. A: Plasma glucose measurements (mmol/l)and B: 
Area under the curve (AUC). Ad libitum fed mice were injected at 0700 on the day of the study 
and fasted until the ipGTT at 1300. Blood samples were collected at -30, 0, 30, 60, 90 and 120 
minutes following ip glucose administration. Plasma glucose measurements shown in fig. 3.11A: 
data were analysed using two way repeated measures ANOVA with Bonferroni’s post test. 
**p<0.01, ***p<0.001 versus saline controls. #p<0.05, ##p<0.01 versus G(Y) and G(Z) in 
combination. AUC shown in fig. 3.10B: data were analysed using one way ANOVA with Tukey’s 
post test. ***p<0.001 versus saline controls, #p<0.05 versus G(Y) and G(Z) in combination. n=10-
12/group. 
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Figure 3.11 Insulin values following intraperitoneal (ip) glucose tolerance test on day 70 
following chronic administration of G(Y) and G(Z) alone and in combination. A: Serum 
insulin measurements (ng/ml) and B: Area under the curve (AUC). Insulin samples were taken at 
T=0, 30, 60 and 120 minutes following ip glucose. Insulin values and AUC are shown. Insulin 
measurements were analysed using  two way repeated measures ANOVA with Bonferroni’s post 
test. *p<0.05, ***p<0.001 versus saline controls. #p<0.05, ##p<0.01 versus G(Y) and G(Z) in 
combination. AUC data were analysed using one way ANOVA with Tukey’s post test. *p<0.05 
versus saline controls. n=10-12/group. 
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3.4.2.3 Investigation of the effects of chronic administration of long acting 
glucagon and GLP-1 analogues on markers of energy expenditure and 
gluconeogenesis.    
 
3.4.2.3.1 The effects of chronic administration of long acting glucagon and GLP-1 
analogues on liver, brown adipose (BAT) and white adipose (WAT) tissue mass. 
 
Chronic administration of G(Y) significantly decreased liver weight compared to vehicle 
(mean liver weight as % of total body weight: 5.8 ± 0.3 [vehicle] vs. 4.2 ± 0.2% [G(Y)], 
p<0.001 vs. vehicle, n=10-12/group, fig. 3.12A). There was no significant difference in 
liver weight between G(Z) or G(Y)+G(Z) and vehicle controls.  
 
G(Z) alone and in combination with G(Y) decreased BAT mass compared to vehicle 
whereas G(Y) alone had no effect (mean BAT weight as % of total body weight: 0.86 ± 
0.03 [vehicle] vs. 0.67 ± 0.05% [G(Z)], p<0.05 vs. vehicle; vs. 0.62 ± 0.03% [G(Y)+G(Z)], 
p<0.01 vs. vehicle; n=10-12/group, fig. 3.12B).  
 
G(Y) alone and in combination with G(Z) increased WAT mass compared to vehicle 
(mean WAT weight as % of total body weight: 2.2 ± 0.1 [vehicle] vs. 2.9 ± 0.2% [G(Y)], 
p<0.05 vs. vehicle; vs. 3.0 ± 0.2% [G(Y)+G(Z)], p<0.05 vs. vehicle; n=10-12/group, fig 
3.12C). 
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Figure 3.12. Liver (A), brown adipose tissue (B) and white adipose tissue (C) mass 
following chronic administration of GLP-1 and glucagon analogues. Liver, brown adipose 
tissue (BAT) and white adipose tissue (WAT) were harvested from DIO mice following chronic 
administration of GLP-1 and glucagon long-acting analogues alone and in combination. Data were 
analysed using one-way ANOVA with Tukey post test. *p<0.05, **p<0.01, *** p<0.001 vs. vehicle; 
##p<0.01 vs. G(Y). N=10-12/group. 
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3.4.2.3.2 The effects of chronic administration of long acting glucagon and GLP-1 
analogues on gene expression in liver, brown adipose (BAT) and white adipose tissue 
(WAT). 
 
There were no significant differences in mRNA expression in liver, BAT or WAT between 
any groups (figures 3.13, 3.14 and 3.15). In liver, FGF-21 expression was almost 2.5-fold 
higher following co-administration of G(Y) and G(Z) compared to vehicle however this 
did not reach statistical significance (mRNA expression: 0.96 ± 0.12 [vehicle] vs. 2.33 ± 
0.52 AU [FGF-21], p=ns vs. vehicle, n=7-10/group, fig. 3.13 B).  
 
In WAT, UCP-1 expresion following administration of G(Y) increased over 2-fold. 
However, the number of WAT samples that could be interpreted following rtPCR were 
low due to inadequate mRNA extraction and this difference did not reach statistical 
significance (figure 3.15A).  
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Figure 3.13 mRNA expression in liver following chronic administration of G(Y) and G(Z) 
alone and in combination in DIO mice. Relative mRNA expression of phosphoenolpyruvate 
carboxykinase 1 (PEPCK) (A), fibroblast growth factor-21 (FGF-21) (B), glucose-6-phosphatase 
(G-6-Pase) (C) and acetyl-coenzyme A carboxylase alpha (ACC1) (D) in liver samples. Data were 
analysed using one-way ANOVA with Tukey’s post test. n=7-10/group. 
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Figure 3.14 mRNA expression in brown adipose tissue following chronic administration of 
G(Y) and G(Z) alone and in combination in DIO mice. Relative mRNA expression of 
uncoupling protein-1 (UCP-1) (A), peroxisome proliferative activated receptor gamma co-
activator 1 alpha (PGC1α) (B), peroxisome proliferative activated receptor gamma (PPARγ) (C) in 
brown adipose tissue. Data were analysed using one-way ANOVA with Tukey’s post test. n=8-
10/group. 
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Figure 3.15 mRNA expression in white adipose tissue following chronic administration of 
G(Y) and G(Z) alone and in combination in DIO mice. Relative mRNA expression of 
uncoupling protein-1 (UCP-1) (A), hormone sensitive lipase (HSL) (B), peroxisome proliferative 
activated receptor gamma (PPARγ) (C) in white adipose tissue. Data were analysed using one-
way ANOVA with Tukey’s post test. n=2-6/group. 
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3.4.2.3.3 The effects of chronic administration of long acting glucagon and GLP-1 
analogues on circulating leptin, free tri-iodothyronine, triglycerides and β-
hydroxybutyrate. 
Chronic administration of G(Z) alone and in combination with G(Y) significantly 
decreased circulating leptin concentration (mean leptin concentration: 34.6 ± 0.4 
[vehicle] vs. 29.2 ± 2.1 ng/ml [G(Z)], p<0.05 vs. vehicle; vs. 28.4 ± 1.0 ng/ml [G(Y)+G(Z)], 
p<0.01 vs. vehicle; n=10-11/group, fig. 3.16A).  
There were no significant differences in free tri-iodothyronine (fT3) (fig. 3.16B), 
triglycerides (fig. 3.16C) or β-hydroxybutyrate (fig. 3.16D) between any of the groups. 
Although there was a trend for reduced triglyceride concentration in response to G(Y) 
administration, this did not reach statistical significance (mean triglyceride 
concentration: 2.2 ± 0.2 [vehicle] vs. 1.7 ± 0.3 [G(Y)], p=ns vs. vehicle, n=10-11/group, 
fig. 3.16C). 
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Figure 3.16 The effects of chronic administration of G(Y) and G(Z) alone and in 
combination on circulating concentration of leptin (A), free tri-iodothyronine (fT3) (B), 
trigylcerides (Tg) (C) and β-hydroxybutyrate (D). Markers of energy homeostasis were 
measured from plasma samples in DIO mice following chronic administration of G(Y) and G(Z) 
alone or in combination. Data were analysed using one-way ANOVA with Tukey’s post test. 
*p<0.05, ** p<0.01 vs. vehicle. n=10-11/group. 
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3.5 Discussion 
These studies demonstrate that a dual glucagon/GLP-1 analogue, G(X), reduces food 
intake for up to eight hours with no evidence of major adverse behaviour. Despite this, 
no significant increase in c-fos-ir was detected in the brainstem. The mechanism 
through which G(X) decreases food intake is unclear. Despite similar amino acid 
sequences to native glucagon and GLP-1, previous studies showed that it displayed poor 
binding and activation at both the GCGR and GLP-1R. The anorectic effect may be 
mediated via a different receptor, although the ability of exendin-4(9-39) to almost 
completely inhibit the anorectic effect suggests action of G(X) at the GLP-1R. 
Alternatively, G(X) may act as an allosteric modulator at the GLP-1R. Recent evidence 
shows that allosteric modulation at the GLP-1R can have profound effects on 
downstream signalling. Small molecule GLP-1R modulators have been identified which 
enhance the insulinotropic effect of OXM at the GLP-1R430. It is perhaps surprising that 
G(X) did not cause significant c-fos activation in the brainstem despite a potent 
anorectic effect. Hypothalamic c-fos activation in response to G(X) administration was 
not studied since glucagon and GLP-1 alone did not increase c-fos-ir in any hypothalamic 
nuclei studied. However, activation of an alternative pathway by G(X) to reduce food 
intake cannot be excluded and may involve hypothalamic appetite circuits.  
Due to the discrepancy between receptor binding and activation and anorectic effect 
following G(X) administration, and the finding that G(X) was less potent than exendin-4 
at reducing food intake, two further analogues, G(Y) and G(Z) were designed with 
greater binding affinity and activation at the GLP-1R and GCGR respectively. These 
analogues were administered to DIO mice for 70 days, followed by an ipGTT to assess 
glucose homeostasis. In combination, G(Y) and G(Z) significantly decreased body weight 
without reducing food intake compared to controls, suggesting increased EE. In 
addition, the combination of G(Y) and G(Z) improves glucose homeostasis, although this 
may reflect the weight loss achieved. To further investigate the effects on EE and glucose 
homeostasis, tissues were harvested from the DIO mice and rtPCR undertaken to look at 
specific gene markers of EE.  
There were no significant differences in markers of EE between any of the groups 
studied. Unexpectedly, BAT mass was reduced following chronic administration of G(Z) 
alone and in combination with G(Y). This is in contrast to acute administration of 
glucagon in rats which has been shown to increase BAT mass218. These findings suggest 
that chronic G(Z) administration does not increase EE through BAT thermogenesis, but 
 134 
through an alternative mechanism. My findings also do not support a role for WAT 
‘browning’ as a potential mechanism for increased EE in response to G(Z) , since WAT 
UCP-1 expression was not increased. However, interpretation of mRNA expression in 
WAT in the current study is limited due to small sample numbers. A large number of 
cycles during rtPCR were required in order to reach the threshold of detection of WAT 
mRNA for any of the genes studied, suggesting inadequate mRNA in WAT despite 
quantification during the mRNA extraction process. It is possible that mRNA loss 
occurred during ethanol precipitation or during reverse transcription into cDNA. 
Interestingly, the glucagon analogue G(Z), ameliorated rather than worsened glucose 
control compared to controls and was similar to the GLP-1 analogue G(Y). This was 
despite no significant change in body weight or food intake compared to controls or 
G(Y) treated group suggesting an alternative mechanism for improved glucose 
homeostasis. In addition, G(Z)-treated mice had lower plasma insulin levels following a 
glucose load compared to controls or G(Y) treated mice, suggesting improved insulin 
sensitivity. This is in contrast to findings by other groups, in which antagonism at the 
GCGR has been targeted to ameliorate glucose control. Administration of glucagon-
neutralising antibodies to leptin deficient ob/ob mice acutely decreases blood glucose202. 
Reduction in GCGR expression using antisense oligonucleotides improved glucose 
profiles in leptin receptor deficient db/db mice and Zucker diabetic rats203,204. 
Furthermore, small molecule GCGR antagonists reduce glucagon-induced 
hyperglycaemia in both rodents and humans431,432. Finally, long term (18 weeks) 
inhibition of the GCGR using a monoclonal antibody normalises blood glucose in DIO 
mice205,433. Interestingly, this effect appears to be dependent on a functional GLP-1 
receptor, since the improved glucose tolerance following ipGTT, is diminished by 
exendin(9-39) and in GLP-1R knockout mice433.  
It is possible that chronic glucagon analogue administration, at the dose used in the 
current studies, either upregulates GLP-1 secretion or binds to the GLP-1R. However, 
previous studies have shown that GCGR antagonism results in a compensatory rise of 
circulating glucagon and GLP-1205,434. In mice, the compensatory rise in glucagon and 
GLP-1 is thought to be due to pancreatic α-cell hyperplasia, upregulating 
preproglucagon expression and hence increasing active GLP-1 secretion204,205. Similarly, 
GCGR knockout mice have increased circulating glucagon, increased pancreatic α cell 
hyperplasia and improved glucose tolerance 435. Therefore, antagonism at the GCGR 
causes a paradoxical rise in circulating glucagon and GLP-1 and improved glucose 
control.  
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In contrast, chronically elevated circulating glucagon may cause GCGR receptor 
downregulation, with a similar compensatory rise in preproglucagon expression. 
Hepatic glucagon resistance has been shown to occur in rats fed a high fat diet436,437. DIO 
reduces the number of hepatic GCGRs, and results in a diminished response to glucagon 
during a hyperglucagonaemic clamp437. Furthermore, in vitro  studies using hepatocytes 
have shown that chronic administration of glucagon decreases the adenylyl cyclase 
response over time suggesting desensitisation438. These findings are in contrast to the 
current studies which demonstrate lower circulating glucose levels and improved 
insulin sensitivity in mice following 70 days of G(Z) administration with similar body 
weight and food intake to controls. Despite these findings, there were no significant 
changes in PEPCK or G6Pase mRNA expression in the liver in response to G(Z). Glucagon 
upregulates G6Pase and PEPCK transcription in the liver  both of which are key 
mediators of gluconeogenesis410. This suggests that the improvement in glucose 
homeostasis shown in the current study is not due to downregulation of PEPCK or 
G6Pase.  
Administration of G(Z) alone reduced circulating leptin concentration compared to 
vehicle, despite no significant reduction in body weight. This implies that glucagon 
reduces adiposity, thereby increasing proportional lean body mass. Although, not 
investigated in the current study, this could be assessed using whole body MRI and 
quantification of adiposity439. The combination of G(Y) and G(Z) significantly decreased 
body weight and circulating leptin concentration. This weight loss occurred despite 
similar food intake to vehicle, G(Y) or G(Z) alone, suggesting an increase in EE. It is 
therefore surprising that G(Z) alone acting predominantly through the GCGR did not 
significantly reduce body weight through increased EE. G(Z) may have been 
administered at an insufficient dose to achieve weight loss, however in combination 
with G(Y), a synergistic effect may have occurred.  Synergism between two drugs 
implies a potentiated effect that is significantly greater than the added effects of the two 
compounds alone440. Synergy usually implies multiple sites of action of a drug and is 
dependent on receptor occupancy441. Therefore, the current study suggests that 
glucagon and GLP-1 analogues act synergistically when co-administered to reduce body 
weight although the mechanism through which this occurs is unknown. 
Finally, the GLP-1 analogue, G(Y) significantly reduced liver weight alone, and in 
combination with G(Z) compared to vehicle. GLP-1 analogues have been shown to 
protect against NASH by increasing fatty acid oxidation, decreasing lipogenesis and 
improving hepatic glucose metabolism416. In one study, these benefits were apparent 
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despite a lack of weight loss following liraglutide442. In addition, there was a trend 
towards reduced circulating triglyceride levels following chronic G(Y) administration 
compared to vehicle, although this did not reach significance. Therefore, reduced liver 
mass in response to G(Y) administration may be secondary to reduced hepatic 
triglyceride content. This could be investigated further by direct hepatic triglyceride 
quantification and other markers of hepatic steatosis such as histological analysis and 
plasma alanine aminotransferase. 
In summary, these experiments demonstrate the ability to design and administer 
glucagon and GLP-1 analogues that in combination cause significant weight loss and 
improved glycaemic control in mice. Although the mechanism is unclear, an increase in 
EE appears to be the cause. Long-acting glucagon and GLP-1 receptor analogues may be 
useful tools in the investigation of the chronic effects of glucagon and GLP-1 receptor 
agonism in energy homeostasis and reflect a potential therapy for obesity and type 2 
diabetes mellitus.  
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ADMINISTRATION OF GLUCAGON 
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4.1 Introduction 
Glucagon and GLP-1 are derived from the same preproglucagon gene. Data from my 
studies in rodents and from others87,181,182,343,345 support similar anorectic roles for these 
peptides. However, they demonstrate different roles in glucose metabolism and 
EE162,209,405,443. These effects may be exploited to reduce body weight and improve 
glucose homeostasis. OXM is also derived from the preproglucagon gene, is released 
postprandially from the gut and is an agonist at both the GCGR and GLP-1R 220,444. In 
rodent and human studies, OXM has been shown to reduce food intake and body weight, 
increase EE and improve glucose control220,222,223. It has been proposed that the effects of 
OXM on food intake occur mainly via the GLP-1R, whereas increased EE is due to GCGR 
agonism227. Kosinski et al, have developed an OXM agonist that differs from OXM by only 
one residue, yet has no significant activity at the GCGR227. This OXM agonist significantly 
reduces food intake in DIO mice following administration for 14 days, with a modest 
reduction in body weight (3%). This is in keeping with activation at the GLP-1R. In 
contrast, OXM which has retained activity at the GCGR and GLP-1R, significantly 
decreases food intake and reduces body weight by 14%, suggesting a beneficial weight-
lowering effect through GCGR agonism227. Studies in GLP-1R and GCGR knockout mice 
have also demonstrated the important contribution of GCGR agonism in EE and weight 
loss228,229. Repeated administration of a dual glucagon and GLP-1R agonist results in 
weight loss and reduced food intake in wild-type mice, however this effect is attenuated 
in GCGR knockout mice228. Similarly, administration of a dual glucagon and GLP-1R 
agonist for one month to DIO mice, significantly decreases food intake, body weight and 
fat mass and increases EE compared to controls229. These effects are still evident 
following administration in GLP-1R knockout mice229. Therefore OXM provides a unique 
model of dual receptor agonism, causing weight loss through a reduction in food intake 
via the GLP-1R and increased EE via the GCGR. 
The mechanism through which glucagon increases EE is unknown and few studies have 
investigated its effects in humans. Animal and in vitro studies suggest glucagon may 
increase EE via BAT213,214. Glucagon administration in rodents increases whole body 
oxygen consumption and body temperature in addition to increased BAT mass, blood 
flow and temperature 209,215,216. It is thought that many of these effects occur via the 
SNS217,218,407,445.  In humans, there have been no studies investigating the effects of 
glucagon infusion alone and EE. Glucagon increases EE in healthy volunteers by 15% 
when co-infused with somatostatin, whilst somatostatin alone has no effect on EE210. In 
contrast, several studies have investigated the effects of GLP-1 analogues and EE. In 
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obese non-diabetic patients, daily injection of exenatide for three months does not alter 
weight-adjusted EE405. Similarly, once daily injection of liraglutide in patients with type 
2 diabetes does not significantly increase resting EE (REE)406. No studies have 
investigated the effect of co-administration of glucagon and GLP-1 on EE in humans. 
Acute administration of glucagon increases circulating glucose in humans443 through 
hepatic glycogenolysis and gluconeogenesis. Since GLP-1 reduces glucose through an 
incretin effect, the combination of glucagon and GLP-1 may offer an attractive 
therapeutic option for obese patients with type 2 diabetes due to reduced food intake, 
increased EE and improved glucose control. Consistent with this hypothesis, OXM 
reduces food intake and increases EE causing considerable weight loss in obese 
volunteers with no net effect on glucose control 223,446. However, the separate and 
combined effects of glucagon and GLP-1 on EE, food intake and glucose control has not 
been investigated in humans. In addition, the ratio of GCGR to GLP-1R agonism that is 
optimal for increased EE and reduced food intake whilst improving glycaemia is 
unknown.   
This study therefore aims to investigate the effects of glucagon and GLP-1 
administration in overweight human volunteers, when administered independently and 
in combination, on EE and substrate oxidation. I hypothesised that glucagon increases 
REE and that this effect is retained following co-administration with GLP-1. In addition, I 
hypothesised that the acute hyperglycaemic effects following glucagon administration 
could be ameliorated by co-administration with GLP-1. 
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4.2 Hypothesis and aims 
  
4.2.1 Hypothesis 
 
I hypothesised that glucagon administration increases EE and any rise in glucose is 
ameliorated by co-infusion with GLP-1. To investigate this hypothesis, I measured EE 
using indirect calorimetry in non-diabetic overweight human volunteers during infusion 
of vehicle, each hormone separately and in combination. In addition, I hypothesised that 
glucagon and GLP-1 co-administration improved circulating glucose levels compared to 
glucagon alone. 
 
4.2.2 Aim 
 
My aim was to investigate the effect on EE and glucose homeostasis following glucagon 
and GLP-1 co-administration in overweight volunteers. 
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4.3 Materials and Methods 
4.3.1 Investigation of the acute effects of glucagon and GLP-1 co-
administration on energy expenditure in humans. 
 
4.3.1.1 Peptides 
 
Glucagon and GLP-1(7-36) amide were purchased from Novo Nordisk (Crawley, UK) and  
Bachem Ltd (Switzerland) respectively. Glucagon was dissolved in the solvent provided 
by Novo Nordisk (1 ml water for injection, lactose monohydrate, hydrochloric acid and 
sodium hydroxide for pH adjustment) whilst GLP-1(7-36) amide was dissolved in 1 ml 
sterile 0.9% saline (Bayer, Haywards Heath, UK).  
 
4.3.1.2 Subjects 
 
Ten non-diabetic overweight volunteers, three women and seven men, of mean age 35.8 
+/- 3.1 years (range 23-49) and mean BMI 29.3 +/- 1.0 kg/m2 (range 25.6-36 kg/m2), 
were recruited by advertisement. All completed the study with no adverse effects. 
Inclusion criteria were: age 18 years or over; stable body weight for preceding three 
months and BMI 25-40 kg/m2.  Exclusion criteria were: substance abuse, current 
smoker, significant past or current history of physical or psychiatric illness, regular 
medication other than contraceptives and pregnancy or breastfeeing. All subjects were 
screened and determined to be healthy by medical history, physical examination, 
haematological and biochemical testing and 12-lead electrocardiogram. All female 
participants were premenopausal and had regular menstrual cycles. Women of child-
bearing age were advised to avoid pregnancy during the study and underwent urine 
tests to exclude pregnancy prior to each infusion.  
 
The study was approved by the West London Research Ethics Committee (reference no.: 
09/H0707/76). Written informed consent was obtained for all volunteers and the study 
was carried out according to the principles of the Declaration of Helsinki. 
 
4.3.1.3 Protocol 
 
The study was designed as a randomised, double-blinded, placebo-controlled crossover 
study comparing four different pairs of infusion as shown in table 4.1. Volunteers 
received iv infusions of placebo (gelofusine), glucagon (50 ng/kg/min, Novo Nordisk, 
Crawley, UK), GLP-1(7-36) amide (0.8 pmol/kg/min, Clinalfa Basic, Bachem Ltd, 
Switzerland) or combined glucagon and GLP-1(7-36) amide at the above mentioned doses. 
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The dose of glucagon was selected after a dose finding study to determine the dose of 
glucagon that increased EE without causing side-effects. The dose of GLP-1 was based 
on previous studies investigating the effects of GLP-1 on food intake and glucose 
homeostasis in humans156,447,448.  
 
 
 
 
 
 
 
Table 4.1 Randomised, double-blinded peptide infusion administration. 
Volunteers received two simultaneous infusions in order to compare the effects of GLP-
1 and glucagon alone and in combination on EE.  
 
Volunteers attended for five consecutive visits spaced at least three days apart. The 
initial visit was an unblinded ‘dummy’ visit where gelofusine (Braun, Crawley, UK) was 
infused to acclimatise volunteers to study procedures. For avoidance of liver glycogen 
depletion, volunteers were asked to avoid alcohol and strenuous exercise for 24h prior 
to each study visit and were given a high energy snack (each containing 3.8g fat, 20.4g 
carbohydrate and 1.9g protein; Alpen, Weetabix, UK) to consume at 2200h the night 
before the study. They arrived at the clinical research facility at 0830h having consumed 
a small, low-fat breakfast of two McVitie’s Rich Tea biscuits (each containing 1.3g fat, 
5.9g carbohydrate and 0.6g protein; United Biscuits) at 0700h. Upon arrival, volunteers 
were asked to empty their bladder and then urine was collected at the end of each study 
visit to provide an estimate of urinary nitrogen excretion. 
 
The protocol for each visit is shown in figure 4.1. Peripheral venous cannulae were 
inserted in both forearms, one for infusions and one for blood sampling. A three-way tap 
(BD Connecta Plus Stopcock, Becton Dickinson & Co., USA) was attached to the infusion 
cannula, to allow connection of two separate infusion lines.  
 
 
 
 
 
A B 
Vehicle Vehicle 
GLP-1 (0.8 pmol/kg/min) Vehicle 
Glucagon (50 ng/kg/min) Vehicle 
GLP-1 (0.8 pmol/kg/min) Glucagon (50 ng/kg/min) 
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Figure 4.1 Protocol of study. Following acclimatisation, indirect calorimetry readings were 
commenced at t=0 for a total of 90 minutes. An infusion of vehicle/vehicle, glucagon/vehicle, 
GLP-1/vehicle or glucagon/GLP-1 was commenced at t=45 minutes and continued for 45 
minutes. Blood samples were taken at time points indicated. 
 
 
 
At 0 min (0900h), subjects were placed under the indirect calorimetry canopy (Gas 
Exchange Monitor, GEM Nutrition, Daresbury, UK). Before each measurement, the 
calorimeter was calibrated with ‘zero’ (0.00% O2 and 0.00% CO2) and ‘span’ gases (20% 
O2 and 1.00% CO2) (BOC gases, Surrey, UK). Volunteers lay semirecumbent on a bed and 
were allowed to watch television or listen to music. Calorimeter measurements were 
allowed to stabilise during the first thirty minutes. REE, respiratory quotient (RQ) and 
carbohydrate and fat oxidation rates were estimated from measurements of VO2 and VCO2 
recorded each minute, with adjustment made for urinary nitrogen excretion. Protein 
oxidation rate over the entire study visit was estimated from urinary nitrogen excretion 
alone449,450. The formulae used to determine EE, carbohydrate, fat and protein oxidation 
were as follows and are based on the Weir equation449: 
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Energy Expenditure 
EE (kcal/min)= (3.94xVO2 (l/min)) + (1.11xVCO2(l/min)) – (2.17 x nitrogen excretion) 
 
Nitrogen excretion 
Nitrogen excretion (g/min) = 0.028 x ((urine urea (mmol/l) x urine volume 
(litres))/time elapsed since last passed urine (mins))  
 
Respiratory Quotient 
RQ = VCO2(l/min) /VO2(l/min) 
 
CHO oxidation  
CHO oxidation (g/min) = (4.55 x VCO2(l/min)) – (3.21xVO2(l/min)) – (2.87 x nitrogen 
excretion) 
 
Fat oxidation 
Fat oxidation (g/min) = 1.67 x (VO2(l/min) - VCO2(l/min)) – (1.92 x nitrogen excretion) 
 
Protein oxidation 
Protein oxidation (g/min) = nitrogen excretion x 6.25 
 
 
Baseline REE was defined as the mean of measurements taken during the final 15 
minutes of the 45 minute baseline phase. REE following infusion was determined from 
measurements taken during the final 15 minutes of the infusion phase. 
 
At 45 minutes, a hormone infusion was started, which lasted for 45 minutes. Each 
volunteer received two infusions, A and B, simultaneously, at each visit. Infusion 
allocation was determined in a four-way randomised design. Gelofusine was used as the 
vehicle for hormone infusions in order to minimise adsorption of peptides to infusion 
line and syringes451.  In addition, gelofusine was drawn up into the syringes and giving 
sets and left for 30 minutes prior to expelling. Each infusion was drawn up and 
delivered in a separate 50 ml syringe (Graseby 3100, SIMS Graseby Ltd, Watford, UK) to 
allow the use of two different infusion rates. The infusion rate was ‘ramped’ to establish 
stable plasma hormone levels rapidly, with an infusion rate four times the nominal rate 
for 5 minutes reduced to twice the nominal rate for the next 5 minutes and then to the 
nominal rate for the remaining 35 minutes.  
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Calorimetry continued during the 45 minute infusion. As with the baseline phase, 
calorimetry measurements were allowed to stabilise for 30 minutes after the infusion 
was started. Measurements from the final 15 minutes were used to calculate the 
infusion-phase REE, RQ and substrate oxidation rates. At 90 minutes, the infusion and 
calorimetry were stopped and the study terminated at 105 minutes. Blood samples were 
collected at 30, 45, 60, 75, 90 and 105 minutes, into lithium heparin-coated BD 
Vacutainer tubes (International Scientific Supplies Ltd, Bradford, UK) containing 1000 
kallikrein inhibitor units (0.1ml) (Trasylol, Bayer Scherin Pharma, Berlin, Germany) for 
gut hormone analysis. In addition, blood samples were collected into plain serum 
Vacutainer tubes containing clot activators and fluoride oxalate tubes for insulin and 
glucose assay respectively. Cryogenic vials (Alpha Laboratories, Eastleigh, UK) 
containing 20 ls of 0.8M HCl were used for ghrelin quantification and lithium heparin-
coated tubes for non-esterified fatty acids (NEFAs). Samples were stored on ice until 
centrifugation (4C, 4000 rpm, 10 minutes) after which, plasma was separated 
immediately and stored at -20C until analysis. The pulse and blood pressure of each 
subject was measured at t=0, 45 and 90 minutes. 
  
 
4.3.1.4 Plasma hormone assays 
 
Glucagon and GLP-1 radioimmunoassay (RIA) 
Glucagon and total GLP-1 were measured using established in-house 
radioimmunoassays (RIAs)132,162. All samples were assayed in duplicate. Glucagon and 
GLP-1 were purchased from Bachem Ltd (Switzerland). All other reagents and materials 
were supplied by Sigma (Poole, Dorset, UK). The glucagon and GLP-1 labels were 
prepared by Professor M. Ghatei (Professor of Regulatory Peptides, Metabolic Medicine, 
Faculty of Medicine, Imperial College) who iodinated the peptide using the iodogen 
method452 and was purified by reverse-phase HPLC.   
 
Assays were performed in veronal buffer (1l distilled water containing 10.3g sodium 
barbitone, 0.3g sodium azide), at pH 8 with 0.3% BSA (and 0.02% tween for the GLP-1 
assay) (VWR, UK). Standard curves were prepared in assay buffer at 0.25 and 0.5 
pmol/ml for GLP-1 and glucagon respectively, added in duplicate at volumes of 1, 2, 3, 5, 
10, 15, 20, 30, 50 and 100 µl.  The glucagon antibody (RCS5) was raised in rabbits 
against the C-terminal of glucagon and is therefore specific for pancreatic glucagon. In 
this assay the antibody was used at a dilution of 1:50000. The GLP-1 antibody was 
 146 
raised in rabbits against the N terminal of GLP-1(7-36) and binds to all amidated forms of 
GLP-1 (1-36, 7-36, 9-36). Experimental samples of 50 µl, 100 µl glucagon or GLP-1 antibody 
solution and 100 µl of glucagon or GLP-1 label solution were used and all tubes were 
buffered to a total volume of 700 µl with assay buffer.  The assays were incubated for 96 
hours at 4oC. Free peptide was separated from bound using charcoal adsorption.  To 
each tube, 4 mg of charcoal, suspended in 0.06 M phosphate buffer with gelatine was 
added immediately prior to centrifugation. The samples were then centrifuged at 1500 
rpm, 4oC, for 20 minutes.  Bound and free label were separated and both the pellet and 
supernatant counted for 180 seconds in a γ-counter (model NE1600, Thermo Electron 
Corporation).  Plasma glucagon and GLP-1 concentrations in the samples were 
calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and 
results calculated in terms of the standard.  
Ghrelin ELISA 
 
Ghrelin was measured using total ghrelin (intact and des-octanoyl forms) and active 
(acylated) ghrelin ELISA assay (Millipore, Watford, UK).  In both cases, the 
manufacturer’s protocol was followed. The kits use a competitive inhibition enzyme 
immunoassay technique, in which monoclonal anti-ghrelin antibodies were immobilised 
on the surface wells. After washing with buffer, these antibodies bound to ghrelin in the 
sample (20 µl added), standard or control solutions during a 2 hour incubation. After 
washing, to remove unbound material, a second biotinylated, monoclonal anti-ghrelin 
antibody was added to the wells which bound to the already captured ghrelin. Further 
washing preceded the addition of streptavidin-horseradish peroxidase, which bound to 
biotin. After excess streptavidin-enzyme conjugate was washed away, a substrate for 
horseradish peroxidase was added (3,3’, 5, 5’-tetramethylbenzidine). The peroxidase 
reaction was stopped by the addition of 0.3M HCl. Enzyme activity was measured 
spectrophotometrically (Multiskan RC microplate reader, Labsystems, Vienna, VA, USA) 
by the increased absorbancy at 450 nm and 620 nm. Absorbance at 450nm was 
subtracted from that at 620 nm. A standard curve was constructed and sample 
concentration derived from this (GraphPad Prism 5.0d, GraphPad Software, San Diego, 
USA).   
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Other blood samples 
 
NEFAs were measured by the Department of Chemical Pathology, Great Ormond Street 
Hospital National Health Service Trust using a Wako NEFA assay kit (Alpha laboratories, 
UK) and the ILab 650 analyser (Instrumentation Laboratory, Massachusetts, US). 
Insulin, glucose, thyroid hormones and cortisol samples were measured by the 
Department of Chemical Pathology, Imperial College Healthcare National Health Service 
Trust. Insulin was measured using a fully automated enzyme immunoassay and an 
Abbott AxSYM analyser. 
 
 
4.3.1.5 Statistical analysis 
 
Change from baseline in EE and substrate oxidation rates, were analysed using one way 
ANOVA with Tukey post test. Two-way repeated measures ANOVA with Bonferroni post 
test was used to compare differences in glucose, insulin, ghrelin, NEFA, thyroid 
hormones and cortisol concentration at different time points. Change in pulse and blood 
pressure from baseline was analysed using one way ANOVA with Tukey post test. 
Results are presented as mean  SEM and statistical significance defined as p<0.05. 
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4.4 Results 
4.4.1 Dose finding study investigating the acute effects of co-administration 
of glucagon and GLP-1 on energy expenditure and glucose homeostasis in 
humans. 
 
4.4.1.1 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on energy expenditure. 
 
Non-diabetic overweight volunteers were recruited as described in section 4.3.1.2 and 
the protocol followed as described in section 4.3.1.3. The initial dose of glucagon was 
based on a previous study in which glucagon and somatostatin co-administration 
increased REE by 15%210. In the current dose finding study, the dose was gradually 
increased until the lowest dose of glucagon that increased REE was determined. As 
shown in figure 4.2, the lowest effective dose of glucagon was 50 ng/kg/min and 
increased REE by 22 kcal/day from baseline (n=1). Subsequent infusions for the 
remainder of the study contained glucagon (50 ng/kg/min) or GLP-1 (0.8 pmol/kg/min) 
administered independently and in combination. 
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Figure 4.2. Dose finding study to determine energy expenditure following the 
administration of glucagon and GLP-1 independently and in combination. Energy 
expenditure (EE) was measured prior to infusion of glucagon (ng/kg/min) and GLP-1 
(pmol/kg/min) alone or in combination. The number of volunteers receiving each dose is shown 
in brackets. Abbreviations: Energy expenditure (EE), glucagon (GCG), vehicle (veh), glucagon-like 
peptide-1 (GLP-1). 
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4.4.1.2 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on plasma insulin and glucose concentrations. 
 
During the dose finding study, glucose and insulin samples were taken at the time points 
shown in figure 4.3. At the lowest effective glucagon dose that increased EE (50 
ng/kg/min), circulating glucose levels did not significantly rise compared to the lowest 
dose tested (3 ng/kg/min) (figure 4.3A). In contrast, there was a dose-dependent 
increase in insulin levels following glucagon infusion with the highest levels observed 
following glucagon/GLP-1 co-administration (figure 4.3B).  
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Figure 4.3. Circulating glucose and insulin levels following the administration of glucagon 
and GLP-1 alone and in combination. Volunteers received an infusion for 45 minutes (denoted 
by grey bar) of glucagon alone or in combination with GLP-1. Glucose and insulin samples were 
collected at the time points indicated. The number of volunteers receiving each dose is shown in 
brackets. Abbreviations: glucagon (GCG), vehicle (veh), glucagon-like peptide-1 (GLP-1). 
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4.4.2 Investigation of the acute effects of glucagon and GLP-1 co-
administration on energy expenditure in humans. 
 
4.4.2.1 Investigation of plasma glucagon and GLP-1 concentrations achieved 
following co-administration of glucagon and GLP-1 
 
Mean baseline plasma concentration of GLP-1 in all volunteers, prior to the start of the 
infusion was 18 ± 1.9 pmol/l (range: 5.1-48.8 pmol/l). Infusion of GLP-1 at 0.8 
pmol/kg/min, increased circulating GLP-1 levels to 103.1 ± 26.0 pmol/l, 15 minutes 
after the infusion was started (Fig 4.4A). In the GLP-1/glucagon combination group, 
GLP-1 levels rose to 89.7 ± 17.2 pmol/l, 15 minutes after the infusion was started. 
Glucagon alone or vehicle infusion caused no rise in circulating GLP-1. 
 
Mean baseline plasma concentration of glucagon in all volunteers, prior to the start of 
infusion was 9.6 ± 1.1 pmol/l (range 2.0-31.6 pmol/l). This rose to a peak of 260.9 ± 
43.8 pmol/l, 15 minutes after starting the glucagon infusion, and 239.3 ± 42.1 pmol/l 
following glucagon and GLP-1 co-administration (Fig 4.4B). GLP-1 alone or vehicle 
infusion did not elevate circulating glucagon. After the infusions were discontinued at 90 
minutes, glucagon and GLP-1 levels decreased to baseline within 15 minutes. 
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Figure 4.4 Plasma GLP-1 (A) and glucagon (B) following peptide infusion. Volunteers 
received an infusion for 45 minutes (denoted by grey bar) of vehicle/vehicle, GLP-1 (0.8 
pmol/kg/min)/vehicle, glucagon (50 ng/kg/min)/vehicle or GLP-1 (0.8 pmol/kg/min)/glucagon 
(50 ng/kg/min). n=10. 
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4.4.2.2 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on energy expenditure 
 
 
REE was measured at baseline and following infusion of vehicle, GLP-1, glucagon or 
combined GLP-1/glucagon. Glucagon significantly increased REE compared to vehicle or 
GLP-1 alone (mean REE: -7.4 ± 22.0 [vehicle] vs. 140.9 ± 18.4 kcal/day [glucagon], 
p<0.001) and (mean REE: -10.6 ± 22.3 [GLP-1] vs. 140.9 ± 18.4 kcal/day [glucagon], 
p<0.001, n=10, fig. 4.5). A further increase in REE was seen following the co-
administration of GLP-1/glucagon compared to vehicle or GLP-1 alone (mean REE: -7.4 
± 22.0 [vehicle] vs. 161.2 ± 30.9 kcal/day [GLP-1/glucagon co-administration], p<0.001 
vs. vehicle, n=10, fig 4.5) and (mean REE: -10.6 ± 22.3 [GLP-1] vs. 161.2 ± 30.9 kcal/day 
[GLP-1/glucagon co-administration], p<0.001, n=10, fig. 4.5). There was no significant 
difference in REE between glucagon and GLP-1/glucagon co-administration.  
 
Substrate oxidation was calculated from RQ measurements during calorimetry at 
baseline and at the end of infusion. Co-administration of GLP-1/glucagon caused a 
significant increase in carbohydrate oxidation (mean carbohydrate oxidation: -0.005 ± 
0.009 [vehicle] vs. 0.074 ± 0.016 g/min [GLP-1/glucagon co-administration], p<0.001, 
n=10, fig. 4.6A) and a significant decrease in fat oxidation (mean fat oxidation: 0.002 ± 
0.004 [vehicle] vs. 0.017 ± 0.006 g/min [GLP-1/glucagon co-administration], p<0.05, 
n=10, fig. 4.6B). Calculation of protein oxidation requires estimation of urinary nitrogen 
excretion over the entire study period. Therefore comparison between baseline and 
following infusion could not be done. There were no significant changes in protein 
oxidation between any of the infusions (fig. 4.6C). 
 
Due to previous evidence suggesting a lipolytic effect of glucagon on adipose tissue417, 
plasma NEFAs were measured. Glucagon and GLP-1/glucagon co-administration 
significantly reduced plasma NEFA during the infusion (mean NEFA: 0.46 ± 0.07 [pre 
glucagon infusion] vs. 0.18 ± 0.03 mmol/l [post glucagon infusion], p<0.001; 0.38 ± 0.06 
mmol/l [pre GLP-1/glucagon infusion] vs. 0.13 ± 0.02 mmol/l[post GLP-1/glucagon 
infusion], p<0.001, n=10, fig. 4.7).   
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Figure 4.5. Change in energy expenditure (EE) from baseline following administration of 
vehicle, GLP-1, glucagon or combination of GLP-1 and glucagon. Volunteers received an 
infusion of vehicle/vehicle, GLP-1 (0.8 pmol/kg/min)/vehicle, glucagon (50 ng/kg/min)/vehicle 
or GLP-1 (0.8 pmol/kg/min)/glucagon (50 ng/kg/min). EE was measured at baseline, prior to 
the start of infusion and continued throughout the infusion. Data were analysed using one-way 
ANOVA with Tukey post test, *** p<0.001 vs. vehicle, ### p<0.001 vs. GLP-1. n=10. 
 
 156 
Vehicle GLP-1 Glucagon GLP-1/ glucagon
-0.05
0.00
0.05
0.10
***
##
A
C
ar
bo
hy
dr
at
e 
ox
id
at
io
n
ch
an
ge
 fr
om
 b
as
el
in
e 
(g
/m
in
)
Vehicle GLP-1 Glucagon GLP-1/ glucagon
-0.03
-0.02
-0.01
0.00
0.01
*
B
Fa
t 
ox
id
at
io
n
ch
an
ge
 fr
om
 b
as
el
in
e 
(g
/m
in
)
Vehicle GLP-1 Glucagon GLP-1/ glucagon
0.00
0.02
0.04
0.06
C
P
ro
te
in
 o
xi
da
tio
n 
ov
er
en
tir
e 
st
ud
y 
pe
ri
od
 (
g/
m
in
)
 
Figure 4.6 Substrate oxidation rates following infusion. Carbohydrate and fat oxidation 
values were calculated during calorimetry from RQ readings at baseline and following infusion. 
Protein oxidation was calculated at the end of the study only. Data were analysed using one-way 
ANOVA with Tukey post test. * p<0.05, ***p<0.001 vs. vehicle, ## p<0.01 vs. GLP-1. n=10. 
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Figure 4.7. Non-esterified fatty acid (NEFA) levels following infusion of GLP-1, glucagon or 
GLP-1/glucagon in combination. Blood samples were collected for NEFAs prior to infusion 
(t=30 mins) and at the end of the infusion (t=90 mins). Data were analysed using two-way 
repeated measures ANOVA with Bonferroni post test. ***p<0.001 vs. pre-infusion. n=10.  
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4.4.2.3 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on plasma insulin and glucose concentrations. 
 
Mean baseline glucose values in all volunteers were 5.1 ± 0.1 mmol/l (range: 3.9-6.3 
mmol/l) prior to peptide administration. A significant rise in glucose was seen following 
glucagon infusion, reaching a peak at t=75 (30 minutes after the start of infusion) (mean 
glucose: 5.1 ± 0.1 [vehicle] vs. 8.3 ± 0.4 mmol/l [glucagon], p<0.001, n=10, fig. 4.8A).  At 
the end of the study (t=105), glucose levels remained elevated following glucagon 
administration despite the infusion having been discontinued 15 minutes prior (mean 
glucose: 5.0 ± 0.1 [vehicle] vs. 6.7 ± 0.5 mmol/l [glucagon], p<0.001, n=10, fig. 4.8A).  
 
The increase in glucose following glucagon administration was significantly attenuated 
by the co-administration of GLP-1/glucagon at t=75 and t=90 (mean glucose at t=90: 6.0 
± 0.7 [GLP-1/glucagon co-administration] vs. 5.1 ± 0.1 mmol/l [vehicle], p=ns; vs. 7.9 ± 
0.4 mmol/l [glucagon], p<0.001, n=10, fig. 4.8A). In addition, the glucose level in 
response to co-administration returned to baseline 15 minutes after the infusion was 
stopped.  
 
Both glucagon and GLP-1/glucagon co-administration significantly increased insulin 
concentration compared to vehicle or GLP-1 alone. The amelioration of glucose control 
in response to GLP-1/glucagon co-administration described above, was accompanied by 
a greater rise in insulin in response to GLP-1/glucagon co-administration compared to 
glucagon alone (mean AUC: 5605 ± 1037 [GLP-1/glucagon co-administration] vs. 2919 ± 
536 [glucagon] mU/l-1min, p<0.01, n=10, fig. 4.9B). Administration of GLP-1 alone did 
not significantly increase glucose or insulin.  
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Figure 4.8. Effects of glucagon, GLP-1 or GLP-1/glucagon in combination on plasma glucose 
concentration. Volunteers received an infusion for 45 minutes (denoted by grey bar) of 
vehicle/vehicle, GLP-1 (0.8 pmol/kg/min)/vehicle, glucagon (50 ng/kg/min)/vehicle or GLP-1 
(0.8 pmol/kg/min)/glucagon (50 ng/kg/min). Data were analysed using (A) two-way repeated 
measures ANOVA with Bonferroni post test and (B) one way ANOVA with Tukey post test. 
**p<0.01, *** p<0.001 vs. vehicle; ###p<0.001 vs. GLP-1; $$ p<0.01, $$$ p<0.001 vs. glucagon. 
n=10. 
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Figure 4.9 Effects of glucagon, GLP-1 and GLP-1/glucagon in combination on serum insulin 
concentrations. Volunteers received an infusion for 45 minutes (denoted by grey bar) of 
vehicle/vehicle, GLP-1 (0.8 pmol/kg/min)/vehicle, glucagon (50 ng/kg/min)/vehicle or GLP-1 
(0.8 pmol/kg/min)/glucagon (50 ng/kg/min). Data were analysed using (A) two-way repeated 
measures ANOVA with Bonferroni post test and (B) one way ANOVA with Tukey post. *p<0.05, 
**p<0.01, *** p<0.001 vs. vehicle; ##p<0.01, ###p<0.001 vs. GLP-1; $$$ p<0.001 vs. glucagon. 
n=10.  
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4.4.2.4 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on cardiovascular parameters 
 
 
Following infusion of glucagon or GLP-1/glucagon co-administration, there was a rise in 
systolic blood pressure (fig. 4.10A) and pulse (fig. 4.10C) although this did not reach 
significance. There was no significant change in diastolic blood pressure in response to 
any of the infusions administered (fig. 4.10B). 
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Figure 4.10. Cardiovascular parameters following infusion of GLP-1, glucagon and GLP-
1/glucagon in combination. Systolic (A), diastolic (B) blood pressure and pulse rate (C) change 
from baseline (t=45 mins) following infusion (t=90 minutes) of GLP-1 (0.8 pmol/kg/min), 
glucagon (50 ng/kg/min) and combination of GLP-1 (0.8 pmol/kg/min)/glucagon (50 
ng/kg/min). Data were analysed using one way ANOVA with Tukey post test. n=10. 
Abbreviations: blood pressure (BP), millimetres of mercury (mmHg). 
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4.4.2.5 Investigation of the acute effects of glucagon and GLP-1 co-administration 
on plasma concentrations of ghrelin, cortisol and thyroid hormones.  
 
There were no significant changes in cortisol, fT4 and fT3 (fig. 4.11 and 4.12A and B), 
however there was a significant reduction in TSH following glucagon infusion (mean 
TSH levels: 1.24 ± 0.25 [TSH pre infusion] vs. 1.05 ± 0.22 mU/l [TSH post infusion], 
p<0.01, n=10, fig. 4.12C).  
 
Previous studies have demonstrated a reduction in circulating ghrelin in response to 
glucagon and GLP-1 alone453-455. Ghrelin samples were collected in this study to assess 
the effect on ghrelin levels in response to GLP-1/glucagon co-administration. Glucagon 
alone reduced total and acylated ghrelin levels although this did not reach significance. 
No effect on total or acylated ghrelin was seen in response to GLP-1 infusion. In contrast 
co-administration of GLP-1/glucagon significantly reduced total and acylated ghrelin 
(mean acylated ghrelin level: 390.5 ± 129.7 [pre GLP-1/glucagon infusion] vs. 191.0 ± 
57.9 pg/ml [post GLP-1/glucagon infusion], p<0.05, n=10, fig. 4.13B). 
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Figure 4.11 Serum cortisol following infusion of GLP-1, glucagon or GLP-1/glucagon in 
combination. Blood samples were collected prior to infusion (t=30 mins) and at the end of the 
infusion (t=90 mins). Data were analysed using two-way repeated measures ANOVA with 
Bonferroni post test. n=10.  
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Figure 4.12. fT4 (A), fT3 (B) and TSH (C) levels following infusion of GLP-1, glucagon or 
GLP-1/glucagon in combination. Blood samples were collected for thyroid hormones prior to 
infusion (t=30 mins) and at the end of the infusion (t=90 mins). Data were analysed using two-
way repeated measures ANOVA with Bonferroni post test. **p<0.01 vs. pre-infusion. n=10. 
Abbreviations: free thyroxine (fT4), free tri-iodothyronine (fT3), thyroid stimulating hormone 
(TSH). 
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Figure 4.13. Total (A) and acylated (B) ghrelin following infusion of GLP-1, glucagon or 
GLP-1/glucagon in combination. Plasma samples were collected for ghrelin prior to infusion 
(t=30 mins) and at the end of the infusion (t=90 mins). Data were analysed using two-way 
repeated measures ANOVA with Bonferroni post test. *p<0.05, **p<0.01 vs. pre-infusion. n=10.  
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4.4 Discussion 
This study demonstrates that glucagon alone and in combination with GLP-1, increases 
REE in humans by approximately 150 kcal/day. In addition, co-administration of GLP-
1/glucagon ameliorates the rise in glucose in response to glucagon infusion alone. The 
effects on EE in response to glucagon may be triggered by glucagon-induced 
sympathetic nervous activation of BAT or increased blood flow to BAT increasing 
thermogenesis. Alternatively, the rise in REE may be due to glucagon-induced release of 
catecholamines 456,457. However a significant rise in pulse and blood pressure would be 
expected458. In this study, whilst although there was a trend towards increased pulse 
and systolic blood pressure, this did not reach statistical significance. Circulating 
catecholamines were not measured in the current study. 
Interestingly, some studies suggest that glucagon stimulates catecholamine release 
indirectly via insulin 377,459. This is in keeping with my findings, in which glucagon 
increased insulin levels and REE, whereas GLP-1 had no effect on either outcome. 
Hyperinsulinaemia produced using a euglycaemic insulin clamp technique in healthy 
volunteers, results in a dose dependent increase in REE460. However, the glucose 
requirements to maintain euglycaemia are increased during the insulin clamp and it has 
been suggested that the increased EE is largely dependent on glucose-induced 
thermogenesis460. Interestingly, the rise in EE during a euglycaemic insulin clamp study 
is blunted in obese patients and abolished in patients with type 1 diabetes and obese 
type 2 diabetics 461,462. Furthermore, the change in REE is significantly correlated to the 
rate of glucose uptake461. These findings suggest that the rise in EE is dependent on 
intact insulin function, facilitating glucose transport into cells. In contrast, somatostatin 
(which inhibits insulin release) and glucagon co-infusion in healthy volunteers increases 
REE despite suppressed insulin levels210. However, during somatostatin and glucagon 
co-infusion, circulating levels of glucose are elevated, supporting the view that increased 
EE may be secondary to glucose-induced thermogenesis alone. Therefore, in the current 
study, the rise in REE in response to glucagon and GLP-1/glucagon co-adminstration 
could be secondary to an insulinotropic effect, increasing glucose utilisation in 
thermogenic tissues. This mechanism requires further investigation.  
The current study shows increased REE in response to glucagon administration. OXM 
increases activity-related EE in humans but has no significant effects on REE 223. 
Similarly, a long-acting glucagon agonist increases EE in mice but is associated with 
increased locomotor activity 463. The difference in findings may be related to the doses 
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used and the degree of GCGR agonism in each study. Although not measured in this 
study, the effect of glucagon on activity-related EE could be measured using portable 
monitoring devices that calculate activity-related EE.   
Both glucagon and GLP-1 can cause nausea at high doses464,465. Subjective feelings of 
nausea at the doses of glucagon and GLP-1 administered was not investigated in the 
current study. Participants were placed under the indirect calorimetry hood for the 
duration of the infusion with minimal movement allowed. This prevented completion of 
VAS to assess nausea and satiety. Before further development of a glucagon/GLP-1 
agonist as a potential treatment for obesity, further investigation of the incidence of 
nausea and vomiting would be needed.  
In the current study, increased EE in response to GLP-1/glucagon co-administration was 
accompanied by an increase in carbohydrate oxidation and reduced fat oxidation. In 
addition, glucagon alone and in combination with GLP-1 significantly reduced plasma 
NEFAs. This is in contrast to the traditional understanding of glucagon in the stimulation 
of lipolysis, increasing fat oxidation and NEFA production466. However, my findings are 
consistent with the insulinotropic effect observed following GLP-1/glucagon co-
administration, whereby the resultant rise in insulin causes inhibition of HSL 467,468. 
Similarly, a recent study has shown a significant decrease in NEFA concentration in 
healthy overweight human volunteers, during concomitant hyperinsulinaemia in 
response to 1mg im glucagon469. These findings are in contrast to Day et al 229, in which 
chronic treatment with a GLP-1/glucagon co-agonist in DIO mice causes 
phosphorylation and activation of HSL. However, in the same study, a significant 
reduction in circulating insulin was shown which could account for the discrepant 
results. 
These results show that at the dose administered, glucagon increased plasma glucose 
levels, most likely through glycogen breakdown. Co-administration of GLP-1 and 
glucagon ameliorated this hyperglycaemic effect although glucose remained elevated 
compared to levels in the vehicle control group. This was due to  an apparent synergistic 
insulinotropic effect of glucagon and GLP-1 co-administration. Both hormones are 
known to stimulate insulin release from pancreatic  cells in vivo and in vitro in 
response to glucose 470-472. An additive insulinotropic effect is also seen following co-
infusion of gastric inhibitory peptide (also a member of the secretin family) and GLP-1 
in healthy volunteers470. This study shows that GLP-1 alone did not increase insulin 
levels compared to vehicle. However, GLP-1 co-administered with glucagon significantly 
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increased insulin levels to above those achieved with glucagon alone. It is likely that the 
lack of GLP-1 induced insulin release is secondary to low glucose levels, since the 
incretin effect of GLP-1 is glucose-dependent. Nevertheless, the apparent synergistic 
effect in response to GLP-1 and glucagon co-administration was not completely glucose 
dependent since combination therapy caused the largest rise in insulin, yet only a 
modest rise in glucose was seen. This is in keeping with previous studies that 
demonstrate glucagon-induced insulin release from human pancreatic  cells is 
independent of hepatic glucose production443,467. The apparent synergistic effect in 
response to GLP-1 and glucagon co-administration has not been investigated. However, 
a reduction in GLP-1-induced insulin release in human pancreatic islets is seen in 
response to administration of  a glucagon antagonist473. This suggests that glucagon and 
GLP-1 may act synergistically at the pancreatic  cell to regulate glucose metabolism.  
In the work outlined in this chaper, the enhanced insulinotropic effect and increased EE 
in response to GLP-1/glucagon co-administration was demonstrated in non-diabetic 
overweight volunteers. Whether these effects are still evident in patients with insulin 
resistance or type 2 diabetes remains unknown. The sensitivity of the pancreatic islets 
to the incretin action of physiological levels of GLP-1 is reduced in patients with type 2 
diabetes474, however pharmacological doses are still able to stimulate significant insulin 
release474. This could be investigated using a similar protocol as described here, 
however comparing weight-matched non-diabetic and type 2 diabetic volunteers.  
Finally, the current study shows that GLP-1/glucagon co-administration reduces total 
and acylated ghrelin levels. There was no effect on ghrelin secretion following GLP-1 
administration alone. This is in contrast to a previous study which shows that GLP-1 
suppresses ghrelin secretion possibly through increased insulin secretion453.  In my 
study, there was no significant increase in insulin in response to GLP-1 administration 
and may explain the different results. In contrast, there was a trend towards 
suppression of ghrelin levels in response to glucagon administration alone. This is in 
keeping with previous studies in which suppression of ghrelin secretion was seen 
following 1 mg im glucagon 454,455. These findings are in contrast with recent work by 
Gagnon et al, in which glucagon administration in vitro showed a dose-dependent 
increase in ghrelin secretion475. However the in vitro findings may simply reflect the 
absence of another modulator of ghrelin secretion through which glucagon acts 
indirectly to reduce ghrelin secretion.  
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In conclusion, my work demonstrates that glucagon increases EE when administered 
alone and in combination with GLP-1. However, the mechanism through which glucagon 
increases EE remains to be investigated. Activation of the SNS or increased circulating 
catecholamines may be involved. Alternatively, the increased EE may be due to an 
insulinotropic effect of glucagon with subsequent increased glucose uptake in 
thermogenic tissues. A secondary finding from this study demonstrates that co-
administration of GLP-1 and glucagon ameliorates the hyperglycaemia observed in 
response to glucagon alone. This is associated with a significant insulinotropic effect 
above that seen with either hormone alone. Despite this rise in insulin secretion, the 
doses used in combination did not significantly improve glucose control compared to 
vehicle over the 45 minute infusion period. Whether these potentially beneficial effects 
on EE and glucose control in humans are sustained over a longer period requires further 
investigation. Nausea, a frequently described side-effect of both glucagon and GLP-1 
administration, was not assessed in this study and requires further investigation should 
glucagon/GLP-1 co-administration be of clinical benefit as a treatment for obesity. 
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5.1 Introduction 
GLP-1R agonists are used to treat patients with type 2 diabetes, improving glucose 
control through their insulinotropic effects and resulting in weight loss due to reduced 
food intake157. However, the magnitude of weight loss is restricted by dose-limiting 
nausea and vomiting476. Glucagon reduces food intake in rodents181,182,343,351 and 
humans180,186 and increases EE209,210. Similarly, its use is limited by nausea and 
vomiting477.  
Data from my earlier rodent studies demonstrate that co-administration of sub-
anorectic doses of glucagon and GLP-1 significantly reduces food intake compared to 
vehicle whilst maintaining eugylcaemia (chapter 2). Rodents do not vomit and there is 
considerable discussion as to whether studies, including CTA protocols, can reliably and 
accurately assess nausea in rodents 424. Using manganese-enhanced magnetic resonance 
imaging (MEMRI) in mice, it has been shown that  signal intensity in the VMN following 
GLP-1 administration closely resembles that generated by peripheral injection of LiCl, 
an agent used to study adverse behaviour such as nausea in animal studies366. This 
suggests that GLP-1 and LiCl may cause adverse symptoms through a common 
hypothalamic pathway in rodents. It has been postulated that the brainstem NTS plays a 
major role in integrating the emetic response in humans and is a target for anti-emetic 
agents478. Rodent studies suggest that both glucagon and GLP-1 reduce food intake via 
vagal mediated pathways87,351 and data from my earlier c-fos studies (chapter 2) 
demonstrate that peripheral administration of glucagon and GLP-1 increases c-fos 
expression in the NTS. This suggests that glucagon and GLP-1 may cause nausea through 
a common pathway via the NTS in the brainstem. Recently, functional magnetic 
resonance imaging has been used in humans to assess signals generated within the CNS 
in response to anorectic doses of gut hormones448. Unfortunately, the imaging 
techniques at present are not sensitive enough to detect changes in individual 
hypothalamic or brainstem nuclei. Therefore animal data demonstrating hypothalamic 
and brainstem pathways involved in nausea in response to anorectic gut hormones have 
still not been confirmed in humans.  
Previous studies in humans have shown that GLP-1/PYY co-administration345,448 and 
OXM/PYY co-administration479 reduce food intake additively. However, following co-
infusion of anorectic doses of OXM/PYY, one-third of participants experienced nausea 
despite the low doses used 479. In contrast, no nausea was reported following GLP-1/PYY 
co-infusion345. In addition, the duration of peptide infusion appears to have a significant 
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effect on the incidence of nausea. Nausea has been reported following 110 minutes iv 
OXM infusion in healthy volunteers 479. In contrast, OXM infusion at the same dose for 90 
minutes demonstrates no side effects222. Similarly, reported nausea following iv PYY(3-36) 
infusion in healthy human participants, increases with the duration of infusion480. There 
is currently no data investigating the duration of GLP-1 or glucagon infusion and the 
incidence of nausea. A previous study administered iv glucagon at 3ng/kg/min which 
was shown to reduce food intake with no reported nausea compared to saline 
controls180. Although plasma glucagon levels were not measured, previous studies have 
shown that the same dose of glucagon administered iv  increases plasma glucagon from 
30 to 75-150 pmol/l481-483. Iv administration of GLP-1 at 0.83 pmol/kg/min reduced 
food intake by 12% when infused over 2 hours with peak levels reaching 60-90 
pmol/l157. Although GLP-1 infusion reduced satiety and feelings of hunger, nausea was 
not specifically measured. In a separate study, 0.4 pmol/kg/min GLP-1 similarly reduced 
food intake compared to vehicle (although this did not reach significance) and 
circulating GLP-1 levels rose to 61.5 pmol/l345 following 90 minutes infusion. 
Throughout the study, there were no reported symptoms of nausea345.  
Data from my earlier work in chapter 4 shows increased EE following glucagon and 
glucagon/GLP-1 co-administration during a 45 minute infusion. However, subjective 
feelings of nausea and satiety were not measured. Therefore, in the current study the 
protocol was adjusted to compare low doses of glucagon and GLP-1 in combination over 
a longer duration, to investigate whether these beneficial effects on energy homeostasis 
are sustained with minimal nausea. In addition to food intake, the effects of low dose 
infusion of glucagon and GLP-1 on glucose homeostasis and EE were investigated. 
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5.2 Hypothesis and aims 
  
5.2.1 Hypothesis 
 
I hypothesised that low doses of glucagon and GLP-1 in combination have an additive 
anorectic effect and increase REE without causing nausea. I hypothesised that co-
administration of glucagon and GLP-1 at these doses ameliorates the rise in glucose 
levels in response to glucagon alone. 
 
 
5.2.2 Aim 
 
My aim was to investigate the effect on food intake, REE and glucose homeostasis 
following co-administration of glucagon and GLP-1 in non-diabetic, overweight human 
volunteers. I chose sub-anorectic doses of glucagon and GLP-1 to aim to minimise 
nausea and vomiting. 
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5.3 Materials and Methods 
5.3.1 Peptides 
 
Glucagon and GLP-1 were obtained as outlined in section 4.3.1.1. 
 
5.3.2 Subjects 
 
Sixteen non-diabetic, overweight volunteers were recruited for the study. Three were 
excluded due to abnormal eating behaviour at the first acclimatisation visit. The 
remaining thirteen completed the study. Four women and nine men, of mean age 31.6 
+/- 2.0  years (range: 21-41 years) and mean BMI 27.3 +/- 0.7 kg/m2 (range 25-33.3 
kg/m2), were recruited by advertisement. Inclusion criteria were: age 18 years or over; 
stable body weight for preceding three months and BMI 25-40 kg/m2.  Exclusion criteria 
were: substance abuse, current smoker, significant past or current history of physical or 
psychiatric illness, regular medication other than contraceptives and pregnancy or 
breastfeeding. All subjects were screened and determined to be healthy by medical 
history, physical examination, haematological and biochemical testing and 12-lead 
electrocardiogram. Potential subjects were screened to exclude those with abnormal 
eating habits, as assessed by the SCOFF questionnaire484 and those with a high level of 
restrained eating as assessed by the Dutch Eating Behaviour Questionnaire485. All female 
participants were premenopausal and had regular menstrual cycles. Women of child-
bearing age were advised to avoid pregnancy during the study and underwent urine 
tests to exclude pregnancy prior to each infusion.  
 
The study was approved by the West London Research Ethics Committee (reference no.: 
10/H0707/80). All subjects gave written informed consent and the study was carried 
out according to the principles of the Declaration of Helsinki. 
 
5.3.3 Protocol 
 
The study was designed as a randomised, double-blinded, placebo-controlled crossover 
study comparing four different pairs of infusion as shown in table 5.1.  
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A B 
Vehicle Vehicle 
GLP-1 (0.4 pmol/kg/min) Vehicle 
Glucagon (10 ng/kg/min) Vehicle 
GLP-1 (0.4 pmol/kg/min) Glucagon (10 ng/kg/min) 
 
Table 5.1. Randomised, double-blinded peptide infusion administration. 
Volunteers received two simultaneous infusions in order to compare the effects of GLP-
1 and glucagon alone and in combination on food intake, EE and glucose homeostasis.  
 
In my previous study investigating the effects of glucagon and GLP-1 on REE in man 
(chapter 4), the dose of GLP-1 used was 0.8 pmol/kg/min. In the current study, I chose 
to investigate lower doses as the duration of infusion was almost three times longer and 
my aim was to achieve positive effects on energy balance but with minimal nausea. 
Doses were selected based on published work investigating the effects of glucagon and 
GLP-1 on food intake in humans156,180,447,448. During the dose-finding study, low doses of 
glucagon and GLP-1 were administered alone and in combination. The initial protocol 
for the dose finding study is shown in figure 5.1. A peptide infusion was commenced at 
t=0 during which a range of glucagon (1.5-100 ng/kg/min) and GLP-1 (0.4-0.8 
pmol/kg/min) doses were administered alone and in combination. A meal was served at 
90 minutes. Blood samples and visual analogue scale (VAS) scores (appendix C) were 
taken at the time points indicated.  
 
 
 
 
Figure 5.1 Protocol of dose finding study. Volunteers were cannulated and an infusion of 
vehicle/vehicle, glucagon/vehicle, GLP-1/vehicle or GLP-1/glucagon infused for 120 minutes. A 
meal was served at 90 minutes and blood samples and visual analogue scale (VAS) scores taken 
as outlined.  
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Following the dose finding study, the protocol was amended to include indirect 
calorimetry and alteration of sampling time points as illustrated in figure 5.2. Blood 
samples were collected at t=-60 and -30 to ascertain fasting blood levels of glucagon, 
GLP-1, insulin and glucose prior to the start of infusion and indirect calorimetry. 
Therefore, volunteers received iv infusions of placebo (gelofusine), glucagon (10 
ng/kg/min, Novo Nordisk, Crawley, UK), GLP-1(7-36) amide (0.4 pmol/kg/min, Clinalfa 
Basic, Bachem, Switzerland) or combined glucagon and GLP-1(7-36) amide at the above 
mentioned doses. Volunteers attended for five consecutive visits spaced at least three 
days apart. The initial visit was an unblinded ‘dummy’ visit where gelofusine (Braun, 
Crawley, UK) was infused to acclimatise volunteers to study procedures. Since the 
primary outcome was food intake, subjects were asked to fast overnight from 2200h 
onwards. 
 
Upon arrival, volunteers were asked to empty their bladder and then urine was 
collected at the end of each study visit to provide an estimate of urinary nitrogen 
excretion. Peripheral venous cannulae were inserted in both forearms, one for infusions 
and one for blood sampling. A three-way tap (BD Connecta Plus Stopcock, Becton 
Dickinson & Company, USA) was attached to the infusion cannula, to allow connection of 
two separate infusion lines.  
 
 
 
 
Figure 5.2 Protocol of study. Following acclimatisation, baseline indirect calorimetry readings 
were taken 30 minutes prior to the start of the infusion. An infusion of vehicle/vehicle, glucagon 
(10 ng/kg/min)/vehicle, GLP-1 (0.4 pmol/kg/min)/vehicle or glucagon (10 ng/kg/min)/GLP-1 
(0.4 pmol/kg/min) was commenced at t=0 and continued for 120 minutes. Further calorimetry 
readings were taken between 40 and 70 minutes after the start of the infusion. A test meal was 
given at 90 minutes and the infusion stopped following this. Blood samples were taken at the 
time points indicated. 
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At -30 minutes (0900h), subjects were placed under the indirect calorimetry canopy 
(Gas Exchange Monitor, GEM Nutrition, Daresbury, UK) for 30 minutes to assess 
baseline REE. Calibration and setting up of the calorimeter is described in section 
4.3.1.3. The iv infusion was started at t=0 (1100h) and lasted for 120 minutes. The 
preparation of peptide infusions and the ramping protocol was identical to that 
described in section 4.3.1.3. Indirect calorimetry was repeated from 40 to 70 minutes to 
assess REE during the infusion. Blood samples were taken at -60, -30, 0, 40, 70, 90, 120, 
150 and 180 minutes for plasma glucose, glucagon, GLP-1 and serum insulin as 
described in section 4.3.1.3. Pulse and blood pressure were taken at each time point and 
volunteers asked to complete a VAS sheet (appendix C). An ad libitum meal, provided to 
excess, was served at 90 minutes (1130h) and volunteers allowed 20 minutes to eat 
until they felt comfortably full. Pre-prepared and standardised ready meals 
(Sainsbury’s) of known macronutrient and calorific content were used (chicken tikka 
masala (178 kcal/100g), macaroni cheese (189 kcal/100g), tomato and mozzarella 
pasta bake (127 kcal/100g), spaghetti bolognaise (188 kcal/100g)). Meals were 
weighed immediately before and after eating. Calorie intake was calculated according to 
weight of food consumed. The infusion was discontinued at 120 minutes (1200h). The 
duration of infusion in the current study was prolonged compared to that used in 
chapter 4, to investigate whether any beneficial effects on energy homeostasis and 
glucose control is sustained in the absence of nausea. Blood sampling and VAS 
measurements continued at 30 minute intervals until 180 minutes (1300h). Volunteers 
were then allowed to go home.    
 
 
5.3.4 Plasma hormone assays 
 
Glucagon and GLP-1 were analysed using in-house RIAs as described in section 4.3.1.4. 
Plasma glucose and serum insulin samples were analysed in the Department of 
Chemical Pathology, Imperial College Healthcare National Health Service Trust.  
 
 
5.3.5 Statistical analysis 
 
Food intake, change from baseline in REE and substrate oxidation rates, pulse and blood 
pressure and palatability VAS score, were analysed using one way ANOVA with Tukey 
multiple comparison post test. Two-way repeated measures ANOVA with Bonferroni 
post test was used to compare differences in glucose, insulin, pulse, blood pressure and 
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VAS scores at each time point.  Results are presented as mean ± SEM and statistical 
significance defined as p<0.05.  
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5.4 Results 
 
5.4.1 Dose finding study investigating the acute effects of co-administration 
of low dose glucagon and GLP-1 on energy balance and nausea in humans. 
 
5.4.1.1 Investigation of the acute affects of low dose glucagon and GLP-1 co-
administration on food intake. 
 
A dose finding study was undertaken to determine the lowest effective dose of glucagon 
and GLP-1 in reducing food intake compared to vehicle. The lowest effective anorectic 
dose of GLP-1 and glucagon alone was 0.8 pmol/kg/min and 15 ng/kg/min respectively 
(Fig. 5.3).  
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Figure 5.3. Percentage reduction in food intake compared to vehicle following the 
administration of glucagon and GLP-1 alone and in combination. Volunteers received an 
infusion of vehicle/vehicle, glucagon/vehicle, GLP-1/vehicle or GLP-1/glucagon for 120 minutes. 
A meal was served at 90 minutes and the percentage reduction in food intake compared to the 
vehicle visit calculated. The number of volunteers receiving each dose is shown in brackets. Data 
were analysed using one-way ANOVA with Tukey post test. Abbreviations: Glucagon-like 
peptide-1 (GLP-1), glucagon (GCG). 
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5.4.1.2. Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on the incidence of nausea. 
 
 
VAS scores were measured to assess the incidence of nausea. There was a dose-
dependent increase in the incidence of nausea and one person vomited following 
glucagon administration (mean VAS nausea score at t=120: 0.9 ± 0.5 [vehicle] vs. 41.7 ± 
21.1 mm [glucagon 50 ng/kg/min], p<0.01 vs. vehicle, n=3-7, fig. 5.4). Similarly, a dose-
dependent increase in nausea was shown in response to GLP-1 0.4 pmol/kg/min and 
escalating doses of glucagon (mean VAS nausea score at t=150: 0.6 ± 0.3 [vehicle] vs. 
26.8 ± 14.0 mm [GLP-1 0.4 pmol/kg/min + glucagon 20 ng/kg/min], p<0.001 vs. vehicle, 
n=5-7, fig. 5.4). 
 
In contrast, there was no significant increase in VAS nausea score in response to GLP-1 
administration at 0.4 or 0.8 pmol/kg/min compared to vehicle. However, there was a 
trend towards an increase in VAS nausea score following 0.8 pmol/kg/min GLP-1 
compared to 0.4 pmol/kg/min (mean VAS nausea score at t=120: 0.3 ± 0.3 [GLP-1 0.4 
pmol/kg/min] vs. 11.0 ± 10.5 mm [GLP-1 0.8 pmol/kg/min], p=ns, n=3-4, fig. 5.4).  
 
Although 0.8 pmol/kg/min GLP-1 was more effective at reducing food intake, the aim of 
this study was to investigate the effects of glucagon and GLP-1 co-administration on 
energy homeostasis without causing nausea. Since there was a trend for increased 
nausea following GLP-1 0.8 pmol/kg/min, doses of 0.4 pmol/kg/min GLP-1 and 
glucagon 10 ng/kg/min doses were chosen for further investigation with the aim to 
avoid nausea whilst demonstrating an additive anorectic affect.  
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Figure 5.4. Incidence of nausea and vomiting following the administration of glucagon and 
GLP-1 alone and in combination. Volunteers received an infusion of vehicle/vehicle, 
glucagon/vehicle, GLP-1/vehicle or GLP-1/glucagon for 120 minutes. A meal was served at 90 
minutes. The incidence of nausea and vomiting was documented throughout the infusion at 
various doses of glucagon and GLP-1, alone and in combination. Data were analysed using two-
way ANOVA with Bonferroni post test. ** p<0.01, *** p<0.001 vs. vehicle. Abbreviations: Veh 
(vehicle), glucagon-like peptide-1 (GLP-1), glucagon (GCG). 
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5.4.2 Investigation of the acute effects of co-administration of low dose 
glucagon and GLP-1 on energy balance and nausea in humans. 
 
5.4.2.1 Investigation of plasma glucagon and GLP-1 concentrations achieved 
following co-administration of low dose glucagon and GLP-1. 
 
Mean baseline plasma concentration of GLP-1 in all volunteers prior to the start of the 
infusion was 21.7 ± 1.6 pmol/l (range: 6.1 - 60.2 pmol/l). Infusion of GLP-1 at 0.4 
pmol/kg/min, increased circulating GLP-1 concentration to a peak of 117.2 ± 17.3 
pmol/l, 70 minutes after the infusion was started (Fig 5.5A). In the GLP-1/glucagon 
combination group, GLP-1 levels rose to 111.5 ± 12.1 pmol/l, 70 minutes after the 
infusion was started. In all four infusion arms, there was a small rise in circulating GLP-1 
levels following the meal. 
 
Mean baseline plasma concentration of glucagon in all volunteers, prior to the start of 
infusion was  16.0 ± 1.9 pmol/l (range 4.0-59.4 pmol/l). At forty minutes, glucagon 
levels rose to 169.1 ± 35.1 pmol/l following glucagon infusion, and 159.0 ± 18.0 pmol/l 
following glucagon and GLP-1 co-administration (Fig 5.5B). GLP-1 alone or vehicle 
infusion did not elevate circulating glucagon. In addition, there was no change in 
circulating glucagon concentration following the meal. After the infusions were 
discontinued at 120 minutes, circulating GLP-1 decreased to post-prandial vehicle levels 
although this took 60 minutes. In contrast, circulating glucagon returned to baseline 
within 30 minutes of stopping the glucagon infusion and 60 minutes after glucagon and 
GLP-1 co-administration. 
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Figure 5.5 Plasma GLP-1 (A) and glucagon (B) following peptide infusion. Volunteers 
received an infusion for 120 minutes (denoted by grey bar) of vehicle/vehicle, GLP-1 
(0.4pmol/kg/min) / vehicle, glucagon (10ng/kg/min) / vehicle or GLP-1 (0.4 pmol/kg/min) / 
glucagon (10ng/kg/min). n=13. 
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5.4.2.2 Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on food intake 
 
Glucagon and GLP-1 alone did not significantly alter food intake at the doses 
administered. In contrast, glucagon and GLP-1 co-administration significantly reduced 
food intake compared to vehicle (mean energy intake: 1086 ± 94.2 [vehicle] vs. 878.5 ± 
94.2 kcal/day [GLP-1/glucagon co-administration], p<0.05 vs. vehicle, fig. 5.6, n=13). 
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Figure 5.6. Energy intake following buffet meal in human subjects. Participants were given a 
meal of known quantity and calorie content during an infusion of vehicle/vehicle, GLP-1 
(0.4pmol/kg/min) / vehicle, glucagon (10ng/kg/min) / vehicle or GLP-1 (0.4 pmol/kg/min) / 
glucagon (10ng/kg/min). Data were analysed using one-way ANOVA with Tukey multiple 
comparison post test. * p<0.05 vs. vehicle, $ p<0.05 vs. glucagon. n=13.  
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5.4.2.3 Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on subjective nausea and satiety 
 
Following the meal (t=120), there was a significant increase from baseline in the VAS 
score related to nausea whilst receiving GLP-1/glucagon co-administration compared to 
vehicle (mean VAS score (change from baseline): 0.8 ± 0.8 [vehicle] vs. 9.7 ± 8.2 mm 
[GLP-1/glucagon co-administration], p<0.01 vs. vehicle, fig. 5.7B, n=13)   There were no 
significant differences in VAS scores between any volunteers in response to other 
questions asked (fig. 5.7). In response to the question ‘How tasty was the meal?’, GLP-
1/glucagon co-administration scored the lowest out of all infusion arms however again, 
this did not reach significance (mean VAS score: 82.3 ± 4.2 [vehicle] vs. 66.9 ± 8.0 mm 
[GLP-1/glucagon co-administration], n=13, fig. 5.7F). 
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Figure 5.7 Change from baseline in visual analogue scale (VAS) scores in human 
participants. VAS scores were measured at each time point in response to the following 
questions: (A) ‘How hungry do you feel right now?’, (B) ‘How sick do you feel right now?’, (C) 
‘How pleasant would it be to eat right now?’, (D) ‘How much do you think you could eat right 
now?’, (E) ‘How full do you feel right now?’ and (F) ‘How tasty was the meal?’. Volunteers 
received an infusion for 120 minutes (denoted by grey bar) of vehicle/vehicle, GLP-1 
(0.4pmol/kg/min)/vehicle, glucagon (10ng/kg/min)/vehicle or GLP-1 (0.4 
pmol/kg/min)/glucagon (10ng/kg/min). Data were analysed with two-way repeated measures 
ANOVA with Bonferroni post test (A-E) and one way ANOVA with Tukey post test (F). **p<0.01 
vs. vehicle.  n=13.  
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5.4.2.4 Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on energy expenditure 
 
An increase in REE was demonstrated following administration of glucagon although 
this failed to reach significance (mean change from baseline in REE: -8.6 ± 12.6 [vehicle] 
vs. 66.8 ± 29.2 kcal/day [glucagon], n=13, fig. 5.8A). Similarly, GLP-1/glucagon co-
administration increased EE but did not reach significance (mean change from baseline 
in REE: -8.6 ± 12.6 [vehicle] vs. 52.5 ± 27.1 kcal/day [GLP-1/glucagon co-adminstration], 
n=13, fig. 5.8A). 
 
Glucagon alone significantly increased carbohydrate oxidation (mean change in 
carbohydrate oxidation: -0.005 ± 0.012 [vehicle] vs. 0.052 ± 0.013 g/min [glucagon], 
p<0.01 vs. vehicle, n=13, fig. 5.8B). Co-administration of glucagon and GLP-1 increased 
carbohydrate oxidation compared to vehicle to a greater extent than glucagon alone 
(mean change in carbohydrate oxidation: : -0.005 ± 0.012 [vehicle] vs. 0.099 ± 0.012 
g/min [GLP-1/glucagon co-administration], p<0.001, n=13, fig. 5.8B). In contrast, 
glucagon alone significantly decreased fat oxidation (mean change in fat oxidation: 
0.001 ± 0.005 [vehicle] vs. -0.015 ± 0.005 g/min [glucagon], p<0.05 vs. vehicle, n=13, fig 
5.8C). Glucagon and GLP-1 co-administration caused a greater reduction in fat oxidation 
compared to vehicle than glucagon alone (mean change in fat oxidation: 0.001 ± 0.005 
[vehicle] vs. -0.035 ± 0.005 g/min [GLP-1/glucagon co-administration], p<0.001 vs. 
vehicle, n=13, fig. 5.8C). There were no significant differences in protein oxidation over 
the entire study compared to vehicle. Glucagon alone significantly increased protein 
oxidation compared to GLP-1 alone (mean protein oxidation: 0.06 ± 0.007 [glucagon] vs. 
0.044 ± 0.004 g/min [GLP-1], p<0.05 vs. GLP-1, n=13, fig. 5.8 D). 
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Figure 5.8 Change from baseline in resting energy expenditure (A), carbohydrate (B), fat 
(C) and protein (D) oxidation rates in human subjects. Indirect calorimetry was used to 
measure energy expenditure (A) before and at the end of an infusion of vehicle/vehicle, GLP-1 
(0.4pmol/kg/min) / vehicle, glucagon (10ng/kg/min) / vehicle or GLP-1 (0.4 pmol/kg/min) / 
glucagon (10ng/kg/min). In addition, substrate oxidation rates were calculated for carbohydrate 
(B), fat (C) and protein (D). Data were analysed using one way ANOVA with Tukey multiple 
comparison post test. * p<0.05, ** p<0.01, ***p<0.001 vs. vehicle; # p<0.05, ## p<0.01, 
###p<0.001 vs. GLP-1; $$ p<0.01 vs. glucagon. n=13. 
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5.4.2.5 Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on plasma insulin and glucose concentrations. 
 
Mean baseline glucose concentration in all volunteers was 4.9 ± 0.1 mmol/l (range: 2.9-
6.0 mmol/l) immediately prior to infusion. A significant rise in glucose was seen in 
response to glucagon administration, reaching a peak 40 minutes after the start of 
infusion (mean glucose: 4.6 ± 0.2 [vehicle] vs. 6.5 ± 0.3 mmol/l [glucagon], p<0.001 vs. 
vehicle, n=13, fig. 5.9A). Glucose returned to baseline 60 minutes after the infusion was 
terminated. The increase in glucose following glucagon administration was significantly 
attenuated by the co-administration of GLP-1/glucagon. Forty minutes after the infusion 
started, there was a trend towards an increase in glucose concentration following GLP-
1/glucagon co-administration (mean glucose: 4.6 ± 0.2 [vehicle] vs. 5.6 ± 0.4 mmol/l 
[GLP-1/glucagon co-administration], n=13, fig. 5.9A). At 70 minutes, glucose levels 
following GLP-1/glucagon co-administration were indistinguishable from those during 
the vehicle infusion. 
Following a meal at t=90 minutes, glucose concentration increased during vehicle, GLP-
1 and combined GLP-1/glucagon infusion. The glucose rise in response to the meal was 
lower in the GLP-1/glucagon co-administration arm compared to vehicle although this 
was not significant (120-180 minutes). Following the meal, glucose concentration did 
not fall during infusion of vehicle, GLP-1 or GLP-1/glucagon despite the infusion 
stopping at t=120 minutes. In contrast, during the glucagon infusion, glucose levels 
remained the same after the meal with a subsequent decline to baseline levels following 
discontinuation of the infusion (figure 5.9A). The differences in circulating glucose levels 
were also accompanied by changes in insulin secretion. All groups demonstrated a rise 
in insulin in response to the meal, with the highest insulin levels seen following 
glucagon infusion. 
Prior to the meal, GLP-1/glucagon co-administration significantly increased insulin 
compared to vehicle (mean insulin: 6.7 ± 1.5 [vehicle] vs. 51.6 ± 6.8 mU/l [GLP-
1/glucagon co-administration, p<0.01 vs. vehicle, n=13, fig. 5.9B). Glucagon also 
increased insulin release compared to vehicle however this did not reach significance. 
There was no change in insulin secretion during GLP-1 infusion (prior to the meal). 
Despite this, there appeared to be a reduction in glucose levels compared to vehicle 
although this was not significant (fig. 5.9A). 
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Figure 5.9 Glucose (A) and insulin (B) levels in human subjects during the study. 
Volunteers received an infusion for 120 minutes (denoted by grey bar) of vehicle/vehicle, GLP-1 
(0.4pmol/kg/min) / vehicle, glucagon (10ng/kg/min) / vehicle or GLP-1 (0.4 pmol/kg/min) / 
glucagon (10ng/kg/min). Glucose and insulin samples were collected at the time points indicated 
and a meal was served at 90 minutes. Data were analysed using two way ANOVA with Bonferroni 
multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs. vehicle; #p<0.05, ###p<0.001 vs. 
GLP-1; & p<0.05, && p<0.01 vs. GLP-1/glucagon. n=13.   
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5.4.2.6 Investigation of the acute effects of low dose glucagon and GLP-1 co-
administration on cardiovascular parameters 
 
There were no significant differences in pulse, systolic or diastolic pressure between the 
infusion arms (figure 5.10). A rise in pulse was seen in response to the meal at t=120 
minutes in all volunteers. Change between baseline and 90 minutes during infusion 
showed no significant changes in response to any of the infusion arms, however there 
was a trend for glucagon alone and in combination with GLP-1 to increase pulse rate and 
diastolic blood pressure (figure 5.10B and 5.10F). 
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Figure 5.10 Pulse (A+B), systolic (C+D) and diastolic blood pressure (E+F) in human 
subjects during the study. Volunteers received an infusion for 120 minutes (denoted by grey 
bar) of vehicle/vehicle, GLP-1(0.4pmol/kg/min)/vehicle, glucagon (10ng/kg/min)/vehicle or 
GLP-1 (0.4 pmol/kg/min)/glucagon (10ng/kg/min). Pulse and blood pressure was measured at 
the time points indicated and a meal was served at 90 minutes. Comparison is also made 
between change in pulse and blood pressure from baseline (t=0) and prior to the meal (t=90). 
Data were analysed using two way ANOVA with Bonferroni multiple comparison test (A,C+E) and 
one-way ANOVA with Tukey post test (B,D+F).  n=13.  Abbreviations: beats per minute (bpm), 
millimetres of mercury (mmHg). 
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5.5 Discussion 
This study demonstrates that sub-anorectic doses of GLP-1 and glucagon significantly 
reduce food intake when co-administered. This additive anorectic effect supports a role 
for glucagon in appetite control in humans. The first study to investigate the effects of iv 
glucagon infusion on food intake in humans was published by Geary et al in 1992180. 
Prior to this, glucagon had been administered im at 1-2mg doses prior to a test meal 
with reports of nausea186,187. Geary et al demonstrated that glucagon infusion 
(3ng/kg/min) for 10 minutes reduced food intake compared to saline infusion in 
healthy normal weight male volunteers. In the current study, the infusion lasted two 
hours and a dose of 10ng/kg/min was given. The discrepancy in effective doses in 
reducing food intake is likely to be due to the  different protocols followed and subjects 
recruited. In the current study, subjects were overweight (mean BMI 27.3) and fasted 
from 10pm the night before the study. In contrast, subjects studied by Geary et al were 
of normal weight (mean BMI 21.8) and had been given a standardised breakfast 
consisting of 300 kcal two and a half hours prior to the start of the study, followed by a 
small meal (190 kcal) five minutes prior to the start of the infusion. Furthermore, the 
infusion only lasted 10 minutes and participants were given the test meal during this 
time period. Therefore in addition to the length of infusion and subjects studied, the 
protocols differ in that the studies are comparing fasted versus fed states.  
The current study demonstrates for the first time that glucagon and GLP-1 co-
administration reduces food intake in an additive manner in humans. It has been 
suggested that peptides from discrete families, which act through entirely independent 
receptor pathways, are more likely to inhibit feeding additively486. Co-administration of 
glucagon and other anorectic gut hormones such as PYY or PP has not been studied but 
would test this hypothesis. GLP-1/PYY and OXM/PYY co-administration at sub-anorectic 
doses have additive effects on food intake reduction345,448,479. In contrast, PYY and PP co-
administration do not reduce food intake compared to controls in rodents or humans486. 
Although PYY and PP reduce food intake via different receptors (Y2 and Y4 receptors 
respectively), both hormones can also activate the Y5 receptor leading to an increase in 
food intake 239,487.  
Similarly, glucagon and CCK alone decrease food intake although co-administration has 
no effect on food intake compared to controls180. The reason for this is unknown. CCK-
1Rs are found on pancreatic α cells488,489. However, in vivo studies have found no effect 
of CCK-8 infusion on plasma glucagon levels in humans490 or sheep491. Similarly, infusion 
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of a CCK antagonist, does not alter plasma glucagon levels in humans492. It is possible 
that CCK and glucagon interact elsewhere in the body to prevent a reduction in food 
intake when administered in combination. Vagotomy studies suggest that both 
hormones act via the vagus nerve to reduce food intake87,351. Therefore antagonism at 
the level of the brainstem or higher centres within the brain could account for the 
results.  
The aim of the current study was to investigate whether beneficial effects of glucagon 
and GLP-1 on energy homeostasis and glucose control was sustained using lower doses 
over a longer infusion period, without causing nausea. Post-prandial nausea score was 
significantly increased following the co-administration of GLP-1 and glucagon. GLP-1R 
agonists used in the treatment of type 2 diabetes are known to cause nausea and 
vomiting especially upon initiation of treatment, however the incidence of such side 
effects generally diminish over time464. Continued glucagon administration in humans 
has not been studied and hence, the effect on nausea is unknown. Most clinical 
indications for glucagon use suggest im injection for short-term use only and include 
reversal of hypoglycaemia493, relaxation of smooth muscle in the gut for radiological 
studies465, β blocker overdose494 and cardiac failure495. Although many of these studies 
describe nausea as a side effect, the effect appears to be transient which is in keeping 
with the rapid glucagon clearance following im administration. 
The mechanism through which nausea and vomiting is largely unknown. Evolutionarily, 
these symptoms served as a defense against the consumption of harmful substances496. 
Activation of the autonomic system results in sweating, salivation and vasoconstriction 
which frequently accompanies symptoms of nausea and vomiting. Nausea can be 
difficult to study in animal models such as rodents that lack an emetic response. 
Although CTA studies have been used as a marker of nausea, it has been argued that it 
does not reliably assess nausea since some drugs of addiction also produce the same 
response497. In addition, CTA studies rely on complex CNS pathways involved with 
learning and memory which can confound results related to nausea and appetite. 
Although a final common neural pathway or ‘vomiting centre’ has not been defined, 
animal studies (including those in animals with a vomiting response) have suggested 
some key areas within the brain important in the emetic response. Gut vagal afferents 
converge on the NTS in the brainstem and it is possible that toxic substances in the 
bloodstream act on the AP, which lacks a complete BBB496. In addition, afferent inputs 
from the cerebral cortex and vestibular system converge in the NTS supporting the 
concept that the NTS is a key integrator for nausea signals496. Data from my rodent 
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studies in chapter 2, showed that glucagon and GLP-1 co-administration increased c-fos 
expression in the cNTS. This would support the hypothesis that co-administration of 
both hormones reduces food intake but at the expense of  nausea. It would be 
interesting to investigate whether co-administration of glucagon and GLP-1 modulates 
fMRI signal in the NTS of humans. Furthermore, there is a lack of data concerning why 
some individuals are more prone to nausea than others. Factors such as adiposity, renal 
and hepatic clearance, hormonal interactions including higher oestrogen levels in 
women and sex hormone binding globulin, and perhaps genetic predisposition may all 
influence the pharmacokinetics of a drug and hence the degree of nausea498. 
In the current study, administration of glucagon alone and in combination with GLP-1 
increased REE although this did not reach statistical significance. Interestingly there was 
a significant rise in carbohydrate oxidation and reduction in fat oxidation following 
glucagon alone and in combination with GLP-1 which supports findings from my 
previous study investigating EE in man (chapter 4). The results also suggest that 
substrate oxidation is not the sole determinant of increased EE in response to glucagon. 
In this study, there was a trend towards increased pulse and systolic blood pressure in 
response to glucagon alone and in combination with GLP-1, although this did not reach 
statistical significance.  
The current study also shows that glucagon and GLP-1 co-administration has a greater 
insulinotropic effect than either hormone alone. Furthermore, although an initial rise in 
glucose was seen in the co-administration arm, this returned to control values within 70 
minutes. Following a meal, there was a smaller rise in glucose following GLP-1/glucagon 
co-administration compared to other infusion arms and may reflect the reduced food 
intake observed following GLP-1/glucagon co-administration. In addition, both GLP-1 
and glucagon delay gastric emptying164,398 which would delay a rise in glucose seen and 
may explain the results. Paracetamol absorption studies or other radiolabelled tracer 
studies could be performed to investigate this.  
Interestingly, administration of GLP-1 did not increase insulin levels yet there was a 
trend for reduced glucose levels. There is increasing evidence that GLP-1 and GLP-1R 
agonists reduce hyperglycaemia independently of insulin. Incubation of human 
hepatocytes with exendin-4 activates cAMP499 and glycogen synthase activity 500. In 
humans, GLP-1 (9-36) amide infusion in fasting and glucose clamp studies decreases 
hepatic glucose output by up to 50% in obese and insulin resistant subjects 501. Within 
the liver, glucose output can also decrease in response to increased glucose utilisation. 
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Glucokinase is an important enzyme which converts glucose into glucose-6-phosphate 
and glucokinase activators are being developed as an alternative treatment in type 2 
diabetes502. Recently, a study has shown that acute and chronic administration of 
exendin-4 dose dependently increases hepatic glucokinase activity in db/db mice 503. 
This effect is abolished by the prior administration of exendin-4 (9-39) (a GLP-1R 
antagonist)503. Furthermore, chronic treatment of exendin-4 in streptozotocin-treated 
mice, a model of diabetes, restores hepatic glycogen with no significant changes in 
serum insulin levels503. Similarly, GLP-1R knockout mice demonstrate impaired ability 
to suppress endogenous glucose production and hepatic glycogen accumulation during 
insulin clamps504. This implies that the GLP-1R is required to control hepatic glucose 
output despite the presence of insulin. Therefore, GLP-1 may improve glycaemic control 
through at least two mechanisms, firstly stimulation of insulin secretion by pancreatic β 
cells and secondly, a direct effect to reduce hepatic glucose output. Results from the 
current study support a role for GLP-1 in reducing hepatic glucose output, since there 
was a trend for reduced glucose concentration following GLP-1 infusion, yet insulin 
concentration remained low. 
In conclusion, this study shows that at low doses of GLP-1 and glucagon, co-
administration reduces food intake additively in non-diabetic, overweight human 
volunteers. However, the increase in nausea is likely to limit the dose at which 
glucagon/GLP-1 co-agonists can be administered. At the doses given, there is a non-
significant increase in REE and no significant deterioration in glucose control over the 
infusion period. These findings suggest that drug therapy aimed at glucagon and GLP-1 
receptor co-agonism could potentially result in weight loss through the dual mechanism 
of reduced food intake and increased EE, without detrimental effects on glucose 
homeostasis. Longer term studies however are required to investigate this and whether 
symptoms of nausea diminish with the duration of administration. 
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6.1 General discussion 
The worldwide incidence of obesity is increasing 1,505. 65% of men and 58% of women in 
England are overweight or obese506. Between 2001 and 2011, the number of hospital 
admissions with a primary diagnosis of obesity increased eleven-fold506. Furthermore, 
obesity is increasing amongst children with 10% of 4-5 year-olds and 20% of 10-11 
year-olds classified as obese506. Although frequently regarded as a cosmetic problem, 
obesity increases the risk of type 2 diabetes, heart attacks, strokes, cancer and 
hypertension507. In addition, obesity reduces life expectancy by approximately nine 
years and accounts for almost six hundred deaths per week in England alone5. 
Therefore, obesity has significant health and socioeconomic implications.  
 
There are currently no effective drug treatments for obesity that result in sustained 
weight loss. Gastric bypass surgery remains the most successful approach in targeting 
obesity508. The rapid weight loss achieved is associated with a rise in gut hormones, 
including PYY509 and GLP-1509. However certain criteria must be fulfilled before 
eligibility for surgery is considered. These criteria include BMI > 40 kg/m2 or BMI 35-40 
kg/m2 and other co-morbidities, such as diabetes, that would be improved by weight 
loss 510. Many patients do not meet these criteria or are unsuitable for surgery which 
itself is associated with significant complications511. Therefore there is a clinical need for 
the development of effective drug treatments to combat obesity. Orlistat® is currently 
the only medication available for the treatment of obesity in the UK. Weight loss is 
achieved primarily through reduced intestinal fat absorption with significant 
gastrointestinal side-effects as a result 512. Weight loss following orlistat treatment is 
disappointing, ranging from no significant benefit513 to 3-4% over two years514. 
Recently, rimonobant and sibutramine were withdrawn by the Medicines and 
Healthcare product Regulatory Agency (MHRA) due to psychiatric and cardiovascular 
side-effects respectively 510,515. A second class of drugs, the GLP-1 analogues are licensed 
for the treatment of type 2 diabetes, and result in approximately 3% weight loss at 6 
months516,517. Recently the Food and Drug Administration (FDA) approved two new anti-
obesity agents, Qysmia®, (combination of phentermine and topiramate) and Belviq® 
(lorcaserin hydrochloride), a serotonin receptor agonist. Ongoing trials are also 
underway for several other drugs including Contrave® (bupropion and naltrexone 
combination)518, Tesofensine®519, a noradrenaline, dopamine and serotonin reuptake 
inhibitor and a combination of bupropion and zonisamine (an anti-epileptic drug)520. 
Several gut hormones are also undergoing clinical trials as potential anti-obesity agents 
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and include ghrelin antagonists521 and analogues of  PYY522, PP523 and OXM524. In 
addition, glucagon/GLP-1 receptor co-agonists are currently in phase I clinical 
development 525,526. 
 
To date, all treatments for obesity have focused on reducing food intake or fat 
absorption. However, it has recently become evident that increasing EE may provide an 
alternative approach to weight loss228,229. OXM, a GCGR and GLP-1R agonist, exemplifies 
this dual approach to weight loss. Animal and human studies have demonstrated the 
efficacy of OXM in modulating energy homeostasis and decreasing body weight219,220,222-
225,227,446,527,528 and phase I trials in man are ongoing524. Although OXM binds to the GLP-
1R and GCGR, it does so with lower affinity than the cognate hormones. Furthermore, 
the mechanisms through which OXM exerts its beneficial effects on body weight are not 
fully understood. Therefore, this thesis investigates glucagon and GLP-1 co-
administration and energy homeostasis, focusing on food intake and EE as a dual 
approach to weight loss.  
 
Glucagon and GLP-1 co-administration and the effect on food intake 
 
In chapter 2, I demonstrated that glucagon and GLP-1 reduced food intake in rodents  
and activated similar areas within the brainstem and amygdala.  The anorectic effect 
following glucagon/GLP-1 co-administration was subsequently confirmed for the first 
time in humans as described in chapter 5. Although central mechanisms underlying the 
anorectic effect of glucagon are unknown, diminished anorectic response to glucagon in 
vagotomised animals and those with AP and NTS lesions353  suggest that a vagal 
mediated pathway via the brainstem may be the main site of action. Similarly, vagotomy 
attenuates the anorectic effect of GLP-1 and hypothalamic c-fos expression in rats87. The 
effects of vagotomy on c-fos expression following peripheral glucagon administration 
are unknown. Such a future study may identify vagal-dependent pathways involved in 
the anorectic action of glucagon. 
 
The anorectic effect following GLP-1 administration is also thought to be mediated via 
the circulation360,529. Previous work using radiolabelled GLP-1 has shown that GLP-1 
crosses the BBB through simple diffusion360.  Although GCGRs are expressed in the 
hypothalamus and brainstem, their expression in specific nuclei within these areas is 
unknown. Central administration of glucagon reduces food intake, suggesting a potential 
hypothalamic site of action 361-363. Glucagon may reduce food intake directly via the 
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circulation in a similar way to GLP-1. Using a radiolabelled technique as described 
above, together with localisation studies to identify neuronal populations activated, may 
improve our understanding of the mechanism underlying the anorectic effect of 
glucagon. 
 
It was previously thought that glucagon reduces food intake indirectly through 
modulation of glucose354-356, insulin190,359, ACTH377 or ghrelin454,455. However, neither 
hyperglycaemia or infusions of insulin or insulin antibodies affect the anorectic 
response to glucagon in animals 356,357,359. A recent study in chicks suggests that central 
administration of glucagon suppresses food intake via a CRH-induced anorexigenic 
pathway361. Although glucagon increases ACTH secretion from the anterior pituitary, the 
c-fos studies presented in this thesis (chapter 2) do not support a role for glucagon and 
hypothalamic neuronal activation. In addition, iv glucagon administration did not 
increase circulating cortisol in man (chapter 4). In contrast, glucagon and GLP-1 co-
administration significantly reduced circulating ghrelin in man (chapter 4). Similar 
findings are seen following iv and ICV OXM222,530, although the effect of ICV OXM is 
attenuated by the prior administration of the GLP-1R antagonist exendin-4(9-39) 530. This 
suggests that the effect on ghrelin levels is mediated via the GLP-1R. In contrast, 
previous studies have shown that glucagon alone decreases ghrelin although this effect 
may be insulin-dependent 454,455.  
  
An alternative explanation may be that glucagon reduces food intake through 
stimulation of the SNS and release of catecholamines. Administration of glucagon 
increases SNS activation379,407 and circulating catecholamines 456,457. Future work in 
animals to test this hypothesis could include attenuation of catecholamine output by 
adrenal medullectomy, adrenal sympathomimectomy or administration of selective β-
adrenoceptor antagonists, prior to studying the effects of glucagon  administration on 
food intake.  
  
In this thesis, I demonstrate that glucagon and GLP-1 co-administration reduces food 
intake additively in rodents (chapter 2) and humans (chapter 5). In man, this effect was 
associated with an increase in nausea score at the doses administered (chapter 5). 
Although the mechanism through which glucagon or GLP-1 induce nausea is unknown, 
direct activation of brainstem neurones eliciting an emetic response, or reduced gastric 
emptying, are likely to be involved. Both glucagon and GLP-1 reduce gastric 
emptying164,398, an effect which may be additive following co-administration of glucagon 
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and GLP-1. This could be further studied in humans using paracetamol absorption 
studies531, 13-C breath test531 or radiolabelled food480 and assessing gut transit time.  
 
My earlier rodent studies (chapter 2) show that glucagon and GLP-1 increase c-fos 
expression in similar areas within the brain, notably the AP, cNTS, PBN and CeA. This 
suggests that both hormones may act through a common pathway to reduce food intake. 
Furthermore, these areas are also implicated in the emetic response496 and gastric 
emptying496. GLP-1 neurones in the brainstem innervate vagal efferent and 
catecholamine neurones associated with cardiovascular control532. These findings 
support a role for GLP-1 and modulation of gastric emptying and cardiovascular 
function. Immunohistochemistry or another method of characterisation could 
determine whether glucagon and GLP-1 induce similar patterns of neuronal activation. 
If both hormones reduce food intake via the same mechanism, this may limit the use of 
glucagon/GLP-1 co-agonists in the treatment of obesity, particularly since side-effects 
may also be additive.  
  
Glucagon and GLP-1 co-administration and the effect on energy expenditure (EE) 
 
Administration of glucagon alone, and in combination with GLP-1, was shown for the 
first time to increase REE in humans (chapter 4). Although the mechanism through 
which glucagon increases REE is unknown, activation of the SNS and BAT thermogenesis 
may be involved acutely 209,214-216,218,407. The increase in REE in response to glucagon was 
associated with a trend towards a rise in pulse and systolic blood pressure, suggesting 
activation of the SNS. ICV administration of glucagon in wild-type mice increases BAT 
thermogenesis, sympathetic nerve activity and increased expression of PGC1-α and 
UCP-1407. Recently, several imaging modalities including FDG-PET533, MRI534,535 and 
MIBG536,537 have demonstrated BAT activation and the ability to quantify BAT mass in 
humans. Furthermore, thermal imaging has been used as a non-invasive technique for 
assessing BAT activation in children538. These imaging techniques may offer an exciting 
opportunity to investigate the role of peripherally administered glucagon and GLP-1 and 
BAT activation in humans.  
 
Until recently, the investigation of glucagon and EE has focused on its acute effects. The 
chronic effects of glucagon administration and EE are largely unknown. Long-term 
glucagon administration is limited due to enzymatic breakdown within the circulation, 
resulting in a short half-life. Recent development of a GCGR agonist was shown to 
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increase EE in wild-type mice following three days of s/c administration463. These 
effects were abolished in FGF-21 knockout mice463 suggesting a role for glucagon in the 
modulation of FGF-21 expression and EE. However, the rise in EE was accompanied by 
increased food intake and subsequently no change in body weight. Therefore, any future 
GCGR-based treatment for obesity will need to demonstrate increased EE in addition to 
reduced food intake to achieve successful weight loss. 
 
Previous groups have designed hybrid glucagon/GLP-1 co-agonists that bind and 
activate the GCGR and GLP-1R228,229. Chronic administration of these co-agonists over 
14-28 days in mice increases weight loss through a simultaneous reduction in food 
intake and increased EE. In chapter 3, I investigated glucagon and GLP-1 analogues 
designed by the Department of Investigative Medicine, Imperial College, London. 
Analogues were selected based on their ability to bind and activate the GCGR and GLP-
1R in vitro, to reduce food intake in rodents and the circulating concentrations achieved 
following administration. Chronic administration of these analogues showed greater 
weight loss following glucagon and GLP-1 analogue co-administration compared to 
either hormone alone. This was most likely due to increased EE through GCGR activation 
since cumulative food intake was the same as controls. rtPCR was used to quantify 
mRNA expression of various gene markers known to be involved in the regulation of EE. 
In contrast to a previous study 229, chronic glucagon analogue administration in DIO 
mice did not  increase UCP-1 mRNA expression in BAT or WAT. Furthermore, there was 
no significant decrease in body weight or food intake in response to chronic glucagon 
analogue administration alone. These findings suggest that at the dose administered, 
long-term glucagon analogue administration has no effect on EE. In contrast, glucagon 
and GLP-1 analogue co-administration significantly reduced body weight and circulating 
leptin with no effect on cumulative food intake. This suggests that chronic 
glucagon/GLP-1 analogue co-administration has a synergistic effect on body weight, 
possibly through increased EE. Unexpectedly, glucagon/GLP-1 analogue co-
administration significantly decreased BAT weight. Although the reason for this remains 
unknown, GCGR agonism may initially increase BAT thermogenesis and BAT mass, but 
prolonged administration may result in BAT atrophy. BAT atrophy has been associated 
with hyperinsulinaemia539, leptin administration540, starvation541 and reduced 
sympathetic activity to BAT542,543. My results suggest an alternative mechanism for BAT 
atrophy in response to glucagon/GLP-1 analogue co-administration, since insulin and 
leptin levels were low, and β-hydroxybutyrate levels did not support evidence of 
starvation.  
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Alternatively, glucagon may increase EE through futile substrate cycling whereby 
energy-consuming cyclical metabolic pathways are stimulated212. In chapter 4, acute 
GLP-1/glucagon co-administration in man increased circulating insulin and 
carbohydrate oxidation. In DIO mice, chronic GLP-1/glucagon analogue administration 
improved glucose control compared to vehicle, with lower circulating levels of glucose 
and insulin, both fasting and in response to ipGTT. These findings may suggest increased 
glucose utilisation in thermogenic tissues. This could be investigated further by 
measuring glucose uptake by peripheral tissues 544-546 and through the use of imaging 
modalities such as FDG-PET 547. The role of glucagon and skeletal muscle-induced 
thermogenesis is unknown. Skeletal muscle accounts for approximately 20-30% of total 
resting oxygen uptake334 and up to 50% of adrenaline-induced thermogenesis in 
humans has been demonstrated to originate from skeletal muscle335. The underlying 
mechanism is unknown however UCP-3 has been implicated in skeletal muscle 
thermogenesis341. In addition, a recently discovered protein, irisin, is secreted by 
skeletal muscle and stimulates UCP-1 expression and BAT-type differentiation in 
WAT342. Furthermore, increased levels of irisin are associated with a rise in EE and 
weight loss342. A role for glucagon and skeletal muscle-induced thermogenesis could be 
investigated using ex vivo muscle samples following chronic administration of glucagon 
and quantifying mRNA expression of UCP-3 and plasma irisin. 
 
Finally, REE was measured in response to glucagon and GLP-1 co-administration in man 
using indirect calorimetry (chapter 4). OXM increases activity-related EE in humans223. 
Although it is unknown whether this effect occurs due to GCGR or GLP-1R activation, 
increased locomotor activity is observed in mice in response to a long-acting glucagon 
agonist463. Although the focus in this thesis was REE, the effect of glucagon/GLP-1 co-
administration on activity-related EE could be measured using a portable monitoring 
device 548. Similarly, chronic administration of glucagon/GLP-1 analogues in DIO mice 
suggested weight loss secondary to increased EE. This could be confirmed using a 
Comprehensive Laboratory Animal Monitoring System (CLAMS). Furthermore, my 
studies measured inter-scapular BAT and epidydimal WAT weight. MRI would provide a 
more accurate assessment of adiposity and lean body mass463. 
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Glucagon and GLP-1 co-administration and the effect on glucose homeostasis 
 
In chapters 2, 4 and 5, I demonstrated that GLP-1 administration in rodents and humans 
ameliorated the acute rise in glucose following glucagon administration. Furthermore, 
glucagon and GLP-1 co-administration in humans had an additive insulinotropic effect 
(chapters 4 and 5). These findings are consistent with glucagon and GLP-1 both 
stimulating insulin release via their respective receptors  on pancreatic β-cells 549-551.  
 
Subsequent studies in DIO mice (chapter 3), showed that chronic co-administration of 
glucagon and GLP-1 analogues reduced glucose and insulin levels. These findings may be 
secondary to improved insulin sensitivity, in part due to the weight loss observed. 
However, similar findings in glucose homeostasis were demonstrated following chronic 
glucagon analogue administration in DIO mice, yet these effects were independent of 
weight loss. This suggests improved insulin sensitivity through a different mechanism. 
One hypothesis may be that chronically elevated GCGR agonism results in glucagon 
tachyphylaxis and receptor desensitisation. Tachyphylaxis is the attenuation of an effect 
observed with repeated administration of a substance and has been shown to occur with 
the gut hormones CCK552, GLP-1553 and PP554. Previous in vitro studies have shown that 
cAMP production is attenuated following repeated glucagon administration, suggesting 
receptor desensitisation555. Furthermore, GCGRs undergo internalisation within thirty 
minutes of glucagon administration556. Glucagon administration and tachyphylaxis has 
been shown during the investigation of hepatic glycogenolysis557, myocardial 
contractility558 and smooth muscle relaxation in the gut559. Consistent with these 
findings, obese Zucker rats require higher doses of ip glucagon compared to lean 
controls to elicit the same anoretic response189 and repeated ip glucagon reduces the 
ability of the hormone to reduce food intake in rats190.  
 
Glucagonomas are tumours of pancreatic α-cells and are characterised by high 
circulating levels of glucagon, type 2 diabetes and weight loss 560. It has been suggested 
that patients with glucagonomas are ‘glucagon-resistant’ 561,562. In one case report of a 
glucagonoma patient, long-term alterations in energy balance were minimal and the 
weight loss seen was not attributable to increased EE 563. In another case report, the 
circulating cAMP response to iv glucagon infusion was studied pre- and post-operatively 
following removal of the glucagonoma561. Pre-operatively, in the presence of 
hyperglucagonaemia, there was no rise in plasma cAMP. However, following curative 
surgery, and restoration of physiological glucagon levels, the cAMP response to glucagon 
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infusion was normal. This suggests that chronically elevated glucagon levels lead to 
GCGR desensitisation, which may be ameliorated following restoration of normal 
circulating glucagon concentrations.  
 
A glucagon resistant state or tachyphylaxis in association with receptor internalisation 
may explain the marked improvement in glucose regulation and also lack of expected 
weight loss due to chronic GCGR activation. In chapter 3, chronic co-administration of 
glucagon and GLP-1 analogues in DIO mice demonstrated an apparent synergistic effect 
on weight loss despite no reduction in food intake. These findings suggest that GLP-1 
may ameliorate tachyphylaxis of glucagon-induced EE. This could be tested initially in 
vitro to see whether GCGR internalisation still occurs in the presence of GLP-1. In 
addition, quantification of GCGR mRNA in tissue samples following chronic glucagon 
administration may assist in showing an association between prolonged glucagon 
administration and yet apparent lack of glucagon effect on weight loss.  
 
GCGR knockout mice are animal models which have been used to investigate the 
metabolic consequences of glucagon down-regulation. Liver-specific GCGR knockout 
mice develop hyperglucagonaemia and pancreatic α cell hyperplasia, yet have reduced 
fasting blood glucose and improved insulin sensitivity564. Similar findings are found in 
other models of glucagon down-regulation, and are associated with increased 
expression of GLP-1 in pancreatic α-cells and circulating levels of GLP-1204,205,433,435. This 
suggests that α cell hyperplasia results in up-regulation of the preproglucagon gene.  
Although not studied in chapter 3, it would be interesting to investigate the effects of 
chronic glucagon analogue administration in mice and the changes in pancreatic α cell 
morphology, pancreatic GLP-1 expression and circulating levels of GLP-1.  
 
In summary, chronic glucagon analogue administration may lead to GCGR 
internalisation with subsequent pancreatic α cell hyperplasia, hyperglucagonaemia and 
increased pancreatic GLP-1 secretion. Although this initially may lead to increased 
glucose and insulin levels, up-regulation of glucose transporters and futile substrate 
cycling would ameliorate hyperglycaemia within the circulation and increase EE via 
peripheral tissue thermogenesis. This is summarised in figures 6.1 and 6.2. To explore 
this hypothesis further, it would be interesting to investigate whether the expression of 
glucose transporters such as glucose transporter 4 (GLUT4), which modulates glucose 
disposal in peripheral tissues, is up-regulated in response to chronic glucagon receptor 
agonism. GLUT4 over-expressing mice exhibit increased fasting glucose disposal in 
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tissues and thus lowered blood glucose565, and enhanced peripheral glucose utilisation 
in skeletal muscle566,567. DPPIV inhibitors, which result in prolonged GLP-1 action, are 
associated with up-regulation of GLUT4 expression in skeletal muscle in rats568. In 
addition, over-expression of GLUT4 in mice increases UCP3 mRNA expression in skeletal 
muscle and decreases UCP-1 mRNA expression in BAT 569. Therefore, up-regulation of 
glucose transporters in skeletal muscle may explain the amelioration in circulating 
glucose observed following chronic glucagon analogue administration in DIO mice 
(chapter 3). This could be investigated in studies using a similar protocol to those 
outlined in chapter 3, collecting skeletal muscle samples and quantifying GLUT4 and 
UCP-3 mRNA expression using rtPCR. Until recently, researchers have focused 
predominantly on chronic GCGR antagonism in an attempt to improve glycaemia. 
However, these studies suggest that paradoxically, long-term administration of glucagon 
analogues may improve glucose control, independently of hepatic glucose output. 
 
Therefore, the actions of glucagon and increased EE may differ according to the duration 
of treatment. Acute glucagon administration may increase EE through mechanisms 
involving BAT thermogenesis, futile substrate cycling and SNS activation. In contrast, 
chronic administration of glucagon may lead to activation of more complex pathways 
involving up-regulation of glucose transporters, leading to improved glucose control and 
increased EE via peripheral tissue thermogenesis and substrate cycling. Elucidating the 
mechanisms through which glucagon and GLP-1 co-administration increases EE and 
ameliorates hyperglycaemia will assist in the development of dual agonists of the GCGR 
and GLP-1R.  
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Figure 6.1 Schematic diagram depicting the acute effects of glucagon and GLP-1 
administration on food intake, energy expenditure and glucose homeostasis.  Glucagon 
may increase EE acutely via different mechanisms including upregulation of UCP-1 and FGF-21 
effect in BAT, UCP-3 and irisin in skeletal muscle and UCP-1 in WAT. Glucagon and GLP-1 both 
stimulate the release of insulin from pancreatic  cells, which in conjunction with an acute rise in 
glucose in response to glucagon, increases futile cycling in thermogenic tissues and EE. In 
addition, glucagon activates the SNS causing release of catecholamines and a rise in heart rate. 
Glucagon and GLP-1 are thought to reduce food intake via vagal afferent nerves which terminate 
in the brainstem. In addition, GLP-1 may act directly via the circulation to activate neuronal 
pathways in the hypothalamus that are involved with the regulation of appetite. Glucagon and 
GLP-1 have been shown to reduce circulating levels of ghrelin which may also potentiate the 
anorectic effect. Although central pathways through which glucagon reduces food intake are 
unknown, it has been suggested that a CRH-dependent pathway may be involved. Furthermore, 
stimulation of vagal efferents with reduced gastric emptying may reduce food intake but also 
cause nausea. Abbreviations: Paraventricular nucleus (PVN), corticotrophin hormone (CRH), 
adrenocorticotrophic hormone (ACTH), amygdala (Amyg.), glucose (glc), glucagon-like peptide-1 
(GLP-1), energy expenditure (EE), heart rate (hr), uncoupling protein-1 (UCP-1), uncoupling 
protein-3 (UCP-3), fibroblast growth factor-21 (FGF-21). 
 
 211 
 
Figure 6.2 Schematic diagram depicting the hypothesised chronic effects of glucagon 
administration on energy expenditure and glucose homeostasis. Chronic 
hyperglucagonaemia may result in a state of ‘glucagon tachyphylaxis’ and GCGR internalisation. 
As such, direct acute effects of glucagon on BAT, muscle and WAT have minimal effects on EE.  
However, chronically elevated levels of glucagon and inability to stimulate GCGRs adequately 
results in pancreatic  cell hyperplasia and elevated expression of pancreatic GLP-1. Initial 
insulin and glucose levels subsequently rise as a result of elevated glucagon and GLP-1 
concentration. However, in the presence of upregulated GLUT4 expression in peripheral 
thermogenic tissues, rapid glucose disposal increases futile cycling of substrates and hence EE. 
Abbreviations: glucose (glc), glucagon-like peptide-1 (GLP-1), glucagon receptor (GCGR), energy 
expenditure (EE), glucose transporter 4 (GLUT4).  
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Glucagon/GLP-1 co-administration as a potential treatment in obesity 
 
The work presented in this thesis demonstrates that glucagon and GLP-1 co-
administration reduces food intake, increases EE and improves glycaemic control. 
However, the mechanisms through which these effects occur are unknown and further 
studies are warranted before glucagon/GLP-1 receptor co-agonists are considered as a 
potential treatment for obesity. The increased incidence of nausea in subjects following 
glucagon and GLP-1 co-administration requires further investigation. In particular, 
neuronal pathways involved in glucagon and GLP-1-mediated anorectic effects need 
further characterisation. If both hormones reduce food intake via the same pathway,  
then the therapeutic potential of glucagon and GLP-1 in combination may be limited by 
the presence of nausea and vomiting. OXM has been shown to cause these symptoms in 
human subjects446. Although GLP-1 analogues can also cause nausea and vomiting, these 
symptoms frequently resolve with the duration of treatment. Further studies are 
required to see whether similar attenuation of symptoms are seen following chronic 
glucagon administration.    
 
Recently, there has been concern about the use of GLP-1 analogues and the associated 
risk of pancreatitis570 and thyroid medullary cell cancer571,572. There is some evidence 
that glucagon administration may be beneficial in the treatment of pancreatitis573. In 
addition, recent studies suggest that the presence of pancreatic  cells improves  cell 
function and survival574. Prior to any phase I study involving the administration of 
glucagon/GLP-1 receptor co-agonists, toxicology and safety testing will need to be 
performed and should include histological analysis of the pancreas and thyroid gland.  
 
In the human studies reported here (chapters 4 and 5), there was a trend towards 
increased pulse and blood pressure in response to glucagon. This raises concerns about 
the cardiovascular safety profile of glucagon and GLP-1 in combination. A recent meta-
analysis has suggested an association between GLP-1 analogues and a small increase in 
heart rate575. In contrast, there is some evidence that GLP-1 therapies are beneficial in 
the control of blood pressure155,576. OXM has been shown to increase heart rate in mice 
but not humans 223,446,577. Increased heart rate is positively associated with a higher 
mortality rate in man 578. In patients with type 2 diabetes, an increase in resting heart 
rate of just 10 beats per minute is associated with a 15% increase in mortality579. Since 
both glucagon and GLP-1 can activate the SNS, long-term studies in animal and humans 
are required to assess cardiovascular safety parameters.    
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In conclusion, glucagon and GLP-1 co-administration may provide an alternative 
approach to weight loss through a simultaneous reduction in food intake and increased 
EE. However, further long-term studies are required, particularly in humans, to assess 
the incidence of side-effects such as nausea and cardiovascular parameters. In order to 
replicate the successful weight loss observed following gastric bypass surgery, it is likely 
that a combination of hormones will be required. The current trends in obesity highlight 
the urgency with which new treatments are required and the importance of research in 
this area. 
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6.2 Future work 
 
 
 To investigate the effects of chronic glucagon and GLP-1 administration in 
humans, I aim to undertake a randomised, single-blinded, cross-over study in 
overweight volunteers during which participants will receive an infusion of 
vehicle, glucagon alone, GLP-1 alone, or a combination of glucagon and GLP-1. 
Each infusion will be administered s/c via a portable infusion for one week 
whilst participants are at home. REE, food intake and carbohydrate tolerance 
will be measured at the end of each week. Heart rate will be monitored using  a 
non-invasive portable device which also has the ability to measure activity-
related EE. Subjective feelings of nausea and satiety will be recorded using VAS 
scores during each treatment week. 
 
 The Department of Investigative Medicine, Imperial College, London is currently 
undertaking a programme of dual glucagon/GLP-1 analogue development. These 
analogues may permit the study of longer-term glucagon and GLP-1 receptor 
agonism in humans through prolonged action and improved pharmacokinetic 
profile compared to the native hormones. I aim to undertake a multiple 
ascending dose finding study in human volunteers using a selected 
glucagon/GLP-1 analogue. The analogue will be selected based on in vitro work 
demonstrating the ability of this analogue to bind and activate the GCGR and 
GLP-1R. Prior to studies in man, the analogue will be administred to rodents and 
dogs to study its effects on food intake, glucose levels and its duration within the 
circulation. In man, I will measure breakdown products of this glucagon/GLP-1 
analogue and study its pharmacokinetic profile following administration. In 
addition, I will investigate the effects of this analogue on glucose, insulin and 
food intake in addition to feelings of nausea. The results from this initial dose-
finding study in humans will determine the dose of glucagon/GLP-1 analogue 
that will be administered in a subsequent phase I study.  
 
 
 
 
 
 
 215 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 216 
APPENDIX A: ABBREVIATIONS FOR AMINO ACIDS 
 
Code  Name   
Ala (A) Alanine 
Cys (C) Cysteine 
Asp (D) Aspartic acid 
Glu (E) Glutamic acid 
Phe (F) Phenylalanine 
Gly (G) Glycine 
His (H) Histidine 
Ile (I)  Isoleucine 
Lys (K) Lysine 
Leu (L) Leucine 
Met (M) Methionine 
Asn (N) Asparagine 
Pro (P) Proline 
Gln (Q) Glutamine 
Arg (R) Arginine 
Ser (S)  Serine 
Thr (T) Threonine 
Val (V) Valine 
Trp (W) Tryptophan 
Tyr (Y) Tyrosine 
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APPENDIX B: PEPTIDE STABILITY DATA 
B1. Amino acid sequences of glucagon, GLP-1, exendin-4, oxyntomodulin 
and the glucagon/GLP-1 analogues G(X), G(Y) and G(Z). 
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B2. Receptor binding and cAMP activation assays in response to G(X), G(Y) 
and G(Z). 
 
 
 
 
              Receptor Binding Assays (n=1-3) 
 
IC50 (nM) mGCGR hGLP-1R 
G(X) 6794 309.2 
G(Y) >10000 6.49 
G(Z) 0.45 141 
 
 
 
 
               cAMP activation (n=1-4) 
 
EC50 (nM) 
hGCGR (fold 
lower than 
GCG) 
hGLP-1R (fold 
lower than GLP-
1) 
G(X) 630 9.63 
G(Y) >10000 0.89 
G(Z) 4 36.5 
 
 
 
 
Table B1. Receptor Binding and cAMP assays for G(X), G(Y) and G(Z). HEK 293 cells 
were transfected with mouse GCGR (mGCGR) for RBA studies and human GCGR (hGCGR) 
for cAMP activation. Human GLP-1R (hGLP-1) was transfected for both RBA and cAMP 
studies.  
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B3. Pharmacokinetic profiles of G(Y) and G(Z) in rats. 
 
 
Figure B2. Pharmacokinetic profiles of G(Y) and G(Z) in rats. Ad libitum fed rats were 
injected s/c at the onset of the light phase with G(Y) or G(Z). Tail vein blood samples were taken 
at the time points indicated. n=3-5.  
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B4. Acute feeding studies following administration of G(X), G(Y) and G(Z). 
 
Figure B3. Acute feeding studies in mice following the administration of G(X), G(Y) and 
G(Z). Mice were fasted from 1600 the preceding day and injected s/c at the onset of the light 
phase. Mice were then returned to their cages with a known quantity of food. Food weight was 
measured at time points indicated. n=5. Abbreviations: exendin-4 (Ex-4). 
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APPENDIX C: EXAMPLE OF VISUAL ANALOGUE SCALE SHEET 
 
 
How hungry do you feel right now? 
 
  NOT AT ALL             EXTREMELY 
 
How sick do you feel right now?  
 
  NOT AT ALL               EXTREMELY 
 
How pleasant would it be to eat right now? 
 
  NOT AT ALL             EXTREMELY 
 
How much do you think you could eat right now? 
 
  NOTHING             A LARGE AMOUNT 
 
How full do you feel right now? 
 
  NOT AT ALL               EXTREMELY 
 
How tasty was the meal? 
 
 NOT AT ALL                                                EXTREMELY 
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